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SUMMARY 
 
The discovery and development of novel cancer therapies is an important research field as 
cancer is an international health problem with limited effective treatments.  Anticancer 
peptide therapy is an emerging field that uses bioactive therapeutic peptides to kill cancer 
cells due to their strong tumoricidal activity and low toxicity towards normal cells.  
 
Myxoma virus (MYXV), a member of the Poxviridae family has gained noteworthy attention 
from researchers for its oncolytic properties in human cancers.   Therefore, this study aims to 
evaluate the biological effects of the synthetic peptide (RRM-MV) which mimics the 
bioactivity of selected MYXV proteins in the ability to proliferate in human cancer cells.  
RRM-MV (MDDRWPLEYTDDTYEIPW) is a short peptide analogue for MYXV‘s M-T5 
protein which has been computationally designed using the Resonant Recognition Model 
(RRM).  The suitability of the bioactive peptide RRM-MV as a therapeutic candidate for skin 
cancer was investigated on cancerous and normal cells in vitro.  The cell lines used in this 
study were human malignant melanoma (MM96L), human squamous cell carcinoma (COLO-
16), normal human epidermal melanocytes (HEM), and normal human dermal fibroblast 
(HDF).   
 
The anti-cancer activity of RRM-MV was evaluated by cellular morphological changes 
(apoptosis and necrosis), cell viability, and lactate dehydrogenase (LDH) activity assays.   
The confocal laser scanning microscopy (CLSM) observations of RRM-MV treated cells 
indicated distinct changes in the growth patterns of melanoma and carcinoma cells including 
apoptotic and/or necrotic effects and cell detachment from the adherent confluent layer within 
 2  
 
3-18 h following treatment.  However, the CLSM observation of normal cells treated with 
RRM-MV showed no significant induction of apoptotic and/or necrotic cells.    The results 
from cytotoxicity and cell viability of melanoma and carcinoma cells demonstrated that the 
bioactive peptide induced cell death in a time- and dose-dependent manner.  A second dose (a 
repeated treatment) of RRM-MV administered at 16 h significantly reduced cellular viability 
in these cancer cells.  Furthermore, the viability of normal skin cells was not affected by the 
different doses of RRM-MV treatment over various time points.  Detection of early apoptotic 
events in treated cancer cells by gel electrophoresis showed that RRM-MV treatment led to a 
clear DNA degradation in melanoma cells; however, this was not observed in carcinoma cells.   
 
In order to proof the RRM concept, two non-bioactive peptides (RRM-C and RRM-MV-C) 
were designed by the RRM lacking the specific bioactive frequencies and phases of RRM-
MV and were similarly evaluated as negative control peptides.  The activity of RRM-C 
(CVLQDCVLQDCVIQDCVLQDCV) was investigated on the previously mentioned cancer 
and normal cell lines.  The results revealed that RRM-C treatment did not appear to induce 
apoptotic and/or necrotic effects or to reduce cellular viability on all tested cell lines even at 
the highest concentrations.  Notably, the characteristic DNA pattern for RRM-C treated 
cancer cells was unchanged indicating that RRM-C did not trigger apoptosis in cancer cells.  
The evaluation of the second non-bioactive peptide RRM-MV-C 
(DDDCWHVLEKWTDDDRQA) also showed that it did not trigger morphological changes, 
cytotoxic effects, or a reduction in cell viability in either human skin cancer cells or in normal 
human skin cells. 
 
Moreover, in order to confirm that the biological activity of RRM-MV is conserved in its 
unique amino acid sequence, the order of one amino acid at a time within this sequence was 
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changed.  Three scrambled peptide sequences (MV-C1, MV-C2, and MV-C3) were also 
tested as an additional proof of concept.  The toxicity of the above mentioned peptides was 
evaluated on human skin cancer cells and normal cells in vitro and compared with the 
bioactive peptide RRM-MV.  The evaluations were performed by measuring the characteristic 
morphological changes and cell viability.  The findings from these evaluations revealed that 
any change in the order of the amino acids of RRM-MV will lead to the loss of its anticancer 
activity.  
 
Furthermore, the toxicity of RRM-MV on human erythrocytes was investigated by the 
quantitative hemolysis assay to assess its suitability as a candidate for cancer therapy.  The 
experimental data indicated that human erythrocytes were not affected by the peptide 
treatment.  Similarly, no hemolytic effects were detected on human erythrocytes when all 
negative control peptides were tested by this assay.  
 
Cell death signalling pathways were investigated in melanoma and carcinoma cells to 
understand the influence of RRM-MV treatment on cancer cells.  The levels of apoptosis-
related proteins in the absence or presence of RRM-MV were detected using a human 
apoptosis protein array kit.  Data analysis showed that RRM-MV induced pro-apoptotic 
protein expression and reduced the anti-apoptotic protein expression in both types of treated 
cancer cells.  Because the tumor-suppressor protein p53 and the cleaved casapase-3 protein 
play a significant role in cell death and were shown to be targeted by the RRM-MV treatment, 
the expression of p53 and cleaved casapase-3 proteins were evaluated at different incubation 
times.  The results revealed that the levels of these proteins were affected by the RRM-MV 
treatment. 
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Another focus of this study was to investigate the influence of the bioactive peptide on Akt-
activation in skin cancer cell lines.  Immunoblot analysis indicated that different endogenous 
levels of p-Akt were expressed in the presence or absence of the PI3 kinase inhibitor 
(LY294002), in skin cancer cells following treatment with RRM-MV under serum or serum 
starvation conditions.  Yet, the treatments did not appear to affect p-Akt expression in normal 
cells.   
 
Taken together the data obtained from this study suggests that the RRM approach can be 
applied to design therapeutic anti-cancer peptides, and the bioactive peptide RRM-MV is a 
potential candidate for future skin cancer treatment. 
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CHAPTER 1 
Introduction 
 
1.1 Skin Structure 
The Skin, also known as the integument, covers the entire external surface of the human body 
and plays a vital role in providing a barrier against the adverse external environment.  The 
skin guards internal tissues from exposure to ultraviolet (UV) radiation, trauma, temperature 
extremes, bacteria and toxins.  Other functions of the skin include the immunologic 
surveillance, avoiding excessive water loss from the aqueous interior, temperature regulation 
and sensation.  Damage to genes from the sources inside or outside of the cell or by hereditary 
factors can generate irregularities in cell division which may form cancer in the tissues of the 
skin (Croce, 2008). 
 
The three layers of skin from outside toinside in are epidermis, dermis and subcutis are shown 
in Figure 1. 1.  The bottom of the epidermis layer is made up of basal cells, which divides to 
form keratinocytes.  The keratinocytes produce keratin, a protein that helps the skin to protect 
the body.  The outermost part of the epidermis has the dead keratinocytes that are replaced 
when new ones emerge.  Therefore, the keratinocytes are responsible in replenishing the 
epidermis.  The cells in epidermis layer are known as squamous cells.  Melanocytes are 
another types of cells that are present in the epidermis.  Melanocyte cells produce a brown 
pigment called melanin (the skin tan) which guards the inner layers of the skin from quite alot 
of harmful effects of the sun.  The epidermis is separated from the deeper layers by the 
basement membrane layer (McGrath & Uitto, 2010).   
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The middle layer, dermis is the much thicker than the epidermis and contains hair shafts, 
sweat glands, blood vessels, and nerves.  The final and deepest layer is the subcutis which 
keeps in heat and has a shock-absorbing effect for protecting the body organs from injury 
(McGrath et al., 2008). 
 
The keratinocyte cells of the epidermal layer act as a cutaneous barriers to the external 
environment.  The follicular and interfollicular regions of the skin are occupied with these 
cutaneous epithelial cells.  The prolonged exposures to hazardous environment can increase 
the possibility of turning body cells cancerous (McGrath & Uitto, 2010). 
 
Cancers of the skin generally develop in the cells within the outermost layer of skin, the 
epidermis which initially appears as a tumor.  When the cancer becomes complex, it grows 
through the basement membrane layer (McGrath & Uitto, 2010). 
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Figure 1.1.  Epidermis and skin appendages.  The epidermis, the dermis and the fat tissue 
layers of the skin.  Skin appendages such as hair follicles and sweat glands reside in the 
dermis (WebMD, 2009).  
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1.2 Types of Skin Cancer  
Skin cancer medically known as malignant neoplasm is the uncontrolled growth of abnormal 
cells in the body.  It normally originates from the cutaneous epithelial cells.  Cancerous cells 
or malignant cells divide and grow uncontrollably causing the formation of malignant tumors 
which may spread to other parts of the body through the lymphatic system or bloodstream 
(Norbury & Hickson, 2001).  As the tissues of skin are made up of basal cells, squamous cells 
and melanocytes, the skin cancer types are named as basal cell carcinoma (BCC), squamous 
cell carcinoma (SCC) and melanocarcinomas (MM).  BCC and SCC are often grouped 
together and known as non-melanoma skin cancers (Green & Khavari, 2004).  The most 
common skin cancers are the ones originating from the epithelial cells known as cutaneous 
carcinomas (BCC and SCC) and the ones arising from melanocytes (MM) known as the 
cutaneous melanomas (Leiter & Garbe, 2008).  The molecular pathogenesis of the BCC, SCC 
and MM are still not understood properly (Nouri et al., 2008).  Many treatment modalities are 
becoming available to explore or develop the new molecular therapeutics with large clinical 
trials to prove their efficacy, including topical regimens (Nouri et al., 2008; Green & Khavari, 
2004). 
 
According to the Australian Bureau of Statistics (ABS, 2012), Australia has one of the highest 
rates of skin cancer in the world.  The factors that trigger the skin cancer among Australians 
are due to the high UV levels in the sunlight caused by the proximity to the equator, fair skin 
and more outdoor activities.  The statistics show that each year over 1850 Australians die 
from skin cancer (ABS, 2012) and Australians have higher chance to develop skin cancer by 
the age of 70, with the risk being higher in men (2 in 3) than women (3 in 5) (Clarke, 2012). 
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1.2.1 Basal Cell Carcinoma 
Basal cell carcinoma (BCC) is the most common but least dangerous form of skin cancer that 
develops in the basal cells of the skins‘ surface (Owens & Watt, 2003).  BCC is described by 
the World Health Organization Committee on the histological typing of skin tumors as ―a 
locally invasive, slowly spreading tumor which rarely metastasize, arising in the epidermis or 
hair follicles and in which, in particular, the peripheral cells usually simulate the basal cells of 
the epidermis‖.  BCCs constitute approximately 75% of non-melanoma skin cancers (Owens 
& Watt, 2003).  BCC accounts for about two-thirds of skin cancers among the fair-skinned 
populations (lightly pigmented individuals) and usually develop on the head, neck and upper 
body resulting from the long-term exposure to the sun (Kerr et al., 2012).  Even though the 
BCC grows slowly and doesn‘t usually spread to other parts, the untreated BCC may grow 
deeper into the skin and damage nearby tissue resulting in complicated problems.  According 
to microscopic studies, BCC shows no initial signs and can be grouped into three types based 
on location and difficulty for therapy.  The first type of BCC is the superficial basal-cell 
carcinoma (in-situ) which can be effectively treated with topical chemotherapy.  The second 
type of BCC is the nodular basal-cell carcinoma which can come across morphologic features 
of several variants of basal-cell cancer in the same tumor.  The third type of BCC is the 
infiltrative basal-cell carcinoma, which often includes morpheaform and micronodular basal-
cell cancer and is not easy to treat with traditional treatment methods such as cryotherapy, 
surgery, radiotherapy, and curettage and electrodessication (Bonerandi et al., 2011; Nouri et 
al., 2008).   
 
The identification of histological subtypes, identifying the anatomic locations that can 
increase the risk of spread, and understanding the limitations of all available treatment 
procedures are crucial in treatment of carcinomas.  The typical microscopic features of BCC 
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consist of nuclei at the tumor periphery, dimples at tumor–tissue interfaces and peri-tumor 
stromal tissue formation (Carucci & Lefell, 2003).  The morphologic study in tissue section 
shows that the large percentage of BCCs might occur from Keratinocytes and hair follicle.  
The BCCs are clinically characterized by thier local invasion and contiguous spread, yet 
metastasis of BCC is a very rare condition (Carucci & Lefell, 2003; Miller, 1991a; Miller, 
1991b).  The selection of treatment such as surgical excision or non-surgical procedures 
should be determined based on the histological subtype of a lesion, its size and location with 
the intention of complete removal, good cosmetic outcome and moreover to preserve the 
function of skin (Nouri et al., 2008). 
 
1.2.2 Squamous Cell Carcinoma 
Squamous cell carcinoma (SCC) is an uncontrolled growth of abnormal cells arising in the 
squamous cells in the epidermis (Brand & Ackerman, 2000; Vargo, 2003).  Squamous cells 
produce keratin, the horny protein that makes up hair, skin and nails.  SCC is the second most 
common type of skin cancer in Australia and US, accounting for about 15-20% of all skin 
cancers (Little & Eide, 2012).  SCC is generally locally invasive, grows gradually and has the 
potential to metastasise to other organs.  SCC is a malignant tumor of epithelial origin and its 
behavior depends on its site of origin i.e. each anatomic location has its own particular spread 
pattern and prognosis.  Histologically, the features of SCCs are the presence of keratinization 
within the cells, intercellular bridges, pleomorphism of the tumor cells and dermal invasion 
by abnormal cells from the epidermis.  Intraepithelial keratin in the shape of a whorl is termed 
squamous eddy or pearl.  SCC is grouped among lesions with the same oncogenesis or not, 
and it develops gradually from its precursors actinic keratosis (represents a focal dysplasia of 
epidermal keratinocytes) and Bowen‘s disease (carcinoma in situ) (Green & Khavari, 2004; 
Kao, 1986).  The risk of SCC was found to be found high in patients receiving 
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immunosuppressive therapy and of heritable conditions such as xeroderma pigmentosum, 
dyskeratosis congenital, recessive dystrophic epidermolysis bullosa, oculocutaneous albinism 
and epidermodysplasia verruciformis (Grossman & Lefell, 2003).  Since the genetic defects 
are not specific for SCC, the targeted therapies are not much developed and the most adopted 
treatment is surgery (Bonerandi et al., 2011). 
 
1.2.3 Melanoma 
Melanoma (MM) is less common than either BCC or SCC but it is the most dangerous type of 
skin cancer that can cause death.  Melanoma is caused by changes in melanocytes, the 
epidermic cells.  Melanocytes produce a skin pigment called melanin, which is responsible for 
skin and hair color (Langley & Sober, 1997).  Melanoma can begin as a mole or on other 
areas that have changed in appearance or can appear on normal skin.  Some moles that are 
present at birth may develop into melanomas.  The different types of melanoma are superficial 
spreading melanoma (most common type), lentigo maligna melanoma (occurs in sun-
damaged skin on the face, neck, and arms of elders), nodular melanoma and acral lentiginous 
melanoma (uncommon type) (Kanzler & Swetter, 2003).  The factors that can trigger 
melanoma are over exposure to the sun, having blistering sunburns during childhood, 
hereditary factors, atypical dysplastic moles or birthmarks, weakened immune system and risk 
of developing melanoma increases with age (Langley et al., 2003).  Since melanoma can 
spread very rapidly; therfore, its non healing cancer sores may attack nearby healthy tissues or 
lymph nodes, the early detection and treatment is crucial to survive from melanoma (Kanzler 
& Mraz-Gernhard, 2001; Shashanka & Smitha, 2012; Swetter, 2003). 
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1.3 Skin Cancer and Treatment   
The spread of cancer within the skin or other parts of the body is rated into stages.   The 
information collected from the staging process is used to plan treatment.  A biopsy test is the 
only test normally used to determine the stage of skin cancer (Fujiwara et al., 2009).  The 
three ways that cancer spreads in the body are by attacking the surrounding normal tissues or 
by attacking the lymph system and spreads to other places in the body through the lymph 
vessels or spreading to other parts in the body through the blood in the veins and capillaries 
(metastasis) (Chambers et al., 2002; Mantovani et al., 2008; Woodhouse et al., 1997).  Choice 
of treatment depends on the diagnosed precancerous skin condition, the stage of the cancer, 
the size and location of the tumor, the type of skin cancer and the patient‘s general health 
(Clarke, 2012). 
 
1.3.1 Types of Treatments for Skin Cancer 
Based on the information of histopathologic growth pattern of the biopsy, the treatment plan 
is arranged.  Two commonly used techniques for skin biopsies are shave biopsies and punch 
biopsies.  In shave biopsies, a surface sample of tissue is collected whereas in punch biopsies 
a deeper tissue sample is taken (Marmur et al., 2004).  Different skin cancer treatment 
methods are detailed below. 
 
1.3.1.1 Surgery 
Surgical removal of the tumor is one of the most commonly used methods for the treatment of 
skin cancer (Rass & Tilgen, 2008).  Some of the frequently used surgical approaches are 
Mohs micrographic surgery (Goldberg et al., 2008), conventional excision, electrodesiccation, 
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curettage (Knox et al., 1960)  and cryosurgery  (Neville et al., 2007).  Mohs micrographic 
surgery (MMS) is a specialised form of skin cancer surgery to remove large, deep or recurring 
cancers (Mohs, 1941).  MMS is commonly used for complete removal of locally recurrent 
high-risk skin cancers such as basal cell carcinomas (BCC) and squamous cell carcinomas 
(SCC) (Leibovitch et al., 2005).  This technique uses Mohs map to correlate the histological 
findings from the surgical margins in order to control the tumor margins.  Upon microscopic 
examination, if microscopic margins are positive i.e. residual cancer is found, additional 
tissue is removed until all margins are negative.  MMS is a preferred method because it 
provides the most complete histologic analysis of tumor margins, superior cure rates and 
maximal tissue conservation.  Excision is the other highly effective treatment for the removal 
of non-melanoma skin cancers.  Recommended excision margins for the removal of 95 to 
99% of low-risk tumors vary from 2 to 15 mm (Thomas et al., 2003).  Ablative techniques 
such as curettage (removal of tissue by scraping or scooping) and electrodesiccation 
(destruction of tissue by dehydration) can provide cure in patients with low-risk superficial 
tumors (Knox et al., 1960).  Cryosurgery is a therapy to destroy diseased tissues by applying 
extreme cold.  The freezing temperatures applied using liquid nitrogen, carbon dioxide, argon 
or dimethyl ether-propane results in tearing the cells apart.  This minimally invasive 
procedure is a quick, cost effective, high cure rate and successful treatment for selected non-
melanotic skin cancer (Kuflik, 2004).  However, the damage to nerve tissues is a concern for 
this therapy (Margaret, 2000). 
 
1.3.1.2 Radiation  
Radiotherapy or radiation oncology is the medical use of ionizing radiation applied to the 
cancerous tumor to control the cell growth (Veness, 2008).  Fractionated doses of radiation 
usually delivered in the form of superficial X-rays, orthovoltage or deep X-rays, or electron-
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beam therapy, damages the DNA of exposed tissue and only normal tissue recovers between 
treatments.  Thus, the cancerous cells are more susceptible to death.  This therapy causes less 
damage to the surrounding healthy tissues.  Radiation therapy is not recommended for 
patients under 50 years of age who does not have uncomplicated skin tumors because of the 
side effects (Bolke et al., 2008). 
 
1.3.1.3 Topical Chemotherapy 
Chemotherapy is the treatment used to prevent the spread of cancerous cells with an 
antineoplastic drug by killing cells that divide rapidly.  In topical chemotherapy, the medicinal 
creams are applied to the skin for increasing erythema and superficial erosions at affected 
sites.  5-fluorouracil (5-FU) is mostly used for cutaneous tumors to interact with DNA 
synthesis in actively dividing cells (Detlef, 1981).  The topical chemotherapeutic agent most 
widely used for cutaneous tumors is 5-fluorouracil (5-FU), which interferes with DNA 
synthesis in actively dividing cells causing tumor death.  Topical 5-FU application is not good 
for curing persistent, deeper-invasive tumors (Mohs et al., 1978).  This therapy causes side 
effects such as myelosuppression, immunosuppression, mucositis and hair loss (alopecia).  It 
harms cells that divide rapidly under normal circumstances i.e. cells in the bone marrow, 
digestive tract and hair follicles (Bonerandi et al., 2011).   
 
1.3.1.4 Photodynamic Therapy 
Photodynamic therapy is a treatment by applying photosensitizing compound to the infected 
part of the skin and the exposure to a specific wavelength of light.  The activated 
photosensitizing compound by the light source produces a form of oxygen that kills nearby 
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cells (Dolmans et al., 2003; Vrouenraets et al., 2003).  Since the wavelength determines how 
far the light can travel into the body, the photosensitizers and wavelengths of light are 
selected according to the treatment required for different areas of the body.  This therapy is 
used for local treatment and cannot be used for metastasized cancers because the light cannot 
pass far into these tumors (Tseng et al., 2009).  Photodynamic therapy has minimal damage to 
healthy tissue such as burns, swelling, pain, and scarring due to tendency of photosensitizer to 
build up in tumors (Agostinis et al., 2011).  However, careful continuing follow-up is 
essential because of higher recurrence rates.  The side effects such as coughing, trouble 
swallowing, stomach pain, painful breathing, or shortness of breath from this therapy is 
usually temporary (Schuitmaker et al., 1996).  The photosensitizing agent can also be injected 
into the bloodstream.  The injected photosensitizing agent is absorbed by cells all over the 
body but stays in cancer cells longer than it does in normal cells.  After a certain interval, the 
tumor is exposed to light so that the agent will be only on the cancer cells which kill the 
cancer cells (Bonerandi et al., 2011).  Photodynamic therapy is also used to damage the blood 
vessels in the tumor to prevent the reception of nutrients by the cancer cells.  This therapy 
may also activate the immune system to prevent the growth of tumor cells (Dolmans et al., 
2003). 
 
1.3.1.5 Retinoids 
Retinoids are synthetic derivatives of vitamin A which is used as an effective means for the 
control of cell differentiation in many epithelial tissues (Sporn  et al., 1976).  It has chemo-
preventative effect to prevent the risk of developing basal cell carcinomas and squamous cell 
carcinomas by boosting collagen to reduce fine lines, unblocking pores and speed cell 
turnover to reduce discoloration and smooth the skin.  Retinoids applied as a cream or taken 
as a tablet induce apoptosis and prevent the tumor proliferation (Tang & Gudas, 2011).  
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Retinoids are recommended for transplant patients who suffer from squamous cell carcinomas 
due to immunosuppression.  The commonly available retinoids are Accutane (isotretinoin) 
and Soriatane (acetretin).  Due to the undesirable effects of retinoids such as cheilitis 
(inflammation of the lip), hair loss, and xerosis (abnormal dryness of the skin or mucus 
membranes) laboratory monitoring is needed.  Thus, this therapy is performed only for 
hospitalized high-risk patients by starting with low doses and increasing gradually (Bachelor 
& Owens, 2009; So et al., 2008).   
1.3.1.6 Targeted Cancer Therapies  
Targeted cancer therapies use molecularly targeted drugs which interfere with specific 
molecules that prevent the growth and spread of cancer.  Targeted cancer therapies aim to 
induce apoptosis by blocking signals that cause cell growth and proliferation, by stimulating 
the immune system to identify and destroy cancer cells and/or by delivering toxic substances 
directly to the cancer cells (Gray-Schopfer et al., 2007).  Numerous targeted drugs with high 
prospective in skin cancer treatment such as pathway inhibitors, especially hedgehog pathway 
and pro-apoptotic drugs, especially cyclooxygenase (COX) inhibitors have been developed 
recently (Naylor, 2010).  These therapies are less harmful to normal cells and more effective 
because they target cancer specific cellular changes (Ellis & Hicklin, 2008).  Vemurafenib is 
one type of targeted cancer therapy which is known as zelboraf or PLX4032 (Bollag et al., 
2010).  It is a low molecular weight serine-threonine kinase inhibitor (BRAF) that functions 
by binding to the adenosine triphosphate (ATP)-binding domain of mutant BRAF (Joseph et 
al., 2010; Tsai et al., 2008).  It has marked antitumor effects against melanoma cell lines with 
the BRAF V600E mutation but not against cells with wild-type BRAF mutations (Bollag et 
al., 2010; Joseph et al., 2010; Lee et al., 2010; Tsai et al., 2008).  Vemurafenib has been 
approved by the United States Food and Drug Administration (US FDA) for the treatment of 
metastatic and inoperable melanomas that carry an activating BRAF V600E mutation 
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(Chapman et al., 2011; Spagnolo & Queirolo, 2012; Yadav et al., 2012).  It has been reported 
that vemurafenib produced improved rates of survival in patients with previously untreated 
melanoma with the BRAF V600E mutation (Amaria et al., 2012; Chapman et al., 2011).  In 
recent clinical studies in metastatic melanoma patients carrying mutant BRAF, a single-agent 
vemurafenib treatment exhibited a robust efficacy with a response rate of 50% (Flaherty et al., 
2010).  Although the safety profile in vemurafenib-treated patients was consistent with that 
reported in previous studies, there were some common adverse events which included 
arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous cell carcinoma, 
photosensitivity, nausea, and diarrhoea (Heakal et al., 2011; Spagnolo & Queirolo, 2012).  
Almost all patients whom initially responded to vemurafenib therapy developed drug 
resistance and eventually relapsed within an average of seven months (Sabourin, 2012).  
Therefore, the acquired resistance to BRAF inhibition presents a significant therapeutic 
challenge to the long-term survival benefit in the patient population, as has been seen in many 
other targeted therapies (Bollag et al., 2010; Koya et al., 2012).  
 
1.3.1.7 Cancer Immunotherapy 
Cancer immunotherapy, a form of biologic therapy, is the use of the immune system to reject 
cancer.  The main premise is to stimulate the patient's immune system to attack the cancer 
cells that are responsible for the disease.  Immunotherapy can be either through immunization 
of the patient, in case the patient's own immune system is trained to recognize cancer cells as 
targets to be destroyed, or through the administration of therapeutic antibodies as drugs to 
destroy cancer cells by the therapeutic antibodies (Bhatia et al., 2009; Block et al., 2002). 
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1.3.1.7.1 Interferon Therapy  
Interferon (IFN) is produced by diverse cell types in response to different stimuli, such as 
exposure to a virus, bacterium, parasite, or other antigen, and that prevents viral replication in 
newly infected cells and, in some cases, modulates specific cellular functions (Kirkwood, 
1995; Slaton et al., 1999).  The IFN family includes interferon alfa-2a, interferon alfa-2b, 
interferon alfacon-1, interferon alfa-n3 interferon-β, interferon beta-1a, interferon beta-1b, 
interferon-γ, interferon gamma-1b (Kirkwood et al., 2002).  IFN-α2b has multiple effects on a 
variety of malignancies that range from antiangiogenic to potently immunoregulatory, 
differentiation-inducing, antiproliferative, and proapoptotic effect (Davar et al., 2012; Tarhini 
et al., 2012).  IFN therapy is recommended only for patients whom surgery is not optimal 
because of low recovering rate and lack of durability with high-risk tumors (Naylor, 2010).  
IFN therapy can cause several side effects such as a reduction in the number of white blood 
cells, flu-like symptoms such as fever, chills, drowsiness, nausea and aches, anemia, nose 
bleeding due to reduction in the number of platelets in the blood, liver problems, heart 
problems and hair thinning (Garbe et al., 2011; Neville et al., 2007).  The toxicity of IFN is 
dependent on the dose as well as the individual patient‘s susceptibility, which is difficult to 
predict (Tannir et al., 2006).  The rationale for using low or intermediate doses of IFN is to 
allow for longer treatment durations while reducing toxicity at the same time, since IFN 
exposure and bioavailability most likely determine the side effect profile (Daud et al., 2012; 
Kirkwood et al., 2012). 
 
1.3.1.7.2 Interleukin-2 Therapy 
Interleukin-2 (IL-2) or aldesleukin is a glycoprotein that binds to IL-2 receptors on T-cells 
and augments lymphocyte mitogenesis and cytotoxic activity.  It is essential for T-cell 
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immunity and exerts its anticancer activity by acting as a growth factor for T lymphocytes, 
increasing interferon-gamma production, stimulating antigen-independent natural killer cells, 
and facilitating the movement of lymphocytes to sites of malignancy (Bhatia et al., 2009; 
Rosenberg et al., 1989).  IL-2 was first identified in 1976, and it was approved by the USFDA 
in 1998 for the treatment of metastatic melanoma based upon its ability to produce consistent, 
complete responses in melanoma disease (Antony & Dudek, 2010; Atkins et al., 1999; Bhatia 
et al., 2009; Rosenberg et al., 1994).  A wide spectrum of dosing schedules and regimens 
exists for IL-2 therapy; most oncologists use the standard dose, but only high-dose IL-2 has 
been shown to have a proven impact on overall survival (Atkins et al., 1999; Atkins et al., 
2000).
  
The common side effects associated with IL-2 therapy include fever, chills, increased 
capillary permeability, cardiac arrhythmias, oliguria, volume overload, delirium, hypotension 
and rash (Bhatia et al., 2009; Rosenberg et al., 1998).
 
 
1.3.1.7.3 Ipilimumab Therapy 
Ipilimumab is a monoclonal antibody that targets the cytotoxic T-lymphocyte antigen-4 
(CTLA-4), a negative regulator of T-cell activation (Eggermont & Robert, 2011; Hodi et al., 
2010; Patel & Woodman, 2011).  This treatment was initially developed by Steve Rosenberg 
and colleagues at the Surgery Branch of the National Cancer Institute in patients with 
metastatic melanoma and metastatic renal cell cancer (Rosenberg et al., 1998).  Ipilimumab 
was shown to be capable of inducing long-lasting responses (Hersh et al., 2011; Kirkwood et 
al., 2010).  In 2011, and it was approved by the USFDA and European Medicines Agency for 
patients with advanced melanoma as a first- and second-line treatment (Hodi et al., 2010; 
O'Day et al., 2010; Robert et al., 2011; Wolchok et al., 2010).  Ipilimumab represents a 
significant advance in the treatment of metastatic melanoma and in the field of cancer 
immunotherapy (Mansh, 2011).  The most common adverse events with Ipilimumab therapy 
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are colitis and dermatitis that respond to systemic steroids without significantly affecting the 
efficacy of ipilimumab therapy (Beck et al., 2006). 
 
1.3.1.7.4 Bevacizumab Therapy 
Bevacizumab, known as avastin, is a recombinant humanized monoclonal antibody to 
vascular endothelial growth factor (VEGF), a potent mediator of tumor angiogenesis (Hurwitz 
& Saini, 2006; Strickler & Hurwitz, 2012).  Bevacizumab has been approved by the USFDA 
for the treatment of metastatic colorectal cancer, non-small cell lung cancer, and metastatic 
renal cell carcinoma (Hamilton & Blackwell, 2011; Kreisl et al., 2009).  Bevacizumab has a 
safety profile; however, most adverse events associated with bevacizumab do not appear to be 
dose-related, with a few exceptions (Usakova et al., 2013; Vokes et al., 2013).  The most 
frequently reported adverse events with bevacizumab therapy are hypertension, proteinuria, 
and haemorrhage.  Conversely, the less common events include arterial and venous 
thromboembolic events, gastrointestinal perforations, wound-healing complications, and 
congestive heart failure/cardiomyopathy (Aguilera et al., 2013; Bendell et al., 2012; Hurwitz 
et al., 2012; Pansy et al., 2013). 
 
1.3.1.7.5 Imiquimod 
Imiquimod (r-837) known as Aldara or zyclara, which is marketed by Graceway 
pharmaceuticals and iNova pharmaceuticals is a topical immune-response modifier by in-situ 
application is effective against surface BCCs, small nodular BCCs and SCCs (Hemmi et al., 
2002). The drug promotes innate and acquired immune responses via secretion of cytokines 
(interferon-α, interleukin-6 and tumor necrosis factor-α) and is a novel synthetic 
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imidazoquinolone that binds cell surface receptors of toll-like receptor 7 (TLR7) and TLR-8, 
commonly involved in pathogen recognition (Zagon et al., 2008).  It also activates the Th-1 
cell-mediated immunity (Neville et al., 2007).  Recent in-vitro studies have shown that 
imiquimod has anti-proliferative effects independent of immune system activation (Zagon et 
al., 2008).  Imiquimod causes antiviral and antitumor effects by having long-term cytokine-
induced immune responses and can protect the recurrence of tumor cells.  Imiquimod has also 
been shown to promote the expression of cellular receptors that are associated with apoptosis 
(Meyer et al., 2003). 
 
1.4 Oncolytic Viral Therapy 
Oncolytic virotherapy is an emerging cancer treatment platform with the help of 
advancements in the genetic modification of oncolytic viruses (Eager & Nemunaitis, 2011).  
Oncolytic viruses have highly versatile viral genomes and are able to be modified to direct 
their cytotoxicity towards cancer cells (Antonio, 2002).  Virotherapy uses oncolytic viruses 
with specified oncogenic phenotypes that are engineered to selectively kill cancer cells 
instead of healthy cells.  From the detection of virus in nineteenth century, researchers have 
distinguished the prospective of virus in the treatment of cancer.  Nowadays, many different 
genetically engineered, tumor-targeting viruses are used in oncolytic virotherapy (Stanford & 
McFadden, 2007).   
 
Nemunaitis et al., 2000 developed a genetically engineered virus called ONYX-015 (an 
oncolytic adenovirus) for the treatment of cancer.  In this virus the E1B-55kDa gene has been 
deleted allowing the virus to selectively replicate and lyse p53-deficient cancer cells.  In order 
to evaluate the selectivity of ONYX-015 replication and cytopathic effects for the first time in 
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humans, they carried out a Phase II clinical testing of intratumoral and peritumoral ONYX-
015 injection in 37 patients with recurrent head and neck carcinoma.  This study confirmed 
both the safety and anti-tumor potential of this approach and served as a base for developing 
far more effective approaches in virotherapy (Nemunaitis et al., 2000). 
 
Mullen and Tanabe 2002 reviewed the general mechanisms by which oncolytic viruses 
achieve their antitumor efficacy and specificity.  The principles of viral oncolysis are the 
mechanisms of antitumor efficacy, the mechanisms of antitumor specificity and the effects of 
the immune responses.  In the mechanisms of antitumor efficacy (tumor cell destruction) the 
virus directly lyses the cell as a result of viral replication.  This process is repeated with 
progeny virion to infect the adjacent cells to destroy them.  This process of replication 
provides a continuous amplification until no more susceptible cells exist.  Another mechanism 
is to generate proteins during oncolytic viruses‘ replication, which are directly cytotoxic to the 
tumor cells.  For example, adenoviruses express E3-11.6 kD and E4ORF4 proteins which are 
cytotoxic proteins to cells (Mullen & Tanabe, 2002).  The use of chemotherapy and radiation 
therapy can increase the sensitivity of oncolytic viruses towards cancer cells.  For instance, 
E1A gene product of the adenovirus is an effective chemosensitizer especially in cells with 
functional p53 (Lowe et al., 1994).   
 
The different effective mechanisms by which oncolytic viruses destroy malignant cells are 
listed in Table 1.1.  Another mechanism for the antitumor efficacy is the expression of 
therapeutic transgenes inserted into the viral genome (Quirin et al., 2010).  The two 
mechanisms that are used to achieve tumor-selective viral replication are 1.  By deleting viral 
genes that are dispensable upon infection of neoplastic cells but are critical for viral 
 20  
 
replication in non-neoplastic cells.  2.  By placement of tumor-specific promoters upstream of 
viral genes that are critical for efficient viral replication (Hallenbeck et al., 1999; Mullen & 
Tanabe, 2002). 
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Table 1.1.  Mechanism of antitumoral efficacy of oncolytic viruses (Mullen & Tanabe, 2002). 
 
 
Mechanism Examples 
1 Direct cell lysis due to viral replication Adenoviruses Herpes simplex viruses 
2 Direct cytotoxicity of viral protein Adenovirus E4ORF4 
3 Induction of antitumoral immunity Nonspecific 
(e.g., TNF) 
          Specific (e.g., CTL response) 
 
Adenovirus (E1A)  
Herpes simplex virus 
4 Sensitization to chemotherapy and radiation 
therapy 
Adenovirus (E1A)  
Adenovirus (AdTK-RC) 
5 Transgene expression Herpes simplex virus (rRp450) 
Vaccinia virus (GM-CSF) 
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1.4.1 Myxoma Virus for Oncolytic Viral Therapy 
Myxoma virus (MYXV) belongs to Chordopoxvirinae subfamily of the Poxviridae family that 
causes a fatal disease called myxomatosis in European rabbits (Oryctolagus cuniculus) 
(Fenner & Ratcliffe, 1965; Stanford et al., 2007c; Werden et al., 2007).  However, there is no 
known history of causing diseases in any other vertebrate species including humans (Fenner, 
2000; McFadden, 2005).  Although the MYXV is widely carried by mosquitoes in countries 
like Australia, there is no evidence of MYXV infection to any vertebrates including humans.  
Human myxoma infection or seroconvertion in man have not been reported to date even for 
humans living in a virus distributed areas (Stanford et al., 2008).   
 
MYXV is a promising therapy for human cancer because it can infect a number of cancer cell 
lines without infecting normal cells, easy to engineer, has a sequenced genomeand natural 
tropism is highly restricted to European rabbits (Kerr & McFadden, 2002; Lun et al., 2005).  
However, the mechanism underlying the strict MYXV species barrier are not known (Wang et 
al., 2004b).  Studies showed that MYXV infection of primary mouse embryo fibroblasts 
elicited extracellular signal-regulated kinase (Erk) signalling and Erk inactivation or 
disruption of interferon signalling mediated by the transcription factor STAT1, which breakes 
the cellular blockade to MYXV multiplication (Wang et al., 2004a).  One of the important 
features of MYXV is its species specific ability to cause disease only in rabbits.  Although 
there is extremely narrow species host range in nature, myxoma virus can productively infect 
many nonrabbit cells including immortalized baby monkey kidney (BGMK) and some 
primary human dermal fibroblasts (Johnston et al., 2005a). 
 
Experiments have been conducted with MYXV as a novel oncolytic agent against human 
malignant glioblastoma in mice xenografted model.  It shows that MYXV can infect, and kill 
the glioblastoma cells (Lun et al., 2005; Werden & McFadden, 2010; Woo et al., 2008). 
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Recent experiments also showed that MYXV can infect the majority of human tumor cells 
tested from a wide spectrum of tissue types  (Barrett et al., 2007; Stanford & McFadden, 
2007; Stanford et al., 2008; Sypula et al., 2004; Wang et al., 2006; Wennier et al., 2012; Woo 
et al., 2008) and in xenografted mice in vivo (Lun et al., 2005; Lun et al., 2007; Wu et al., 
2008). 
 
Studies have demonstrated that MYXV is capable of targeting and destroying tumors while 
causing no significant disease in an immunocompetent host.  This has been performed with 
drugs such as rapamycin, further supporting the potential of this virus as a significant 
oncolytic candidate in cancer therapy (Stanford et al., 2008).   
 
1.4.1.1 Intracellular Signalling Manipulation: The Role of M-T5  
The ability of MYXV to replicate in a spectrum of human cancer cells has generated 
significant interest into characterizing the viral and cellular host range factors responsible for 
this unique tropism.  M-T5 is is an ankyrin-repeat host range protein in MYXV Tropism (Kerr 
& McFadden, 2002).  It prevents apoptosis during infection of rabbit T lymphocytes and is a 
virulence factor for myxomatosis progression in infected rabbits (Mossman et al., 1996).  
Studies conducted by Lun et al have shown that MYXV exhibits strong oncolytic activity for 
human cancer and M-T5 is a critical determinant of MYXV tropism in human cancer cells 
(Lun et al., 2005; Sypula et al., 2004).   
 
M-T5 was found to be responsible for the intracellular complexes formed with at least two 
cellular proteins from human cells.  The two proteins are Cullin-1 (Johnston et al., 2005b) and 
Akt 1/PKB (Wang et al., 2006).  The interaction of the protein with Cullin-1 results in the 
reprogramming of the cell cycle control mechanism of the infected cells whereas  Akt 1/PKB 
directly interacts with M-T5 in human cells.  The interaction of M-T5 with Akt 1/PKB is 
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believed to directly regulate MYXV permissiveness in cancer cells (Wang et al., 2006; 
Werden & McFadden, 2010).   
 
A number of aspects of M-T5 indicate that it exerts its host range functions and has the ability 
to bind and activate cellular Akt, directing to free MYXV imitation in a variety of different 
human cancer cell lines (Wang et al., 2006).  Akt or Protein Kinase B, is a serine/threonine 
protein kinase which has an important role in the regulation of cellular processes such as 
apoptosis, glucose metabolism, cell proliferation and angiogenesis.  Variety of stimuli that 
can activate Akt are protein phosphatase inhibitors, growth factors, and depend on the cellular 
stress in a phosphatidylinositol 3-kinase (PI3K) (Haas-Kogan et al., 1998; Nicholson & 
Anderson, 2002; Pedrero et al., 2005).  Three genes characterized in Akt human are Akt1, 
Akt2, and Akt3.  These three isoforms share the same structural organization with a conserved 
N terminus pleckstrin homology domain, a central kinase domain and a C-terminal regulatory 
domain (Song et al., 2005).  Akt1 is considered as a major factor in cellular survival pathways 
by inhibiting apoptotic processes.  It contains two phosphorylation sites, Thr-308 in the kinase 
domain and Ser-473 in the regulatory domain and is able to induce protein synthesis 
pathways.  Akt2 is more specific for the insulin receptor signalling pathway and the role of 
Akt3 is less apparent (Datta et al., 1999). 
 
Akt/PKB found to be commonly constitutively active in many types of human cancers.  
Constitutive Akt activation is caused by two reasons such as the amplification of PKB/Akt 
genes or mutations in components of the signalling pathway that activates Akt.  Although the 
mechanism involved is still not clear, constitutive Akt signalling is believed to prop up 
proliferation and increased cell survival and thereby contributing to cancer progression 
(Nicholson & Anderson, 2002).   
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Several studies have demonstrated that the main restriction determinant for MYXV tropism in 
a permissiveness of human cancer cells is the direct interaction between M-T5 and Akt.   
Experiments have been conducted to investigate the tropism of MYXV on cellular pathways 
in human cancer cells.  They have indicated that replication of MYXV in human cancer cells 
is associated with the hyperactivation of the serine/threonine kinase Akt in cancer cells (Hyun 
et al., 2000; Kim et al., 2005; Kim et al., 2010; Li et al., 2005b; Nicholson & Anderson, 
2002; Pedrero et al., 2005; Shi et al., 2002; Staal et al., 2002; Testa & Bellacosa, 2001; Wang 
et al., 2006; Wennier et al., 2012).  Recent studies on majority of human cancers have 
revealed that the Akt pathway is either mutated or constitutively activated, contributing to 
cancer progression through both the inhibition of apoptosis and stimulation of cellular 
proliferation (Hafner et al., 2012; Langley et al., 2003; Nicholson & Anderson, 2002).   
 
Wang et al screened a wide spectrum of human cancer cells for MYXV permissiveness and 
divided into three categories, designated Type I, Type II and Type III based on their ability to 
support replication of wild type MYXV and vMyxT5KOb.  It is evident that in all human 
cancer cells MYXV permisivess is directly related to the level of endogenous phosphorelated 
Akt.  Type I cells were infected by either MYXV or vMyxT5KO.  Type II cells were not 
permissive for vMyxT5KO infection and type III cells did not support productive infection by 
either virus (Wang et al., 2006).  Wang et al have explored the tropism of MYXV in human 
cancer cells by examining the significant human cancer cellular pathways.  Their Results 
showed that tumor cell lines expressed detectable levels of Akt but exhibited either high or 
low levels of endogenous phosphorylated Akt, or did not express any detectable phospho-Akt.  
High levels of endogenous phospho-Akt were associated with type I cells, low or very low 
levels in type II cells, and type III cells with no detectable endogenous phospho-Akt.  Akt 
activation correlation with permissiveness for MYXV in severl cell linesare shown in the 
Table 1.2 (Wang et al., 2006).   
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Table 1.2.  Akt activation correlation with permissiveness for MYXV. 
   Endogenous  p-Akt  Permissive 
 Cell line Cell origin Ak
t 
p-Akt  vMyxla
c 
vMyxT5
KO 
 vMy
xlac 
vMyxT5K
O 
Controls RK-13 Kidney 
(rabbit) 
+ High  + +  + + 
BGMK Kidney 
(primate) 
+ High  + +  + + 
HEK293 Kidney 
(human) 
+ High  + +  + + 
Type I HOS Osteocarcoma + High  + +  + + 
Caki-1 Renal cancer + High  + +  + + 
PC3 Prostate 
cancer 
+ High  + +  + + 
Type II HCT116 Colon cancer + Low  + -  + - 
 786–0 Renal cancer + Low  + -  + - 
 ACHN Renal cancer + Low  + -  + - 
 SK-OV-3 Ovarian 
cancer 
+ Low  + -  + - 
 U373 Glioma + Low  + -  + - 
Type III MCF-7 Breast cancer + None  - -  - - 
 COLO205 Colon cancer + None  - -  - - 
 MDA-
MB435 
Breast cancer + None  - -  - - 
 SK-MEL5 Melanoma + None  - -  - - 
  + indicates the cells permissive to MYXV infection; - represents undetectable 
endogenous phosphorylated Akt Ser-473 or Thr-308 or cells that were nonpermissive 
to infection by MYXV (Wang et al., 2006). 
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1.5 Application of Therapeutics Peptides 
Derivatives of peptides and peptides of various size are widely used as therapeutic drugs 
(Wieland, 1995 ).  Peptides can be produced by a variety of methods, including biosynthetic and 
chemical synthesis methods. Biosynthetic methods are based on naturally occurring products or 
recombinant microbial fermentations.  In chemical synthesis methods, peptides are incorporated 
with non-natural amino acids or conjugated with other small molecules.  Conjugation of small 
molecules to peptides is widely used as targeting of cytotoxic agents for anti-tumor therapy 
(Merrifield, 1995).  There are many potential applications for peptide therapies (Lien & Lowman, 
2003). 
 
Peptides and their homologous compounds, such as proteins and antibodies, can be used for 
multiple pathologies, including allergies, asthma, arthritis, baldness, cardiovascular diseases, 
diabetes, gastrointestinal dysfunction, growth problems, haemostasis, immunity diseases, 
impotence, incontinence, inflammation, obesity and osteoporosis (Loffet, 2002; Stevenson, 
2009).  Peptides are being used in vaccinations (Dutoit et al., 2002; Zwaveling et al., 2002), drug 
targeting (Arap et al., 1998a; Arap et al., 1998b; Koivunen et al., 1999; Pasqualini & Ruoslahti, 
1996) and to promote cellular uptake (Luhrs et al., 2002). 
  
All higher organisms naturally produce a large number of antimicrobial peptides, such as 
defensins and cathelicidins. Therefore, peptides could potentially be used as antimicrobial 
therapeutics (Ganz & Lehrer, 1998).  Many of these peptides are short, cationically charged and 
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are able to form amphipathic structures in non-polar solvents. They act against and disrupt the 
electrostatic attraction of membranes (Fjell et al., 2012; Gao et al., 2011; Kazemzadeh-Narbat et 
al., 2012; Ma et al., 2011).  Antimicrobial peptides have also been used for the induction of 
apoptosis in cancer cells (Javadpour et al., 1996).  
 
It has been found that peptides such as cationic antimicrobial peptides can mediate a diversity of 
cellular processes in vertebrates (Ntwasa et al., 2012).  These peptides have attracted 
considerable attention as targets for the development of therapeutic agents effective against 
microorganisms such as bacteria, fungi, viruses and parasites.  Although the efficiency of 
antimicrobial peptides against the different pathogens are not as strong as traditional antibiotics, 
they are effective for killing multi-drug-resistant bacteria (Afacan et al., 2012; Brogden, 2005; 
Fernandez et al., 2012; Kindrachuk et al., 2012; Lynn et al., 2011).  Marr et al showed that 
antimicrobial peptides can include numerous bacterial cellular targets (Marr et al., 2006).  
Previous studies have also shown that some cationic peptides have anticancer properties, which 
may be due to the negative charge in the plasma membrane, in a broad spectrum screening of 
cancer cell types (Andres & Dimarcq, 2005; Emelianov, 2012; Schweizer, 2009; Slaninova et al., 
2012; Yeung et al., 2011).  
 
1.5.1 Application of Therapeutics Peptides in Cancer Therapy 
Most currently used anticancer treatments are specific and have significant side-effects. 
Therapeutic peptides are widely used in anticancer therapy, and can help to prevent some of these 
side effects (Schmidt & Wittrup, 2009; Zwaveling et al., 2002).  In the last two decades, 
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researchers have developed peptides capable of eliciting therapeutic responses in cells and the 
contact of these peptides with proteins could result in useful therapeutic molecules (Bidwell & 
Raucher, 2009; Lien & Lowman, 2003). 
 
The studies conducted by Alder et al have shown that therapeutic peptides have no effect on 
normal pancreatic cells.  This was proved through studies conducted using penetration fused 
PNC2 and PNC7 peptides in human HT-1080 fibrosarcoma cells and pancreatic cancer cells 
(Adler et al., 2008).  This work was extended by Kanovsky et al who found that peptide-treated 
cells were no longer tumorigenic when injected into nude mice (Kanovsky et al., 2003).  Another 
study explored the possibility that peptides can inhibit cell proliferation in breast cancer cell lines, 
such as MDA-MB-468, MCF-7 and MDA-MB-157; however, peptides had no effect on the 
normal breast cell line MCF-10-2A (Dutoit et al., 2002). 
 
A review article published by Bidwell and Raucher showed that therapeutic peptides can be 
developed for inhibition or reactivation of a variety of important signaling molecules.  It also 
explained that therapeutic peptides can be very specific to target proteins in cancerous cell types, 
suggesting that therapeutic peptides have a promising future in cancer therapy (Bidwell & 
Raucher, 2009).  
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1.5.2 Advantages and Disadvantages of Peptides in Drug Therapy 
Peptides have several advantages over proteins and antibodies.  Synthetic therapeutic peptides are 
generally less immunogenic than recombinant proteins and antibodies.  They are less costly to 
manufacture, can be stored at room temperature due to their greater stability, have reduced 
potential for interaction with the immune system and are superior at organ or tumor penetration 
because of their small size.  Therapeutic peptides can be used in place of traditional medicines. A 
peptide is the smallest functional part of a protein and provides efficacy, selectivity and 
specificity (Bidwell, 2012; Hummel et al., 2006).  The degradation products of peptides are 
amino acids, which minimises the risk of systemic toxicity because peptides have a short half-life 
and can easily accumulate in tissues (Loffet, 2002).  
 
Therapeutic peptides have great potential as anticancer agents as they can be easily designed to 
target any protein of interest Peptides are easily produced and their sequence can be modified 
using chemical synthesis or molecular biology techniques.  Therefore, peptide delivery vectors 
are important for this new and very promising class of anticancer agents (Hruby, 2002). 
 
Although therapeutic peptides have numerous advantages, their utility for cancer therapy is 
limited due to poor pharmacokinetic parameters and tumor deposition (Vlieghe et al., 2010).  
Peptides rapidly degrade in circulation and their impermeability to cancer cell membranes makes 
their use in cancer therapy difficult (Pichereau & Allary, 2005).  Studies have shown that 
application of peptides in cancer therapy can be successful with the use of non-natural amino 
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acids or macromolecular carriers and cell penetrating peptides (Latham, 1999; Pichereau & 
Allary, 2005; Sato et al., 2006). 
 
1.6 Application of Digital Signal Processing for Computational Analysis of Proteins 
It is generally recognised that the relationship between a protein's structure, its biological 
function and its abilities to bind to a specific ligand, can be enunciated in terms of a multistage 
process which involves specific bio-recognition, chemical binding and energy transfer.  Property-
pattern algorithmic procedures are based on the representation of the primary structure of a 
protein as a numerical series by assigning a numerical value of a physicochemical parameter to 
each amino acid (Cosic, 1994b; Cosic, 1995).  
 
1.6.1. Quantitative Structure-Activity Relationship (QSAR) 
Quantitative Structure-Activity Relationship (QSAR) methods are used to develop correlations 
between biological activity and physicochemical properties of a set of molecules. It describes the 
main parameters used to quantify physicochemical properties in terms of the general concepts of 
electronic, steric and hydrophobic effects (Taboureau et al., 2006; Taboureau, 2010).  A QSAR 
attempts to find consistent relationships between the variations in the values of molecular 
properties and the biological activity for a series of compounds so that these "rules" can be used 
to evaluate new chemical entities (Taboureau, 2010). 
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A QSAR generally takes the form of a linear equation. 
Biological Activity = Const + (C1  P1) + (C2  P2) + (C3  P3) + ... 
 
Where the parameters P1 through Pn are computed for each molecule in the series and the 
coefficients C1 through Cn are calculated by fitting variations in the parameters and the 
biological activity.  These relationships are generally discovered through the application of 
statistical techniques (Taboureau, 2010).  
 
QSAR has shown promising results in the optimization and discovery of peptide candidates 
(Taboureau, 2010).  In silico approaches based on computer-aided design and quantitative 
structure–activity relationship (QSAR) analysis can rationalize the design of potent therapeutic 
Antimicrobial peptides (AMPs) (Cherkasov & Jankovic, 2004; Taboureau, 2010).  The main idea 
behind QSAR is that any chemical sequence or structure can be described with measured or 
calculated physico-chemical parameters, also called descriptors, and correlated to their respective 
biological activity using diverse mathematical models.  Then, these models can be used for the 
prediction of AMP analogues with a potentially higher biological activity QSAR model and with 
better activity; and optimization of the lead compound to reduce toxicity and increase selectivity 
(Dudek et al., 2006; Taboureau, 2010).  Currently, QSAR studies can provide the means of rapid 
design and virtual screening of combinatorial anti-infective libraries, as well as for rational data 
mining for novel antibiotic candidates (Cherkasov & Jankovic, 2004).  
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1.6.2 The Resonant Recognition Model (RRM) 
The Resonant Recognition Model (RRM) interprets the linear information of a protein sequence 
using digital signal analysis (Cosic, 1994b; Cosic, 1995).  The RRM concept is based on the 
finding that there is a significant correlation between spectra of the numerical representation of 
the amino acids and their biological activity.  It is assumed that proteins with the same biological 
function or interactive activity have the same periodic components in the distribution of 
delocalized electron energies along the protein molecule.  It was found that the RRM frequencies 
represent the characteristic features of proteins' biological functions or interactions (Cosic, 
1994b; Cosic, 1995; Pirogova et al., 2002).  It is proposed that these characteristic frequencies 
(RRM frequencies) are relevant parameters for mutual recognition between bio-molecules, and 
are significant in describing the selectivity of interaction between proteins and their substrates or 
targets but are not chemical binding (Cosic & Hearn, 1991; Cosic et al., 1991; Cosic, 1995)  
 
The RRM concept was used to predict the hot spot amino acid distribution in primary sequences 
of the neuropeptide Y family. The study concluded that for the prediction of hot spots, the set of 
amino acid residues in the N- and C- terminal halves must be conserved equally (Arap et al., 
1998b).  The Wavelet Transform (WT) was introduced into the RRM to enable researchers to 
predict locations of protein active/binding sites directly from analysis of a protein primary 
sequence (de Trad et al., 2000).  The incorporation of the WT into the RRM was successful for 
the selected protein examples (Cosic et al., 1994; de Trad et al., 2000; de Trad et al., 2002). 
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1.6.2.1 The application of RRM in The Design of Short Peptide Analogues 
The RRM is based on the representation of a protein's primary structure as numerical series by 
assigning a physical parameter value to each amino acid relevant to the protein's biological 
activity.  The parameter employed in these studies, i.e. electron-ion interaction potential (EIIP) 
(Veljkovic & Slavic, 1972) describes a physicochemical property of amino acids (the energy 
states of valence electrons which are important for interaction between molecules) within a 
protein sequence.  By assigning the EIIP values to the corresponding amino acid in the protein 
sequence the original protein is converted into the numerical sequence.  The obtained numerical 
series can then be analysed by discrete Fourier transformation, and converted into a discrete 
spectrum, which carries the same information content about the arrangement of the amino acids 
in the sequence as the original numerical sequence (Cosic, 1994b; Cosic, 1997; Mishra et al., 
2006; Pirogova et al., 2002).  Comparative analyses of several hundred proteins and their 
biological function have shown that: (i) each functional group of proteins exhibits at least one 
characteristic frequency in their Fourier spectra; and (ii) proteins and their receptors have the 
same characteristic frequency with opposite phases at this frequency (Cosic et al., 1994; Cosic, 
1997; Cosic & Pirogova, 2007).  Hence, from corresponding Fourier Transformation for a 
particular protein, the amplitude and phase for the specific characteristic frequency can be 
calculated. 
 
Determination of the characteristic frequency and phase for a selected protein sequence is 
essential for de novo design of bioactive peptide analogues, which can mimic the biological 
activity of a selected parent protein sequence (Cosic et al., 1994; Cosic, 1997; Cosic & Pirogova, 
2007).  For this design, it is possible to determine the RRM characteristic frequency from the 
analysis of proteins' power spectra.  In addition, the corresponding phase for the particular 
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frequency can be identified from the analysis of their phase spectra.  Amino acid sequences (short 
peptides) having specific characteristics related to the proteins' biological function can be 
designed on the basis of the determined RRM characteristic frequencies and phases for a 
particular group of protein sequences.  Hence, the designed RRM peptide is expected to exhibit 
the desired biological activity (Cosic & Hearn, 1991; Cosic et al., 1994; Cosic, 1997; Cosic & 
Pirogova, 2007). 
 
Furthermore, the RRM approach was applied to structure-function analysis of basic fibroblast 
growth factor (bFGF) and for analysis of HIV envelope proteins (Cosic et al., 1994; Krsmanovic 
et al., 1998).  Property-pattern characteristics for biological activity and receptor recognition for a 
group of FGF-related proteins were defined and then used to aid the design of a set of peptides 
which can act as bFGF antagonists.  Molecular modelling techniques were then employed to 
identify the peptide within this set with the greatest conformational similarity to the putative 
receptor domain of bFGF (Cosic et al., 1994). 
 
The interaction between HIV virus envelope proteins and CD4 cell surface antigen has a central 
role in the process of virus entry into the host cell.  Thus, blocking the interaction between the 
envelope glycoproteins and CD4 surface antigen, known to be the HIV receptor, should inhibit 
infection.  For this purpose, six peptides, each of 20 amino acids in length, were designed using 
the RRM methodology.  The activities of the designed peptides were evaluated experimentally to 
validate the RRM computational predictions. The results obtained showed significant cross-
reactivity to the polyclonal antibodies raised against peptides that share at least one characteristic 
frequency and phase at this frequency (Krsmanovic et al., 1998). 
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Pirogova et al also determined oncogenes‘ characteristic frequency and functional active sites; 
and performed the design of the peptide analogous using Fourier transform and continuous 
wavelet transform analysis methods.  The results provided new insights into the structure–
function relationships of the analysed oncogene protein family (Pirogova et al., 2002). 
 
1.6.2.2 de novo Designof Peptide with Anticancer Activity Using The RRM 
Interleukin-12 (IL12) has therapeutic potential in cancer and infectious diseases. It is a key 
regulator of cell mediated immunity and has an essential role in the interaction between the innate 
and adaptive arms of immunity (Gately et al., 1992).  Recently, the studies conducted by 
Pirogova et al  have shown that RRM approach can be successfuly used for the structure -
function analysis of IL-12 proteins and the computational design of a short bioactive peptide 
possessing IL12-like activity.  Experimental studies were conducted to analyse the toxic 
antitumor activity.  In this experiment, thirteen IL-12 proteins from different origins were 
analysed using the RRM.  Mouse IL-12 was selected as a parental protein to design a bioactive 
peptide having IL12-like activity.  A negative control peptide analogue (RRM-C), which has a 
different ―inactive‖ frequency and phase was also designed and used for biological cytotoxicity 
assays (Pirogova et al., 2011).  The cytotoxic effects of RRM IL-12 were evaluated on mouse 
cancer and normal cells. Phase contrast microscopy was used to evaluate the detachment of a 
large number of cells from the adherent confluent layer of treated cell cultures versus the 
untreated cultures.  Confocal immunoflurescence microscopy was used to evaluate the cellular 
cytotoxicity by detecting apoptosis and necrosis.  The results obtained indicated that RRM 
designed peptide analogue can induce cytotoxic effects on cancer cells only (Pirogova et al., 
2010; Pirogova et al., 2011) 
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1.7 Cell Death 
Cell death occurs either by apoptosis and necrosis.  Apoptosis is a morphologically distinct form 
of cell death. It is a vital component of various processes including normal cell turnover, proper 
development and functioning of the immune system, hormone-dependent atrophy, embryonic 
development and chemical-induced cell death.  Inappropriate apoptosis leads to human 
conditions such as neurodegenerative diseases, ischemic damage, autoimmune disorders and 
many types of cancer (Debnath et al., 2005; Kerr, 2002).  Apoptosis is a homeostatic mechanism 
and occurs during development and aging.  It also occurs as a defence mechanism and is involved 
in immune reactions as well as the cell damage caused by a disease or a noxious agent (Norbury 
& Hickson, 2001).  Although pathological and physiological stimuli can elicit apoptosis, only 
few cells will die in response to the same stimuli. Irradiation or drugs used for cancer 
chemotherapy can cause DNA damage in some cells by causing apoptotic death through the p 53 
pathway (Elmore, 2007; Zeiss, 2003). 
 
Another form of cell death, known as necrosis where the cells die uncontrollably and that may 
lead to inflammations, lysis of cells and to possibility serious health problems. Necrosis is a 
passive, toxic process that causes an energy-independent mode of cell death (Elmore, 2007).  The 
morphological changes that occur with necrosis are: cell swelling; cytoplasmic vacuoles; 
distended endoplasmic reticulum; cytoplasmic blebs; condensed; swollen or ruptured 
mitochondria; desegregation and detachment of ribosomes; disrupted organelle membranes; 
swollen and ruptured lysosomes; and finally disruption of the cell membrane (Majno & Joris, 
1995).  This loss of cell membrane causes release of the cytoplasmic content into surrounding 
tissue which triggers cell inflammation (Kerr et al., 1972; Majno & Joris, 1995).  
 38  
 
The process of apoptosis and necrosis can happen independently, sequentially or simultaneously. 
Depending on the tissue type, the nature of the cell death signal, physiological conditions and the 
developmental stage of the tissue determines the type of cell death (Li et al., 2005a; Zeiss, 2003).  
Table 1.3 shows the comparison of morphological features of apoptosis and necrosis where the 
pyknosis and karyorrhexis are also part of the cytomorphological change in the necrosis process 
(Elmore, 2007). 
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Table 1.3.  comparison of morphological features of apoptosis and necrosis (Elmore, 2007). 
 
Apoptosis Necrosis 
Single cells or small clusters of cells Often contiguous cells 
Cell shrinkage Cell swelling 
Pyknosis and karyorrhexis Karyolysis, pyknosis, and karyorrhexis 
Intact cell membrane Disrupted cell membrane 
Cytoplasm retained in apoptotic bodies Cytoplasm released 
No inflammation Inflammation usually present 
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1.7.1 Morphological Features of Apoptosis 
Healthy cells control their own growth and cells die in response to a variety of stimuli. The 
complex process of cell division is usually strictly controlled.  During apoptosis (programmed 
cell death) genetically determined cell death occurs in regulated, controlled manner.  The process 
of apoptosis is an energy-dependent biochemical mechanism which plays an important role in the 
proper development and functioning of the immune system, normal cell turnover, embryonic 
development, hormone-dependent atrophy and chemical-induced cell death (Norbury & Hickson, 
2001).  When cells experience apoptosis, a number of distinctive changes occur in the cell.  In the 
initial stages of apoptosis a group of cysteine proteases known as caspases are activated and a 
complex cascade of events that link the initiating stimuli to the final demise of the cell (Lordan et 
al., 2009).  The process of apoptosis maintains cell populations in tissues and is characterized by 
distinct morphological changes that occur from the plasma membrane to the nucleus of the cell. 
When the cell receives stimulus, it shrinks, the cytoplasm becomes dense, the organelles appear 
tightly packed, chromatin undergoes condensation into compact patches against the nuclear 
envelope (pyknosis) and it becomes discontinuous.  The DNA will be fragmented (karyorrhexis) 
and the cell breaks apart into several vesicles which are then phagocytosed. Apoptosis takes place 
rapidly and its products are quickly removed and do not produce anti-inflammatory cytokines 
(Häcker, 2000).  The process of apoptosis does not cause any inflammatory reaction because no 
cellular constituents are released into the surrounding interstitial tissue (Kurosaka et al., 2003; 
Savill et al., 2002).  However, inappropriate apoptosis either too little or too much may lead to 
neurodegenerative diseases, ischemic damage, autoimmune disorders and many types of cancer 
(Elmore, 2007). 
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1.7.2 Mechanism of Apoptosis 
Apoptosis is a complex process involving an energy dependent cascade of molecular events. Two 
main  Apoptotic pathways are the extrinsic or death receptor pathway and the intrinsic or 
mitochondrial pathway.  Igney and Krammer have stated that these two pathways are linked 
together and the molecules in one pathway can influence the other pathway (Igney & Krammer, 
2002).  T-cell mediated cytotoxicity and perforin-garnzyme-dependent killing of the cell are 
included under an additional pathway which drives the mechanism of Apoptosis (Figure 1.2).  
The three pathways such as extrinsic, intrinsic and perforin/grandzyme B pathway congregate on 
the same pathway known as execution pathway. Processes such as DNA fragmentation, 
degradation of cytoskeletal and nuclear proteins, cross linking of proteins and formation of 
apoptotic bodies can activate the execution pathway.  Granzyme A pathway is activated in 
parallel via single stranded DNA damage (Martinvalet et al., 2005).  
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Figure 1.  2.   Schematic representation of the apoptotic pathway showing different apoptotic 
pathways such as extrinsic, intrinsic and execution pathways (Elmore, 2007). 
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1.7.2.1 Extrinsic Pathway 
Transmembrane receptor mediated interactions mediate the extrinsic pathway.  These include 
Tumor necrosis factor (TNF) receptor family named as death receptors (Locksley et al., 2001).  
The members of the TNF receptor family have a cytoplasmic domain of 80 amino acids named as 
death domains and these death domains play a major role in transmitting the death signal from 
the cell surface to the intracellular signalling pathways (Ashkenazi & Dixit, 1998).  There is 
evidence to suggest that FasL/FasR, TNF-α/TNFR1, Apo3L/DR3, Apo2L/DR4 and Apo2L/DR5 
may be the best characterised ligands associated with inducing apoptosis (Ashkenazi & Dixit, 
1998; Chicheportiche et al., 1997; Peter & Krammer, 1998; Rubio-Moscardo et al., 2005; 
Suliman et al., 2001).   Apoptotic signalling pathways are illustrated in Figure 1.3. 
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Figure 1. 3.  The intrinsic and extrinsic pathways of apoptosis (Green, 2011). 
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The specific steps in the Fatty acid synthetase ligand (FasL) and TNF-α pathways are the best 
defined of all extrinsic apoptotic pathways.  These models showed homologous trimeric ligands 
that bind to receptor clusters.  Once the ligand binds to its receptor, cytoplasmic adapter proteins 
are recruited and their death effector domains also bind to their corresponding receptors.  The 
adapter protein Fas-associated death domain (FADD) binds to the Fas ligand and receptor.  
Similarly, the adapter protein TNF receptor-associated death domain (TRADD) binds to the TNF 
ligand and leads to the recruitment of FADD and Receptor-interacting protein (RIP) (Hsu et al., 
1995; Wajant, 2002).  FADD then associates with procaspase-8 via dimerization of the death 
effector domain.  At this stage, the formation of death-inducing signalling complex (DISC) 
stimulates procaspase-8 autocatalysis, which activates apoptosis (Kischkel et al., 1995).  Death 
receptor-mediated apoptosis can be inhibited by FLICE-inhibitory protein (c-FLIP) which binds 
to FADD and caspase-8 (Kataoka et al., 1998; Scaffidi et al., 1999).  TOSO can also regulate 
apoptosis by blocking caspase-8 processing during Fas-induced apoptosis in T-cells (Hitoshi et 
al., 1998).  Table 1.4 shows the major proteins that play a role in extrinsic signalling pathways.  
The table also includes the common abbreviations and some of the alternative nomenclature used 
for each protein. 
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Table 1.4.  Extrinsic pathway proteins, abbreviations, and alternate nomenclature (Artimo et al., 
2012; Prasad et al., 2009). 
Abbreviation Protein Name Select Alternate Nomenclature 
TNF-α Tumor necrosis factor 
alpha 
TNF ligand, TNFA, cachectin 
TNFR1 Tumor necrosis factor 
receptor 1 
TNF receptor, TNFRSF1A, p55 TNFR, 
CD120a 
FasL Fatty acid synthetase 
ligand 
Fas ligand, TNFSF6, Apo1, apoptosis antigen 
ligand 1, CD95L, CD178, APT1LG1 
FasR Fatty acid synthetase 
receptor 
Fas receptor, TNFRSF6, APT1, CD95 
Apo3L Apo3 ligand TNFSF12, Apo3 ligand, TWEAK, DR3LG 
DR3 Death receptor 3 TNFRSF12, Apo3, WSL-1, TRAMP, LARD, 
DDR3 
Apo2L Apo2 ligand TNFSF10, TRAIL, TNF-related apoptosis 
inducing ligand 
DR4 Death receptor 4 TNFRSF10A, TRAILR1, APO2 
DR5 Death receptor 5 TNFRS10B, TRAIL-R2, TRICK2, KILLER, 
ZTNFR9 
FADD Fas-associated death 
domain 
MORT1 
TRADD TNF receptor-
associated 
death domain 
TNFRSF1A associated via death domain 
RIP Receptor-interacting 
protein 
RIPK1 
DED Death effector domain Apoptosis antagonizing transcription factor, 
CHE1 
caspase-8 Cysteinyl aspartic 
acid-protease 8 
FLICE, FADD-like Ice, Mach-1, Mch5 
c-FLIP FLICE-inhibitory 
protein 
Casper, I-FLICE, FLAME-1, CASH, CLARP, 
MRIT 
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1.7.2.2 Intrinsic Pathway 
Apoptosis can also be mediated by non-receptor mediated stimuli that produce intracellular 
signals.  These signals act directly on intracellular targets and lead to mitochondrial-initiated 
events in a positive or negative fashion.  In negative signalling, different processes, such as 
withdrawal of factors, loss of apoptotic suppression and subsequent apoptosis activation, may fail 
to suppress death programs and trigger apoptosis.  In contrast, positive stimuli such as radiation, 
toxins, hypoxia, hyperthermia, viral infections and free radicals, may actively induce apoptosis.  
A positive or negative stimulus can change the inner mitochondrial membranes and cause the 
formation of mitochondrial permeability transition pores.  The pores release two main groups of 
pro-apoptotic proteins that are sequestered within the intermembrane space into the cytosol 
(Saelens et al., 2004).  Apoptotic signalling pathways are illustrated in Figure 1.3. 
 
The first group of proteins, which is responsible for activating the caspase-dependent 
mitochondrial pathway, consists of cytochrome c, Smac/DIABLO and serine protease 
HtrA2/Omi (Du et al., 2000; Garrido et al., 2006; van Loo et al., 2002a).  When the caspase-
dependent mitochondrial pathway is activated, cytochrome c binds and activates Apaf-1 and 
procaspase-9 to form an ―apoptosome‖ (Chinnaiyan, 1999; Hill et al., 2004).  Procaspase-9 then 
clusters to form activated caspase-9 and promote apoptosis.  Smac/DIABLO and HtrA2/Omi 
requires inhibition of IAP (inhibitor of apoptosis proteins) activity to initiate apoptosis 
(Schimmer, 2004; van Loo et al., 2002b).  Moreover, other mitochondrial proteins that interact 
with and inhibit IAP were also identified.  However, gene knockout experiments have suggested 
that IAP binding alone may not be a sufficient proof for a mitochondrial protein to be considered 
―pro-apoptotic‖ (Ekert & Vaux, 2005). 
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The second group of pro-apoptotic proteins from the mitochondria are Apoptosis Inducing Factor 
(AIF), endonuclease G and Caspase-Activated DNAse (CAD).  When a cell has committed to 
die, AIF translocates into the nucleus and causes DNA fragmentation and condensation of 
peripheral nuclear chromatin (Joza et al., 2001).  This nuclear condensation is called ―stage I‖ 
condensation (Susin et al., 2000).  Endonuclease G also translocates into the nucleus and cleaves 
nuclear chromatin to produce oligonucleosomal DNA fragments.  There is evidence to suggest 
that both AIF and endonuclease G function in a caspase-independent manner (Joza et al., 2001; 
Li et al., 2001b).  Subsequently, the CAD protein is cleaved by caspase-3 and then released from 
the mitochondria.  CAD then translocates into the nucleus where it breaks down the 
oligonucleosomal DNA fragments to allow better chromatin condensation (Enari et al., 1998) and 
begin ―stage II‖ condensation (Susin et al., 2000).  Table 1.5 shows the major proteins that play a 
role in intrinsic pathway signalling pathways.  The table also includes the common abbreviations 
and some of the alternative nomenclature used for each protein. 
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Table 1.5.  Intrinsic pathway proteins, abbreviations, and alternate nomenclature (Artimo et al., 
2012; Prasad et al., 2009). 
Abbreviation Protein Name Select Alternate Nomenclature 
 
Smac/DIABLO 
 
Second mitochondrial activator of 
caspases/direct IAP binding protein 
with low PI 
 
 
None 
HtrA2/Omi High-temperature requirement Omi stress regulated 
endoprotease, serine protease 
Omi 
protein A2 
 
IAP Inhibitor of Apoptosis Proteins XIAP, API3, ILP, HILP, 
HIAP2, cIAP1, API1, MIHB,  
NFR2-TRAF signalling 
complex protein 
 
Apaf-1 Apoptotic protease activating factor 
 
APAF1 
Caspase-9 Cysteinyl aspartic acid-protease-9 
 
ICE-LAP6, Mch6, Apaf-3 
AIF Apoptosis Inducing Factor Programmed cell death protein 
8, mitochondrial 
 
CAD Caspase-Activated DNAse CAD/CPAN/DFF40 
 
Bcl-2 B-cell lymphoma protein 2 Apoptosis regulator Bcl-2 
 
Bcl-x BCL2 like 1 BCL2 related protein 
 
Bcl-XL BCL2 related protein, long isoform 
 
BCL2L protein, lon form of 
Bcl-x 
Bcl-XS BCL2 related protein, short isoform 
 
 
Bcl-w BCL2 like 2 protein Apoptosis regulator BclW 
 
BAG BCL2 associated athanogene BAG family molecular 
chaperone regulator 
 
Bcl-10 B-cell lymphoma protein 10 mE10, CARMEN, CLAP, 
CIPER 
 
BAX BCL2 associated X protein Apoptosis regulator BAX 
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BAK BCL2 antagonist killer 1 BCL2L7, cell death inhibitor 1 
 
BID BH3 interacting domain death agonist 
 
p22 BID 
BAD BCL2 antagonist of cell death BCL2 binding protein, BCL2L8, 
BCL2 binding component 6, 
BBC6, Bcl-XL/Bcl-2 associated 
death promoter 
 
BIM BCL2 interacting protein BIM BCL2 like 11 
 
BIK BCL2 interacting killer NBK, BP4, BIP1, apoptosis 
inducing NBK 
 
Blk Bik-like killer protein B lymphoid tyrosine kinase, 
p55-BLK, MGC10442 
 
Puma BCL2 binding component 3 JFY1, PUMA/JFY1, p53 up-
regulated modulator of  
apoptosis 
 
Noxa 
14-3-3 
Phorbol-12-myristate-13-acetate-
induced protein 1 
Tyrosine 3-
monooxygenase/tryptophan 
5-monooxygenase activation protein 
 
PMA induced protein 1, APR 
14-3-3 eta, theta, zeta, beta, 
epsilon, sigma, gamma 
Aven Cell death regulator Aven None 
 
Myc Oncogene Myc c-myc, Myc proto-oncogene 
protein 
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1.7.2.3 Execution Pathway  
Execution pathway is the final pathway of apoptosis which meets the extrinsic and intrinsic 
pathways at the same point.  It begins by the activation of the execution caspases which in turn 
activates the cytoplasmic endonucleases and proteases.  Cytoplasmic endonuclease degrades 
nuclear materials whereas proteases degrade nuclear and cytoskeletal proteins.  Caspases such as 
caspase-3, caspase-6 and caspase-7 function as effector or executioner caspases and ultimately 
cause the morphological and biochemical changes in apoptotic cells (Slee et al., 2001).   
 
Caspase-3 is most important of the executioner caspases and is activated by any of the initiator 
caspases which will activate the endonuclease CAD.  In apoptotic cells, CAD is released from the 
Inhibitor of CAD (ICAD) by the activated caspase 3.  CAD causes the chromatin condensation 
by degradation of chromosomal DNA leading to disruption of cytoskeleton, cell division and 
signal transduction occurs.  The appearance of phosphotidyl serine on the outer leaflet of 
apoptotic cells and the phagocytic uptake of apoptotic cells is the last component of the apoptosis 
(Sakahira et al., 1998).  Proapoptotic and antiapoptotic signalling pathways regulate the net 
outcome of signalling through the core apoptotic machinery (Herr & Debatin, 2001).  Table 1.6 
shows the major proteins that play a role in the execution pathway.  The table also includes the 
common abbreviations and some of the alternative nomenclature used for each protein.   
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Table 1.6.  Execution pathway proteins, abbreviations, and alternate nomenclature (Artimo et al., 
2012; Prasad et al., 2009). 
Abbreviation Protein name Select alternate nomenclature 
Caspase-3  Cysteinyl aspartic acid-protease-3  CPP32, Yama, Apopain, SCA-1, LICE  
Caspase-6  Cysteinyl aspartic acid-protease-6  Mch-2  
Caspase-7  Cysteinyl aspartic acid-protease-7  Mch-3, ICE-LAP-3, CMH-1  
Caspase-10  Cysteinyl aspartic acid-protease-10  Mch4, FLICE-2  
PARP  Poly (ADP-ribose) polymerase  ADP ribosyl transferase, ADPRT1, 
PPOL  
Alpha fodrin  Spectrin alpha chain  Alpha-II spectrin, fodrin alpha chain  
NuMA  Nuclear mitotic apparatus protein  SP-H antigen  
CAD  Caspase-activated DNAse  DNA fragmentation factor subunit beta, 
DFF-40, caspase-activated nuclease, 
CPAN  
ICAD  Inhibitor of CAD  DNA fragmentation factor subunit alpha, 
DFF-45  
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1.7.3 Apoptosis and Tumorigenesis 
Deficient apoptosis allows genetically unstable cells to survive resulting in tumor pathogenesis 
(Friesen et al., 1996).  Furthermore, it has been found that deregulated apoptosis facilitates 
metastatic chemo- and radio-resistance, and increases the threshold for cell death (Brown & 
Wouters, 1999; Heerema et al., 1999; Villunger & Strasser, 1998).  As early as the 1970‘s, Kerr 
et al had linked apoptosis to the elimination of potentially cancer cells, hyperplasia and tumor 
progression (Kerr et al., 1972).  Thus, reduced apoptosis or its resistance plays a vital role in 
carcinogenesis.  There are many ways a cancer cell can acquire reduction in apoptosis or 
apoptosis resistance. In general, the mechanisms by which evasion of apoptosis occurs can be 
broadly divided into: 1) disrupted balance of pro-apoptotic and anti-apoptotic proteins by 
increase pro-apoptotic proteins levels, modulate anti-apoptotic proteins,  2) reduced caspase 
function and  3) impaired death receptor signalling (Wong, 2011).  Figure 1.4 shows summarises 
of the mechanisms that contribute to evasion of apoptosis and carcinogenesis. 
 54  
 
 
Figure 1.4.  Mechanisms contributing to evasion of apoptosis and carcinogenesis (Wong, 2011). 
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1.7.4 Apoptosis and Cancer Therapy 
Most anti-cancer therapies currently in use were developed using empirical screens designed to 
identify drugs that specifically kill cancer cells.  Most studies focused on the pharmacological 
mechanisms to determine intracellular targets, cellular effects or resistance mechanisms (Dive & 
Hickman, 1991; Kaufmann, 1989; Lowe & Lin, 2000).  Previous studies have shown that 
anticancer therapies can induce apoptosis, but treatment programs also decrease sensitivity to 
therapy and produce multi-drug resistance over time (Dive & Hickman, 1991; Lowe et al., 1993; 
Schmitt & Lowe, 1999). 
Numerous studies have indicated that anti-cancer therapies induce apoptosis not only in tumor 
cells but also in normal cells, which contribute to the side effects associated with cancer therapy 
(Clarke et al., 1993; Lowe et al., 1993).  Studies using animal models suggested the mouse 
thymus, bone marrow, intestine and spleen were affected following exposure to moderate doses 
of radiation and chemotherapy.  On the other hand, p53-knockout mice showed a significant 
reduction in apoptosis and cell loss following radiation or chemotherapy.  These animals were 
also resistant to lethal doses of radiation (Clarke et al., 1993; Clarke et al., 1994; Dive & 
Hickman, 1991; Lowe et al., 1993; Merritt et al., 1994; Westphal et al., 1997). 
 
1.7.5 Proapoptotic Signalling in Cancer Therapy 
1.7.5.1 Caspases 
Caspases act as effector molecules in the drug-induced apoptosis and different forms of cell 
death.  The ability of anticancer agents to activate caspases is a critical determinant of sensitivity 
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or resistance to cytotoxic treatment (Herr & Debatin, 2001; Kaufmann & Earnshaw, 2000).  
Previous studies have shown that inhibition of caspase activation may be an important factor in 
chemoresistance (Herr & Debatin, 2001; Kaufmann & Earnshaw, 2000), and low expression 
levels of caspases may simply impair activation of caspases (Jänicke et al., 1998; Joseph et al., 
1999; Yang et al., 2005).  The frameshift mutation within the exon 3 of the caspase-3 gene causes 
lack of caspase-3 expression in MCF-7 breast carcinoma cells and  can be sensitized by 
transfection of pro-caspase-3 toward treatment with cytotoxic drugs (Jänicke et al., 1998; Yang et 
al., 2005).  Hypermethylation of promoter and of regulatory sequences of the caspase-8 gene are 
examples of epigenetic alterations which cause impairement of caspase expressions in different 
tumors derived from Ewing tumors, neuroblastoma, small lung cell carcinoma and malignant 
brain tumors in primary tumor samples both in vitro and in vivo (Fulda et al., 2001; Teitz et al., 
2000). 
 
1.7.6 Antiapoptotic Signalling in Cancer Therapy 
1.7.6.1 Bcl-2 proteins 
Bcl-2 family proteins are located in intracellular membranes, particularly the mitochondrial 
membrane, and play a vital role in the regulation of mitochondrial pathways (Antonsson & 
Martinou, 2000).  At least 15 Bcl-2 proteins have been identified in mammalian cells (Gross et 
al., 1999).  They include anti-apoptotic members such as Bcl-2, Bcl-XL and Mcl-1, as well as 
pro-apoptotic molecules such as Bax, Bek, Bad and BH3 domain-only molecules.  These 
molecules link the death receptor pathway to the mitochondrial pathway (Antonsson & Martinou, 
2000).  The pro-apoptotic Bcl-2 proteins, along with multidomain Bax, can translocate from the 
cytoplasm to the outer mitochondrial membrane once apoptosis is induced.  They then cause the 
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release of cytochrome c by oligomerizing to form a pore-like structure in the outer mitochondrial 
membrane (Cheng et al., 2001).  Bcl-2 or Bcl-XL anti-apoptotic proteins sequester BH3-domain 
proteins in stable mitochondrial complexes; thus preventing the stimulation and translocation of 
Bax or Bak to the mitochondria (Cheng et al., 2001), and blocking apoptosis by preventing the 
release of cytochrome c from the mitochondrial channel (Kroemer & Reed, 2000; Martinou & 
Green, 2001).  It was found that changing the expression level of Bcl-2 proteins, whether they are 
pro-apoptotic or anti-apoptotic, can change drug response in experimental systems (Minn et al., 
1995; Thomas et al., 2013).  In addition, further studies have suggested that a high level of anti-
apoptotic Bcl-2 proteins confers a chemoresistant phenotype on a spectrum of cancer cells, 
including multiple myeloma, neuroblastoma, malignant brain tumors and prostate carcinoma 
(Bargou et al., 1995; Campos et al., 1993; Prokop et al., 2000; Reed, 1999).  Similarly, poor 
response to chemotherapy and decreased cell survival have been observed in breast or colorectal 
carcinoma with reduced BAX levels.  (Sturm et al., 1999).  On the other hand, it has been found 
that high BAX expression correlated with chemotherapy response in several types of cells in vivo 
(Sturm et al., 2001).   
 
1.7.6.2 Inhibitor of Apoptosis Proteins (IAPs) 
Inhibitor of apoptosis proteins (IAPs) directly block caspase-3, caspase-7 and caspase-9 
activation (Deveraux & Reed, 1999; Holcik & Korneluk, 2001; Reed & Bischoff, 2000).  IAP 
members, such as survivin, are also involved in the regulation of mitosis (Reed & Bischoff, 
2000).  Several studies suggested that IAPs inhibit apoptosis in response to cytotoxic therapy 
(Adida et al., 1998a; Adida et al., 2000; Li et al., 2001a; Tamm et al., 2000).  XIAP, cIAP1 or 
cIAP2 also inhibit apoptosis in vitro after cisplatin, cytarabine, TRAIL or staurosporine 
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treatment, and after UV-C irradiation (Datta et al., 2000; Suliman et al., 2001).  It has been found 
that an increased level of IAP is linked with poor treatment response in myeloid leukemia, and 
elevated survivin level predicted adverse prognosis in different tumor cells, such as lung, colon, 
esophagus carcinoma and neuroblastoma (Adida et al., 1998b; Adida et al., 2000; Li et al., 
2001a; Tamm et al., 2000). 
 
1.7.7 p53-mediated Apoptosis  
p53 is the first tumor suppressor gene linked to apoptosis and is vital for the proper regulation of 
cell proliferation in multi-cellular organisms (Huang & Strasser, 2000).  It is activated by external 
and internal stress signals and induces cell growth arrest or apoptosis.  p53 also plays an 
important role in cellular processes such as differentiation, DNA repair and angiogenesis, which 
also appear to be vital for tumor suppression.  An advanced tumor stage and poor patient 
prognosis are associated with p53 gene mutations (Vogelstein et al., 2000).  Therefore, cancer 
prevention is dependent on p53 expression levels.  p53 is a short-lived protein under normal 
conditions and the p53 inhibitor Mdm2 (Hdm2 in humans) is largely responsible for maintaining 
p53 homeostasis.  Mdm2 promotes proteasome-mediated degradation of p53 and inhibits its 
transcriptional activity (Gottlieb et al., 2002).  p53 activation leads to cell growth arrest, 
senescence or apoptosis.  It activates specific DNA binding and transcriptional activity through 
protein stabilization that is enhanced by extensive posttranslational modifications and protein-
protein interactions with co-factors.  A majority of cancer cases are caused by misregulation of 
p53 inhibitors (Vogelstein et al., 2000) such as Mdm2 or the E6 protein from HPV, or by 
silencing key p53 co-activators such as ARF (Vogelstein et al., 2000; Vogt Sionov et al., 2001).  
Studies have shown an extensive network of signalling pathways triggered by p53 (Gudkov, 
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2002; Mayo et al., 2002; Vogelstein et al., 2000).  Intrinsic mitochondrial pathways involved in 
apoptosome formation, and the culmination of caspases are also mediated by specific p53-
regulated genes.  p53 can also activate apoptosis using transcription-independent mechanisms 
(Luu & Li, 2003).  Additional studies are underway to understand the determinants of cellular 
growth arrest and apoptosis (Haupt et al., 2003). 
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1.8 Project objectives 
This project aimed to investigate the following:  
1. To apply the RRM approach to the structure-function analysis of selected MYXV 
proteins, and to design a short linear bioactive peptide (RRM-MV) that mimics M-T5 
protein‘s activity. 
2.  To evaluate THE toxic effect of bioactive peptide and negative control peptide RRM-C  
was on transformed human skin cancer and normal skin cell lines. 
3. To evaluate the biological activity of negative control peptides (non-bioactive peptide 
RRM-MV-C and three scrambled negative control peptides MV-C1, MV-C2 and MV-C3) 
on cancer and normal cells in vitro in comparison with the bioactive peptide RRM-MV.   
4. To investigate the possible molecular pathways induced by RRM-MV to promote 
apoptosis process in skin cancer cells. 
5. To investigate the influence of the bioactive peptide RRM-MV on Akt activation in 
mammalian skin cancer and normal cell lines. 
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CHAPTER 2 
 
 Materials and Methods 
 
This chapter describes general methods used in this study.  Specific methods are described in the 
relevant chapter.  All materials used in this study are also listed in this chapter.   
 
2.1 General Procedures  
All glassware used for storage of solutions was washed using Pyroneg detergent, rinsed in tap 
water, with a final rinse in dH2O.  All glassware, micropipettes, solution, pipette tips and 
Eppindorf tubes were sterilised by autoclaving before being used at standard conditions (121°C 
for 20 min).  All solutions were prepared in deionised water (dH2O) filtered through a Millipore 
Milli-Q
®
 water system unless otherwise specified.  All chemicals and reagents used in this study 
were purchased in p.a.  quality, if not stated otherwise.  All solutions from 0.02 μL to 10 mL 
were distributed using Finnpipette micropipettes.  A measuring cylinder was used for all volumes 
above 10 mL.  Hydrochloric acid (HCl) and sodium hydroxide (NaOH) were used to adjust the 
pH. 
 
2.2 General Materials 
A list of software, chemicals, reagents, tissue culture media and reagents, commercial kit, 
antibodies, peptides, consumables and equipment used in this study are included in the following 
section:  
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2.2.1 Software 
Software  Manufacturer 
Microsoft Office 20011 Excel software   Microsoft Corporation, Redmond 
Washington USA 
NIS-Element imaging software Nikon Instruments Inc, Japan 
Quantity One Analysis 4.3.0 software Bio-Rad Laboratories 
SPSS statistical software, version 18.0 SPSS Inc., Chicago, IL, USA 
 
2.2.2 Chemicals and Reagents 
Chemicals and Reagents Manufacturers  
2-mercaptoethanol BioRad Laboratories, USA 
3-4,5-dimethylthiazol-2-yl-2,5-diphenyl 
tetrazolium bromide, MTT 
Sigma-Aldritch Pty.  Ltd., USA 
5-Bromo-4-chloro-3-indolyl phosphate toluidine 
salt/Nitro blue tetrazolium chloride substrate 
solution, BCIP/NBT  
Amresco, USA 
Agarose (DNA Grade)  
Bioline Pty Ltd., Australia 
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Ammonium persulfate, APS 
BioRad Laboratories, USA 
Bis-Acrylamide 
Amresco, USA 
Bromophenol blue 
BDH Chemicals, UK. 
Calcium Chloride, CaCl2  
Merck, USA 
Chemiluminescent HRP reagent 
Millipore, Australia 
Coomassie Brilliant Blue R-250 
Sigma-Aldritch Pty.  Ltd., USA 
Dimethylsulfoxide, DMSO  
Millipore, France 
Ethanol 
BDH Chemicals, Australia 
Ethidium Bromide 
Roche Applied Sciences, Germany 
Ethylenediamine tetra acetic acid, EDTA  
BDH Chemicals, Australia 
Ficol-400 
BDH Chemicals, Australia 
Glacial acetic acid 
BDH Chemicals, Australia 
Glycerol 
 BDH Chemicals, Australia 
Glycine 
BDH Chemicals, Australia 
 64  
 
Hydrochloric acid, HCl 
Ajax Chemicals Ltd., Australia 
Isopropanol 
Ajax Chemicals Ltd., Australia 
Lambda DNA, λDNA  
Promega, USA 
N-(2-Hydroxyethyl) piperazine-N'-(2-
ethanesulfonic acid), HEPES  
BDH Chemicals, Australia 
Orange G Dye  
Sigma-Aldritch Pty.  Ltd., USA 
Phosphate Buffered Saline, PBS  
Oxoid Australia Pty.  Ltd. 
Phosphoric Acid 
Ajax Chemicals Ltd., Australia 
PhosphoSafe™ Extraction reagent  
Novagen, USA 
PI3K-AKT Kinase Inhibitors, LY294002 
Cell Signaling Technology, Inc 
Beverly MA, USA 
Precision Plus Protein™ Kaleidoscope Standards BioRad Laboratories, USA 
Prestoblue
TM
 Cell Viability reagent Invitrogen (Gibco®), USA 
Protease Inhibitor Cocktails  Sigma-Aldritch Pty.  Ltd., USA 
Sodium azide, NaN3  Sigma-Aldritch Pty.  Ltd., USA 
Sodium Chloride, NaCl  BDH Chemicals, Australia 
Sodium Dodecyl Sulphate, SDS  BDH Chemicals, Australia 
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Sodium hydroxide, NaOH BDH Chemicals, Australia 
Sodium Hydroxide, NaOH  BDH Chemicals, Australia 
Tris (hydroxymethyl) aminomethane, Tris Boehringer Mannheim, Germany 
Tris Base Roche Diagnostics, Germany 
Tris-HCl  Roche Diagnostics, Germany 
Trypan Blue  Invitrogen (Gibco®), USA 
Tween® 20  Sigma-Aldritch Pty.  Ltd., USA 
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2.2.3 Tissue Culture Media and Reagents 
 
2.2.4 Commercial Kits 
Commercial Kits Manufacturers 
Cytotoxicity Detection Kit Roche Diagnostics, USA 
Human Apoptosis Protein Array Kit R&D Systems, Minneapolis, MN, 
USA 
Medium Manufacturers 
Fetal bovine serum, FBS Bovogen serumBiologicals, Australia 
HEPES Buffer (1 M)  Invitrogen (Gibco®), USA 
Human melanocyte growth supplement, HMGS  Cascade Biologics, Australia 
Low Serum Growth Supplement, LSGS  Invitrogen (Gibco®), USA 
Medium 106  Invitrogen (Gibco®), USA 
Medium 254 Cascade Biologics, Australia 
Penicillin-Streptomycin Invitrogen (Gibco®), USA 
Roswell Park Memorial Institute medium 1640, RPMI Invitrogen (Gibco®), USA 
Trypsin (4%)  Invitrogen (Gibco®), USA 
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Mycoplasma Detection Kit Invitrogen, USA 
Vybrant Apoptosis Assay kit II Invitrogen, USA 
Wizard® Genomic DNA Purification Kit Promega, Australia 
2.2.5 Antibodies 
Antibodies  Manufacturers 
Alkaline phosphatase-conjugated goat anti-
rabbit polyclonal antibody 
Sapphire Bioscience, Australia 
Anti-phospho-p53 (S46) Antibody R&D Systems, Minneapolis, 
MN, USA 
Monoclonal Anti-human/mouse cleaved caspase-3 
(Asp175)  
R&D Systems, Minneapolis, 
MN, USA 
Rabbit monoclonal p-Akt (Ser-473)  
(D9E) XP antibody  
Cell Signaling Technology, Inc.  
Beverly MA, USA 
Rabbit monoclonal p-Akt (Thr308) (C31E5E) antibody Cell Signaling Technology, Inc.  
Beverly MA, USA 
Rabbit polyclonal Akt (pan) (C67E7) antibody Cell Signaling Technology, Inc.  
Beverly MA, USA 
β-Actin antibody  Cell Signaling Technology, Inc.  
Beverly MA, USA 
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2.2.6 Equipment and Materials  
Equipment and Materials Manufacturers 
Analytical Balance Sartorius GMBH, Germany 
Balance (0.1-500g) U-Lab, Australia 
Bench Top Centrifuge  Beckman, USA 
Biological Safety Cabinet Class II  LAF Technologies, Australia 
Countess® Automated Cell Counter Invitrogen, USA 
Electrophoresis Mini-gel  Bio-Rad Laboratories, USA 
Electrophoresis Power Supply PAC300  Bio-Rad Laboratories, USA 
ELISA Plate Reader Thermo Electron Corporation, 
USA 
Gel-Doc System  Bio-Rad Laboratories, USA 
iBlot Dry Blotting System  Invitrogen, USA 
 Microcentrifuge  Eppendorf, Germany 
Microscope: 
(i) Confocal laser scanning microscopy 
Nikon Instruments Inc, Japan 
(ii) Light Microscope  Olympus Optical 
(iii) Phase Contrast Microscope  Nikon Kogaku KK, Japan 
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pH Meter  Radiometer, Denmark 
POLARstar Omega Microplate Reader  BMG LABTECH, Australia 
Spectrophtometer (Biophotometer)  Eppendorf, Germany 
Vortex mixer  Ratek Instruments, Australia 
Electroporation Cuvettes (0.2 cm)  Molecular Bio Products, USA 
Filter (Acrodisc 0.2 μm, 0.45 μm)  Gelman Sciences USA 
Centrifuge Tubes 
(i) 1.5 mL Microcentrifuge Tubes  
Sarstedt, Germany 
(ii) 10 mL Centrifuge Tubes  Greiner Bio-One, Germany 
(iii) 15 mL Centrifuge Tubes  Greiner Bio-One, Germany 
(iv) 50 mL Centrifuge Tubes  Greiner Bio-One, Germany 
Micropipette plastic tips (Blue and Yellow)  Greiner Bio-One, Germany 
Micropipette plastic tips (5 mL and 10 mL) Pathtech Pty Ltd., Australia 
Microtitre Plate: 
(i) Microtitre Plate (96-well, flat bottom)  
 
Greiner Bio-One, Germany 
(ii) Microtitre Plate (24-well) Greiner Bio-One, Germany 
(iii) Microtitre Plate (6-well) Greiner Bio-One, Germany 
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Electroporation Cuvettes (0.2 cm) Molecular Bio Products, USA 
Syringe (5 mL, 10 mL, 20 mL, 50 mL)  Terumo, Pty.  Ltd., Australia 
Tissue Culture Flask (25 cm
2
 and 75 cm
2
)  Greneir Bio-One, Germany 
iBlot® Transfer Stack, Regular, Nitrocellulose Invitrogen, USA 
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2.3 Cell Culture Techniques 
All tissue culture related work was performed in a biological safety cabinet class II to minimise 
risk of contamination.  All buffers and solutions were double sterilization by autoclaving.  All 
instruments and materials were sprayed with 70% ethanol and sterilized with ultraviolet light for 
30 min before using in the experiments. 
 
All tissue culture media were kept at 4°C.  Fetal bovine serum (FBS), 0.05% trypsin-EDTA, 
human melanocyte growth supplement, low serum growth supplement, and penicillin-
streptomycin were kept at -20°C unless specified otherwise. 
 
2.3.1 Cell culture growth conditions 
The cell lines were routinely propagated in 25 cm
2
 or 75 cm
2
 tissue culture flasks, or 6 well or 24 
well or 96 well microtitre plates containing the appropriate medium.  The cultures were incubated 
at 37ºC with 5% CO2 for overnight before being used in an assay.  Cell lines were passaged 
between 9-13 times and discarded before a new frozen cell culture was resuscitated.   
 
The cell cultures were regularly tested and confirmed to be mycoplasma free using a Mycofluor 
Detection Kit.  There were no Mycoplasma infections identified in any of the cell cultures during 
the work with this thesis. 
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2.3.2 Cell lines 
Cell lines used in this study were human malignant melanoma (MM96L), human squamous cell 
carcinoma (COLO-16), mouse skin melanoma (B16F0), normal human epidermal melanocyte 
(HEM) and normal human dermal fibroblast (HDF) cell lines.  
 
Cell cultures were monitored visually using an inverted phase-contrast microscope (4 x and 10 x 
objectives) before starting an experiment and at the end of it. 
 
2.3.3 Splitting Tissue Cultures 
2.3.3.1 MM96L, COLO-16 and B16F0 Cell Lines  
The MM96L, COLO-16 and B16F0 cell lines were grown and maintained as monolayers in 75 
cm
2
 tissue culture flask containing 20 mL RPMI medium supplemented with 10 % (v/v) fetal 
bovine serum (FBS) and 1% (v/v) penicillin-streptomycin.  The medium was changed with fresh 
medium every three days or as necessary.  The cell lines usually reached confluency within 4–5 
days.  Once confluent, the old medium was removed from the flask and the cells were washed 
twice with sterile 1x PBS.  To trypsinize cells, 3 mL of trypsin-EDTA solution was added and the 
flask was then incubated at 37°C for 10-15 min.  The trypsinised cell suspension was washed 
twice in the medium and collected each time by centrifugation at 2000 ×g for 5 min.  Cells were 
resuspended in 1 mL of a complete medium and an appropriated volume was used to seed a new 
75 cm 
2 
tissue culture flask containing 20 mL RPMI medium supplemented with FBS and 
penicillin-streptomycin.   Cell culture was incubated at 37°C in a humidified atmosphere and 5% 
CO2 in air.   
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2.3.3.2 HDF Cell Line 
The HDF cell line was propagated and maintained as monolayers in 75 cm
2
 tissue culture flask 
containing Medium 106 supplemented with 2 % (v/v) low serum growth supplement (LSGS) and 
1% (v/v) penicillin-streptomycin.  The medium was changed every two days.  The HDF cell line 
normally reached confluence within 10-12 days.  Once confluent, the old medium was removed 
from the flask and the cells washed twice with sterile 1x PBS.  To trypsinise, an appropriate 
amount of trypsin-EDTA solution was added and the flask was then incubated at 37°C for 3 min.  
The trypsinised cell suspension was collected by centrifugation at 400 xg for 4 min.  The 
supernatant was then discarded and the cell pellet resuspended in 1 mL of a completed medium. 
Approximately 250 μL of the cell suspension was added to a new 75 cm2 tissue culture flask 
containing 20 mL medium supplemented with LSGS and penicillin-streptomycin.  The cell 
culture was incubated at 37°C in a humidified atmosphere and 5% CO2 in air. 
  
2.3.3.3 HEM Cell Line 
HEM cell line was cultured and maintained as monolayers in 75 cm
2
 tissue culture flask 
containing Medium 254 supplemented with 1% (v/v) human melanocyte growth supplement 
(HMGS ) and 1% (v/v) penicillin-streptomycin.  The media was changed every two days.  The 
HEM cell line normally reached confluency within 10-12 days.  Once confluent, old medium was 
removed from the flask and the cells washed twice with sterile 1x PBS.  To trypsinize, an 
appropriate amount of trypsin-EDTA solution was added and the flask was then incubated at 
37°C for 2 min.  Cells were dissociated by gentle tapping of the flask followed by adding 4 mL of 
1 % (v/v) trypsin neutraliser.  The trypsinised cell suspension was collected by centrifugation at -
300 xg for 3 min.  The supernatant was then discarded and the cell pellet resuspended in 1 mL of 
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a completed medium. Approximately 250 μL of the cell suspension was added to a new 75 cm2 
tissue culture flask containing 20 mL medium supplemented with HMGS and penicillin-
streptomycin and the cell culture was incubated at 37°C in a humidified atmosphere and 5% CO2 
in air. 
 
2.3.4 Cell Counting 
Cell lines were prepared from the previous splitted tissue cultures as explained in section 2.3.3.  
Cell numbers were quantified using Countess® Automated Cell Counter according to 
manufacturer's protocol.  In brief, 10 μL medium-suspended cells were added to similar volume 
of 0.4% trypan blue stain and then 10 µL of the mixture were loaded into a countess chamber.   
 
2.3.5 Cryopreservation of Cell Lines 
2.3.5.1 MM96L, COLO-16 and B16F0 Cell Lines 
Each cell pellet obtained from sections 2.3.3.1 was resuspended gently in 3 mL of RPMI medium 
containing 10 % (v/v) FBS, 1% (v/v) penicillin-streptomycin and 10% (v/v) Dimethyl sulfoxide 
(DMSO).  The cell suspensions were then immediately transferred to a 1.5 mL polypropylene 
cryo-vials and placed at -80 ºC overnight and then placed in liquid nitrogen (-180 ºC) for long-
term storage. 
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2.3.5.2 HDF Cell Line 
The cell pellet obtained from sections 2.3.3.2 was resuspended gently in 4 mL of mixture of 70% 
(v/v) Medium 106, 20% (v/v) FBS, 1% (v/v) penicillin-streptomycin and 10% (v/v) DMSO.  The 
cell suspensions were transferred and stored as described in section 2.3.5.1. 
 
2.3.5.3 HEM Cell Line 
The cell pellet obtained from sections 2.3.3.3 was resuspended gently in 1 mL of Medium 254 
supplemented with 1% (v/v) HMGS, 1% (v/v) penicillin-streptomycin and 10% (v/v) DMSO.  
The cell suspension was transferred and stored as described in section 2.3.5.1. 
 
2.3.6 Defrosting of Cell Lines 
Frozen cell cultures were resuscitated from liquid nitrogen, thawed at room temperature and 
added to a 75 cm
2
 tissue culture flask containing 20 mL of an appropriated medium.  Tissue 
culture flasks were then incubated at 37°C and 5% CO2 overnight before the medium was 
refreshed. 
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2.4 Western Blotting Methods 
2.4.1 Buffers and Reagents 
2.4.1.1 Bradford Coomassie Reagent 
Prepared by dissolving 0.05% (w/v) Coomassie Brilliant Blue R-250 in 25 mL of 95% (v/v) 
ethanol and 50 mL of 88% (v/v), phosphoric acid, then diluted with dH2O to 500 mL.  Reagent 
was filtered using a 0.45 µm filter and stored at 4°C. 
 
2.4.1.2       10x SDS-PAGE Running Buffer 
3% (w/v) Tris Base, 14.4% (w/v) Glycine and 1% (w/v) SDS were dissolved in dH
2
O and 
adjusted to pH 8.3.  This was diluted to 1x buffer for running SDS-PAGE. 
 
2.4.1.3        5x SDS-PAGE Sample Buffer  
The components were 60 mM Tris, pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, 
and 0.1% bromophenol blue in dH
2
O, stored at -20
0
C. 
 
2.4.1.4 Tris Buffered Saline (TBS)   
10 mM Tris Base and 500 mM NaCl were dissolved in dH2O, and the pH adjusted to pH 7.4. 
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2.4.1.5 Detection Buffer  
100mM Tris HCl and 100mM NaCl were dissolved in dH2O and the pH adjusted to pH 9.5.   
2.4.1.6 Substrate Solution 
NBT/BCIP substrate solution was diluted 1/1 with detection buffer. 
2.4.2 Western Blots Techniques 
2.4.2.1 Determination of Protein Concentration  
2.4.2.1.1 Bradford Assay 
Protein quantification was determined using Bradford assay.  A standard curve was set up from a 
1 mg/mL of BSA stock at 30, 60, 90, 120, 150, 180 and 210 μg/mL in 0.15 M NaCl.  Test 
samples were diluted 1:10 ratio with 0.15 M NaCl in a total volume of 100 μL.  Bradford reagent 
(900 µL) was added to each standard and test sample solution, and followed by incubation at 
room temperature for 2 min.  The mixtures (200 μL) were loaded into 96 well plates in duplicate, 
and the absorbance was read on an ELSA plate reader at 595 nm.  
 
2.4.2.2 Polyacrylamide Gel Electrophoresis SDS-PAGE  
The resolving gel (12.5 % w/v) acrylamide and the stacking gel (4.5% w/v) acrylamide for SDS-
PAGE were prepared.  The following components were used for the (12.5%) resolving gel: 
 
 
 
 
 78  
 
dH2O 4.22 mL 
1.5M (w/v) Tris-HCl (pH 8.8) 2.5 mL 
 10% (w/v) SDS 0.1 µL 
40% (v/v) Bis Acrylamid  3.135 mL 
10% (w/v) APS (fresh) 50 µL   
TEMED  10µL 
 
The following components were used for the (4%) stacking gel:  
 
dH2O 3.11 mL 
0.5 M (w/v) Tris-HCl (pH 6.8) 1.25 mL 
 10% (w/v) SDS 50 µL 
40% (v/v) Bis Acrylamid 0.563 mL 
10% (w/v) APS (fresh) 25 µL  
TEMED 5 µL 
 
SDS-PAGE was performed using Mini-PROTEAN Tetra Cell electrophoresis system.  The gel 
was electrophoresed for 30 min at 60 V followed by 50 min at 180 V.  
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2.4.2.3 Protein Sample Preparation  
Samples were prepared according to the method of Laemmli (Laemmli, 1970).  Protein samples 
were mixed with 5x SDS-sample buffer in a volume ratio 3:1 (sample: 5x SDS-sample buffer).  
The mixtures were denatured at 95 ºC for 5 min, cooled and centrifuged prior to loading onto 
SDS-PAGE.  A molecular weight protein standard (Precision Plus Protein™ Kaleidoscope 
Standards), and protein samples were loaded into individual wells. 
 
 2.5 DNA Extraction Methods  
2.5.1 Buffers and Reagents 
2.5.1.1      11x Loading Buffer 
10% (w/v) Ficol-400, 1% (w/v) SDS, 0.5% (w/v) Orange G dye, 50% (w/v) glycerol, 10 mM 
EDTA and 50 mM Tris-HCl, pH 8.0, were dissolved in 7.1 mL sterile dH2O and stored at room 
temperature. 
 
2.5.1.2      50x TAE Buffer 
24.2% (w/v) Tris-base, 1.86% (w/v) EDTA and 5.17% (w/v) glacial acetic acid were dissolved in 
dH2O and diluted to 1x before use. 
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2.5.1.3      λDNA marker 
λDNA                     43 μg  
H buffer                  14 μL 
PstI                        10 μL  
Sterile dH2O             73 μL 
 
All components were mixed, then incubated overnight at 37°C.  A volume of 40 μL of sterile 
dH2O and 20 μL of 11x loading dye was added into the mixture before being stored at -20°C in 
aliquots.  This was used as a molecular weight marker at a final concentration of 100 ng/μL. 
 
2.5.2 DNA Extraction Techniques 
2.5.2.1 DNA Extraction 
DNA was extracted using a Wizard® Genomic DNA Purification Kit according to the 
manufacturer‘s protocol.  In brief, cells were harvested by trypsinization, washed in 1x PBS and 
centrifuged at 2000× g for 5 min.  Cell pellets were then resuspended in 600 µL of nuclei lysis 
and 30 µL of RNase solution then following incubation the mixture at 37°C for 30 minutes. 200 
μL of protein precipitation were added and centrifuged at 13,000× g for 4 min.  The suspensions 
were then mixed with 600 μL of isopropanol and centrifuged at 13,000× g for 1 min.  DNA was 
washed using 70% ethanol and resuspended in 100 μL of DNA Rehydration solution then 
incubated overnight at 4°C. 
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2.5.2.2 Estimation of DNA Concentration 
DNA concentration was determined by measuring the absorbance of the DNA sample at 260 and 
280 nm using a spectrophotometer.  The DNA concentration was calculated as 1:30 at OD 260 
mn and then taking the dilution factor into account.  An OD 260 /OD 280 ratio was used to 
measure the quality of the extracted DNA.  Ratios of 1.8-2.0 indicated good quality DNA 
extraction. 
 
2.5.2.3 Agarose Gel Electrophoresis 
Agarose gels were prepared by dissolving 1.5% (w/v) DNA grade agarose in 1x TAE.  The 
solution was heated in a microwave until it boiled.  After cooling to 50°C, the mixture was gently 
poured into a casting tray with placed a comb inside and was allowed to cool to form gel. Prior to 
electrophoresis, DNA samples were prepared by mixing a 1:10 volume of 11x loading dye with 
the sample.  Samples were then loaded into wells of the gel and λDNA marker was used as a 
marker.  Electrophoresis was carried out using the power supply units at 100 V for 65 min.  
Following electrophoresis, the gels were stained in a 1 mg/mL ethidium bromide solution for 
approximately 5-10 min and then de-stained by washing in a running tap water.  The gels were 
then visualized under ultraviolet light using the BioRad Gel Doc system. 
 
2.6 RRM Peptide Design Methodology  
The bioactive peptide (RRM-MV) and the non-bioactive peptides (RRM-C RRM-MV-C) were 
designed by Dr. Elena Pirogova (Second Supervisor). The candidate (Nahlah Almansour) 
 82  
 
designed and analysed the scrambled negative control peptides where the order of one amino acid 
in the bioactive peptide sequence has been shifted and the most stable three peptide sequences 
were selected. 
 
2.6.1 The RRM Physico-mathematical Basis 
The RRM model incorporates digital signal-processing methods (Cosic, 1994b; Cosic, 1997).  It 
has been shown that certain periodicities (frequencies) within the distribution of energies of 
delocalized electrons along the protein molecule are critical for the protein‘s biological function 
(i.e., interaction with its target).  Once the RRM characteristic frequency for a particular 
biological function or interaction has been determined, it is possible to identify the individual 
amino acids, the so-called hot spots, or domains that contribute most to the characteristic 
frequency and thus to the protein‘s biological function (Cosic, 1994b; Cosic, 1997) The 
application of the RRM involves two stages of calculation.  The first is the transformation of the 
amino acid sequence into a numerical sequence.  Each amino acid is represented by the value of 
the electron-ion interaction potential (EIIP) describing the average energy states of all valence 
electrons in a given amino acid.  The EIIP values for each amino acid were calculated using the 
following general model of pseudopotentials (Veljkovic & Slavic, 1972) , and are presented in 
Table 2.1.   
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Table 2.1.  EIIP Values of Amino Acids (Pirogova et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
amino acid EIIP 
Leu 0 
IIe 0 
Asn 0.0036 
Gly 0.005 
Val 0.0057 
Glu 0.0058 
Pro 0.0198 
His 0.0242 
Lys 0.0371 
Ala 0.0373 
Tyr 0.0516 
Trp 0.0548 
Gln 0.0761 
Met 0.0823 
Ser 0.0829 
Cys 0.0829 
Thr 0.0941 
Phe 0.0946 
Arg 0.0959 
Asp 0.1263 
 84  
 
A unique number can thus represent each amino acid or nucleotide, irrespective of its position in 
a sequence.  Numerical series obtained in this way are then analysed by digital signal analysis 
methods in order to extract information relevant to the biological function.  The original 
numerical sequence is transformed to the frequency domain using the discrete Fourier transform 
(DFT) (Cosic, 1994b; Cosic, 1997). 
 
As the average distance between amino acid residues in a polypeptide chain is about 3.8 Å, it can 
be assumed that the points in the numerical sequence derived are equidistant.  For further 
numerical analysis the distance between points in these numerical sequences is set at an arbitrary 
value d = 1.  Then the maximum frequency in the spectrum is fmax = 1/2d = 0.5.  The total 
number of points in the sequence influences the resolution of the spectrum only.  Thus, for an N-
point sequence the resolution in the spectrum is equal to 1/N.  The n-th point in the spectral 
function corresponds to the frequency f = n/N.   
 
In order to extract common spectral characteristics of sequences having the same or similar 
biological function, the following cross-spectral function was used: 
 
                                               Sn = XnYn* n = 1,2,..., N/2 
 
where Xn are the Discrete Fourier Transform (DFT) coefficients of the series x(n) and Yn* are 
complex conjugate discrete Fourier transform coefficients of the series y(n).   
Peak frequencies in the amplitude cross-spectral function define common frequency components 
of the two sequences analysed.  To determine the common frequency components for a group of 
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protein sequences, the absolute values of multiple cross-spectral function coefficients M have 
been calculated as follows: 
 
                               |Mn| = |X1n|.|X2n|...|XMn|,     where n = 1,2,..., N/2 
 
Peak frequencies in such a multiple cross-spectral function denote common frequency 
components for all sequences analysed. 
 
The multiple cross-spectral functions for a large group of sequences with the same biological 
function have been named the Consensus Spectrum.  The presence of a peak frequency with a 
significant amplitude value in the Consensus Spectrum implies that all of the analysed sequences 
within the group have one frequency component in common (the graphical presentation of the 
RRM approach is shown in Figure 2.1.  This frequency is related to the biological function 
provided the following criteria are met. 
 
1. Only one peak exists for a group of protein sequences sharing the same biological 
function. 
2. No significant peak exists for biologically unrelated protein sequences. 
3. Peak frequencies are different for different biological functions. 
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Figure 2.1.  Graphical representation of the RRM procedure.  Original protein sequence 
Numerical Sequence Single Spectrum Consensus Spectrum (Spectral representation of the 
original protein sequence) (Cosic, 1997). 
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The above criteria have been tested with more than 1000 proteins from 25 functional groups 
(Cosic, 1994b; Cosic, 1997).  The following fundamental conclusion was drawn from our studies: 
one RRM peak frequency characterizes one particular biological function or interaction (Figure 
2.2) (Cosic, 1994b; Cosic, 1997).  Therefore, those peaks are named as the RRM characteristic 
frequencies.   
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Figure 2.2.  Each specific biological function of a given protein can be presented/characterized 
by the unique RRM frequency (Cosic, 1997). 
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In summary, the RRM concept is based on the finding that there is a significant correlation 
between spectra of the numerical presentation of amino acids and their biological activity.  It has 
been found through extensive research that proteins with the same biological function have a 
common frequency in their numerical spectra.  This frequency was found to be a characteristic 
feature of a protein‘s biological function or interaction (Cosic et al., 1991; Cosic, 1997).  Once 
the characteristic frequency for a particular protein function/interaction is identified, it is possible 
to use the RRM to: 
1. Predict the amino acids in the analysed protein sequence (these amino acids were called 
the ―hot spots‖) which predominantly contributed to this frequency and consequently to 
the observed function.   
2. To design peptides having the desired periodicities and thus, desired biological functions. 
 
The description of two applications of the RRM approach: prediction of ―hot spots‖ and bioactive 
peptide design are given below.   
 
2.6.1.1 “Hot Spots” in Terms of The RRM and 3-D Protein Structures 
It is known that proteins cannot express their biological function until they achieve a certain 
active 3-D conformation.  By identifying the characteristic frequency of a particular protein, it is 
possible to predict which amino acids in the sequence predominantly contribute to the frequency 
and consequently to the observed function (Cosic et al., 1991; Cosic, 1994b; Cosic, 1995; Cosic, 
1997).  Since the characteristic frequency correlates with the biological function, the positions of 
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the amino acids that are most affected by the change of amplitude at the particular frequency can 
be defined as hot spots for the corresponding biological function. 
The strategy for this prediction includes the following steps: 
1. The unique characteristic frequency for the specific biological function is determined by 
multiple cross-spectral analysis for the group of sequences with the corresponding 
biological function. 
2. The amplitude is altered at this characteristic frequency in the particular numerical 
spectrum.  The criterion used for identifying the critical characteristic frequency change is 
the minimum number of hot spot amino acids that are least sensitive to further changes in 
the amplitude of the characteristic frequency. 
3. A numerical sequence from the modified spectrum is derived using Inverse Fourier 
Transform (IFT).  It is known that a change in amplitude at one frequency in the spectrum 
causes changes at each point in the numerical sequence.  Thus, a new numerical series is 
obtained where each point is different from those in the original series.  Detecting the 
amino acids corresponding to each element of this new numerical sequence can then be 
achieved using tabulated values of the EIIP or other appropriate amino acid parameters.  
The amino acids in the new sequence that differ from the original ones reside at the points 
most contributing to the frequency.  These ―hot spots‖ are related to this frequency and to 
the corresponding biological function. 
 
The procedure described was used in a number of examples: IL (Cosic et al., 1989); 
hemoglobins, myoglobins, and lysozymes (Cosic et al., 1991); chymotrypsins (Cosic, 1994a); 
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glucagons and tumor necrosis factors (TNF) (Cosic, 1995; Pirogova et al., 2010); EGFs, 
fibroblast growth factors (FGFs) (Cosic et al., 1994).  These examples have shown that such 
predicted amino acids denote residues crucial for protein functions.  It was also found that these 
―hot spot‖ amino acids are spatially clustered in the protein‘s 3D structure in and around the 
protein active site.  As these specific amino acids strongly influence the characteristic frequency, 
their cluster represents a site in the protein where the signal of characteristic frequency for the 
specific protein property is dominant.  Since this cluster of amino acids has been found 
positioned in and around the active site (Figure 2.2), it is proposed that these specific amino acids 
play a crucial role in determining the structure of the active site, and possibly the active structure 
of the whole molecule (Baranyi et al., 1998; Cosic et al., 1991). 
 
2.6.1.2 General Bioactive Peptide Design Procedure  
Following the determination of the RRM characteristic frequencies and corresponding phases for 
particular biological functions, it is possible to design amino acid sequences having those spectral 
characteristics only.  It is expected the designed peptide will exhibit the desired biological 
activity. 
 
The strategy for the design of such defined peptides is as follows: 
1. Within the multiple cross-spectral analysis of the group of protein sequences sharing the 
corresponding biological function, the unique RRM frequency characterizing this specific 
biological function/interaction was determined. 
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2. The characteristic phases are defined at the characteristic frequencies for the particular 
protein that is chosen as the parent for agonist/antagonist peptide design. 
3. A numerical sequence from the known characteristic frequencies and phases is derived.  
This can be done by summing sinusoids of the particular frequencies, amplitudes, and 
phases.  The length of the numerical sequence is defined by the appropriate frequency 
resolution and the required peptide‘s length (L=1/fRRM). 
4. The amino acids that correspond to each element of the new numerical sequence is 
determined.  It can be achieved by the tabulated EIIP or other appropriate amino acid 
parameters (Cosic, 1994b; Cosic, 1995; Cosic, 1997). 
 
The figure 2.3 presents the possible combinations of peptides that can be designed based on two 
RRM frequencies (two most prominent peaks in the Concensus Spectrum) and phases determined 
within the RRM analysis. 
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Figure 2.3.  Peptide library (Cosic, 1997; Krsmanovic et al., 1998). 
 
  
Peptide/frequency f1 f2 1 2
________________________________________
A * * - -
B * -
C * -
D * * + +
E * +
F * +
_______________________________________
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2.6.2 Peptide Synthesis 
Peptides used in this study were manufactures as indicated below: 
 
 
 
 
 
  
Peptides Level of purity Manufacturers 
RRM-MV 95% AUSPEP, Melbourne, Australia 
RRM-C 95% AUSPEP, Melbourne, Australia 
RRM-MV-C 95% GL Biochem, Ltd, Shanghai, China 
MV-C1 95% GL Biochem, Ltd, Shanghai, China 
MV-C2 95% GL Biochem, Ltd, Shanghai, China 
MV-C3 95% GL Biochem, Ltd, Shanghai, China 
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CHAPTER 3 
A Bioactive Peptide Analogue for Myxoma virus Protein 
with a Targeted Cytotoxicity for Human 
Skin Cancer in vitro 
 
3.1 ABSTRACT 
Cancer is an international health problem, and the search for effective treatments is still in 
progress.  Peptide therapy is focused on the development of short peptides with strong 
tumoricidal activity and low toxicity.  In this study, we investigated the efficacy of a myxoma 
virus peptide analogue (RRM-MV) as a candidate for skin cancer therapy.  RRM-MV was 
designed using the Resonant Recognition Model (RRM) and its effect was examined on human 
skin cancer and normal human skin cells in vitro. 
 
Cell cultures were treated with various concentrations of the peptides at different incubation 
intervals.  Cellular morphological changes (apoptosis and necrosis) were evaluated using 
confocal laser scanning microscopy.  The cytotoxic effects of RRM-MV on human skin cancer 
and normal human skin cells were quantitatively determined by cytotoxicity and cell viability 
assays.  The effect on human erythrocytes was also determined using quantitative hemolysis 
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assay.  DNA fragmentation assay was performed to detect early apoptotic events in treated cancer 
cells. 
 
Our results indicate that RRM-MV has a dose-dependent toxic effect on cancer cells only up to 
18 h.  RRM-MV targets and lethally harms cancer cells and leaves normal cells unharmed.  It is 
able to reduce the cancer cell viability, disrupting the LDH activity in cancer cells and can 
significantly affect cancer progression.  Further investigation into other cell signalling pathways 
is needed in the process leading to the in vivo testing of this peptide to prove its safety as a 
possible effective treatment for skin cancer. 
 
This chapter was published as a full research paper in the Journal of Biomedical Science. 2012.  
19:65.   
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3.2 INTRODUCTION 
Cancer is one of the leading causes of death worldwide.  Its occurrence, including in developed 
countries, is increasing (Xue & Stauss, 2007).  Although current treatment regimens, such as 
chemotherapy, immunotherapy, radiation therapy and/or surgery, have considerably improved 
patients‘ overall survival and quality of life, many cancers remain incurable and unmanageable.  
Therefore, there is a need to develop safe and effective anti-cancer agents (Dhawan et al., 2002)  
 
Recently, new technologies have been tested successfully.  These include oncolytic virotherapy, 
in which certain viruses selectively infect and kill cancerous cells, leaving normal cells unharmed 
in vitro (Barrett et al., 2007; Stanford et al., 2007a; Wang et al., 2006; Woo et al., 2008) and in 
xenografted mice in vivo (Lun et al., 2005; Lun et al., 2007; Wu et al., 2008).  Myxoma virus 
(MYXV) is a rabbit-specific poxvirus pathogen that in the past few years has been intensely 
investigated as a potential oncolytic candidate  (France et al., 2011; Kim et al., 2010; Kirn & 
Thorne, 2009; Stanford & McFadden, 2007).  MYXV is non-pathogenic in humans and has the 
benefit of being able to selectively target and terminate a wide range (about 70%) of human 
cancerous cells (Werden et al., 2007).  Furthermore, in vitro investigations into MYXV show its 
ability to infect immortalized baby green monkey kidney (BGMK) cells and some primary 
human dermal fibroblasts (Werden et al., 2007).   
 
The resonant recognition model (RRM) is a novel approach to de novo design of therapeutic 
peptides (Pirogova et al., 2011).  It is a physico-mathematical model used for analysing protein 
structure and function; predicting protein active binding sites and functional mutagenesis; and 
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protein activation using the applied electromagnetic radiation (EMR) of the defined frequency 
(Cosic, 1994b; Cosic, 1995).  The RRM concept is based on the finding that protein biological 
function is characterised by certain periodicities (frequencies) in the distribution of electron-free 
energy along the protein sequence.  By utilizing this approach, it is possible to predict key amino 
acids that can contribute to protein activity and to design new peptides with the desired biological 
activity.  It was suggested that these short, synthetic peptides will have a high tissue penetration 
and relatively low production cost, and can be easily modified for improved bioavailability 
(Cosic, 1994b; Cosic, 1997). 
 
Our previous study (Istivan et al., 2011) demonstrated that RRM-MV has a toxic effect on 
different types of mammalian tumor cell lines, and that this bioactive peptide has targeted and 
lethally harmed cancer cells, but left normal cells unharmed.  In the current study, we have 
extended the evaluation of the toxic effect of RRM-MV and RRM-C on transformed human skin 
cancer and normal cell lines using qualitative and quantitative cellular viability, cytotoxicity and 
DNA fragmentations assays.   
 
3.3 METHODS 
3.3.1 Cell Cultures 
The human malignant melanoma cell line (MM96L), human squamous cell carcinoma cell line 
(COLO-16), normal human epidermal melanocytes cell line (HEM) and normal human dermal 
fibroblast cell line (HDF) were obtained from the School of Medical Sciences, RMIT University, 
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Australia.  MM96L and COLO-16 cell lines were cultured as described in section 2.3.3.1.   HDF 
cell line was grown in as described in section 2.3.3.2 and HEM cell line was propagated as 
described in section 2.3.3.3. 
 
3.3.2 RRM Peptide Design Procedure 
In this study, the bioactive peptide (RRM-MV) and the negative control peptide (RRM-C) were 
designed as explained in 2.6. 
 
In aiming to design the short bioactive peptide analogue (RRM-MV) ten MYXV proteins with 
the following NCBI GenBank codes were analysed using the RRM:  M-T1 (NP_051880); NM-
T2 (NP_051879); T2 (AAA46632); T3C (CAA09973); MT3 (CAA0997; M-T4 (NP_051716); 
NM-T5 (AAC55050); M-T6 (CAA09975), NM-T7 (AAA46631); and M-T8 (AAA46630).  The 
483 aa ankyrin-repeat protein NM-T5 protein (AAC55050) was selected as a parent protein for 
this analysis.   
 
3.3.3 RRM Peptides Preparation 
The bioactive peptide RRM-MV and non-bioactive (negative control) peptide RRM-C were 
designed using RRM.  RRM-MV and RRM-C were freshly dissolved in either RPMI 1640, 
medium 254 or medium 106, according to the cell line used in the experiment.  Peptide stocks 
were then prepared at the following concentrations: 50 ng/mL (21.32 nM RRM-MV or 20.37 nM 
RRM-C), 100 ng/mL (42.6 nM RRM-MV or 40.7 nM RRM-C), 200 ng/mL (85.3 nM RRM-MV or 
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81.5 nM RRM-C), 400 ng/mL (170.5 nM RRM-MV or 162.9 nM RRM-C), 800 ng/mL (341 nM 
RRM-MV or 325.9 nM RRM-C) and 1600 ng/mL (682 nM RRM-MV or 651.7 nM RRM-C). 
 
3.3.4 Apoptosis and Necrosis Assay 
The effects of the RRM-designed peptides on cellular apoptosis and necrosis were determined by 
the apoptosis and necrosis assay.  Cells were stained with the Annexin V-Alexa Fluor 488 
(AF488) conjugate and Propidium Iodide (PI) as described in the manufacturer's protocol manual 
(Vybrant Apoptosis Assay kit II, Invitrogen, USA), with minor modifications.  In brief, the cells 
were seeded at a density of 3 × 10
5
 cells/mL in a 24-well plate and incubated overnight.  Cells 
were treated with 100 ng/mL, 200 ng/mL and 400 ng/mL of RRM-MV or RRM-C, then 
incubated for 3 h or 18 h.  After incubation, they were washed with cold phosphate-buffered 
saline (PBS).  To each sample, 5 µL of AF488 and 1.5 µL of PI were added.  These samples were 
then incubated at room temperature for 20 min before being washed twice and resuspended in a 
binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2 at pH 7.4).  Stained cells were 
kept protected from light until they were examined by confocal laser scanning microscopy 
(CLSM).  CLSM images were taken at 10, 20 and 40 × magnifications, with the pinhole aperture 
set at 1 using Nikon Eclipse Ti-E A1 laser-scanning confocal system (Nikon Instruments Inc, 
Japan).  Images were analysed with the NIS-Element imaging software.  All samples in 
duplicates were tested at least three times in duplicates. 
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3.3.5 Lactate Dehydrogenase (LDH) Assay 
The effect of the bioactive peptide RRM-MV on cell cytotoxicity was determined using the LDH 
assay.  Cells were seeded at a density of 3 × 10
5
 cells/mL in a 96-well plate and incubated 
overnight.  They were then treated in triplicate with 400 ng/mL of RRM-MV or RRM-C and 
incubated for another 3 h.  The LDH released from damaged cells was measured by Cytotoxicity 
Detection Kit (Roche Diagnostics, USA) according to the manufacturer‘s instructions.  The 
background control values were subtracted from each well and the mean percent treatment 
induced cytotoxicity for each cell line was calculated using the following equation: 100× 
[(experimental value – low control)/(high control – low control)], where: 
low control=mean absorbance from the untreated cells (spontaneous release of LDH) and high 
control=mean absorbance from lysis cells (maximum release of LDH) (positive control). 
 
3.3.6 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) Cell Viability 
Assay 
The effect of the RRM-designed peptides on cell viability was determined using the MTT assay 
as described by (Mosmann, 1983) Briefly, cells were seeded at 3 × 10
5
 cells/mL, in a 96-well 
plate and incubated overnight.  Cells were then treated with 100 ng/mL, 200 ng/mL, 400 ng/mL, 
600 ng/mL, 800 ng/mL, 1000 ng/mL, 1200 ng/mL, 1400 ng/mL and 1600 ng/mL of the RRM-
designed peptide for 3 h incubation, or 25 ng/mL, 50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL, 
600 ng/mL and 800 ng/mL) for 18 h incubation.  Followed by adding 25 μL of the MTT solution 
(5 mg/mL; Sigma-Aldrich Company, St.  Louis, MO), while cells were protected from light.  
After 4 h incubation, under standard conditions of 5% CO2 and 37 °C, the purple formazan 
product became visible.  The precipitated formazan was dissolved by adding 100 μL dimethyl 
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sulfoxide (DMSO) (Millipore, France) and placing it on a shaker for 5 minutes.  The absorbance 
was read on ELISA plate reader (Thermo Electron Corporation, USA) at 595 nm.  The blank 
values (medium) were subtracted from each well of the untreated and treated cells.  The results 
were reported as percentage of cell death where the OD measure from untreated cells was 
considered to be 0% of cell death.  The percentage of cell death was calculated as [1 – (OD 595 
nm experiment/OD 595 nm untreated cells)] × 100. 
 
3.3.7 DNA Fragmentation Assay 
DNA fragmentation assay was used to evaluate the effect of RRM-MV on DNA fragmentation in 
skin cancer cells.  Cells were grown in a six-well plate at a density of 7 × 10
5
 cells/mL well and 
incubated overnight.  MM96L and COLO-16 cells were incubated with 200 ng/mL and 400 
ng/mL RRM-MV or RRM-C for 18 h.  Following incubation, DNA was extracted using a 
Wizard® Genomic DNA Purification Kit (Promega, Australia) according to the manufacturer‘s 
protocol as described in section 2.5.2.   
 
3.3.8 Hemolysis Assay 
The hemolytic effect of the RRM-designed peptides on human erythrocytes was carried out in a 
96 well plate as described by (Istivan et al., 2004) with minor modifications.  In brief, 5 mL 
fresh, whole blood was collected from an antecubital vein using a 21-gauge needle into EDTA 
tube.  The blood was then diluted 1:5 with PBS and centrifuged at 1000 xg for 10 min.  The 
erythrocytes pellet was resuspended in PBS to a final concentration of 3% (v/v).  The 
erythrocytes suspension was treated with an equal volume of RRM-MV or RRM-C at the 
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following concentrations: 50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL, 600 ng/mL, 800 
ng/mL, 1000 ng/mL, 1200 ng/mL, 1400 ng/mL and 1600 ng/mL.  A completely lysed erythrocyte 
pellet was used as a positive control.  The erythrocytes pellet was resuspended in sterile distilled 
water to a final concentration of 3% (v/v) for complete lysis.  Following incubation at 37 °C 
overnight, the plate was centrifuged at 1000 xg for 10 min.  The supernatants were collected and 
the OD at 595 nm was measured using ELISA plate reader (Thermo Electron Corporation, USA). 
 
3.3.9 Statistical Analysis 
Statistical analysis was performed using the Microsoft Office 2003 Excel software (Microsoft 
Corporation, Redmond Washington USA) and SPSS statistical software (version 18.0, SPSS, 
Inc., Chicago, IL, USA).  The statistical significance of the differences between treated groups, 
controls groups and untreated groups were analysed by one-way ANOVA and Tukey post hoc 
test.  Experiments were performed at least three times independently.  All values are expressed as 
mean ± standard errors.  Results were considered significant at P < 0.05. 
 
3.4 RESULTS 
3.4.1 The Bioactive Peptide (RRM-MV) 
The RRM characteristic frequency of the selected MYXV proteins was identified at fRRM=0.1152.  
According to the RRM concepts, this prominent peak characterises the common biological 
activity of the analysed MYXV proteins.  Less prominent peaks indicate that these selected 
MYXV proteins can be involved in different biological processes (i.e. interact with other 
proteins).  As a result, the 18 aa linear peptide sequence (MDDRWPLEYTDDTYEIPW) for 
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RRM-MV was designed with the frequency fMV=0.1152 and phase φMV=-0.457.  ExPASy - 
ProtParam tool was used as a tool for the computation of physical and chemical parameters for 
the RRM designed peptide sequence.  RRM-MV predicted MW is 2.345 kDa; theoretical pI: 
3.66; estimated half-life in mammalian reticulocytes: 30 h; and instability index: 27.32 which 
classifies the protein as stable (Artimo et al., 2012). 
 
3.4.2 The Non- Bioactive Peptide (RRM-C) 
The RRM procedure was also used to design the negative control peptide (RRM-C), which has 
different inactive frequency and phase (fC=0.2 and phase φC=1.5) and as assumed, it would not 
express MYXV-like cytotoxic activity.  The designed negative control RRM-C, 22 amino acid in 
length, linear peptide CVLQDCVLQDCVIQDCVLQDCV, has a predicted MW: 2.454 kDa, 
theoretical pI: 3.32, and estimated half-life in mammalian cells is 1.2 h (Artimo et al., 2012). 
 
3.4.3 Detection of Cellular Apoptosis and Necrosis 
3.4.3.1 In human Skin Cancer Cells 
The cytotoxic effects of RRM-MV and RRM-C were detected on the human cancer cell lines 
(MM96L and COLO-16) at different concentrations and different incubation times using CLSM.  
The characteristic morphological changes associated with apoptosis and/or necrosis were 
observed in these cell lines after RRM-MV treatment.  Incubation of MM96L with 100 ng/mL of 
RRM-MV for 3 h induced slight apoptotic or necrotic effects which were not seen in RRM-C-
treated and untreated cells (Figure 3.1A).  Conversely, prolonged incubation of up to 18 h at this 
concentration caused significant apoptotic and necrotic effects in MM96L and COLO-16 which 
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were not seen in RRM-C-treated and untreated cells (Figure 3.1B and 3.2B, respectively).  
Similar effects were observed when the COLO-16 cell line was treated with 100 ng/mL of RRM-
MV for 3 h or for 18 h (Figure 2). 
Treatment with higher concentrations (200 ng/mL and 400 ng/mL) of RRM-MV produced 
significant apoptotic and necrotic effects and detachment in MM96L and COLO-16 cell lines 
after only 3 h of incubation (Figure 3.1A and 3.2, respectively).  Interestingly, no significant 
cytotoxic effects were detected when MM96L and COLO-16 cells were treated with similar 
concentrations of the negative control peptide RRM-C for 3 h and 18 h. 
 106  
 
 
   
 
     
      
      
   
 
 
   
 
   
    
 
Figure 3.1 (A and B). 
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Figure 3.1.  CLSM micrographs of apoptosis and/or necrosis in malignant melanoma cell line 
(MM96L).  Cells were incubated for 3 h with 100 ng/mL, 200 ng/mL or 400 ng/mL of RRM-MV 
or RRM-C in (A); or with 100 ng/mL of RRM-MV or RRM-C for 18 h in (B).  After incubation, 
cells were double stained with AF488 and PI.  CLSM images show that RRM-MV induced cell 
apoptosis/necrosis effects.  Prolonged incubation with RRM-MV caused stronger cytotoxic 
effects.  AF488 channels show apoptotic cells labeled with green-fluorescent, and PI channels 
show necrotic cells labeled with red-fluorescent.  CLSM images were taken with Nikon Eclipse 
Ti-E A1 laser-scanning confocal system, and analysed with the NIS-Element imaging software 
(100 x magnification). 
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Figure 3.2 (A and B). 
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Figure 3.2.  CLSM images of apoptosis and/or necrosis in human squamous cell carcinoma 
(COLO-16) cell line.  Cells were incubated for 3 h with 100 ng/mL, 200 ng/mL or 400 ng/mL of 
RRM-MV or RRM-C.  After incubation, cells were double stained with AF488 and PI.  These 
CLSM images show that RRM-MV induced cell apoptosis/necrosis effects.  AF488 channels 
show apoptotic cells labeled with green-fluorescent and PI channels show necrotic cells labeled 
with red-fluorescent (100 x magnification). 
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3.4.3.2 In Normal Human Skin Cells 
Cellular apoptosis and/or necrosis were also assessed by CLSM in normal human skin cell lines 
(HEM and HDF).  These cell lines were treated with 200 ng/mL and 400 ng/mL of RRM-MV or 
with similar concentrations of RRM-C.  After 3 h of incubation, the CLSM micrographs 
indicated that neither apoptotic nor necrotic effects were observed in HEM and HDF cell lines 
treated with RRM-MV (Figure 3.3A and 3.3B, respectively).  Taken together, no significant 
cytotoxic effects were observed on these cell lines after treatment either with RRM-MV or  
RRM-C. 
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Figure 3.3 (A and B). 
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Figure 3.3.  CLSM images of normal human epidermal melanocytes (HEM) and normal human 
dermal fibroblast (HDF) cell lines following incubation with RRM-MV or RRM-C.  HEM cells 
in (A) and HDF cells in (B) were treated with 200 ng/mL or 400 ng/mL of either RRM-MV or 
RRM-C for 3 h, then double stained with AF488 and PI.  No cytotoxic changes were detected in 
either cell line treated with RRM-MV. 
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3.4.4 Treatment with RRM-MV Induced Lactate Dehydrogenase (LDH) Release 
Quantification of LDH activity released from damaged cells was measured using the LDH assay.  
The ability of the RRM-MV to induce LDH release from MM96L, COLO-16, HEM and HDF 
cell lines was investigated.  Cells were incubated with 400 ng/mL of RRM-MV or RRM-C for 3 
h.  Data analysis of results revealed that the release of LDH from cells into the culture medium 
increased significantly after 3 h in RRM-MV-treated cancer cells compared with untreated cells.  
This suggested that treatment with 400 ng/mL of RRM-MV caused plasma membrane rupture 
and cellular damage in cancer cells.  However, in normal cells, there was no significant 
difference in LDH release between RRM-MV-treated and untreated cells.  Interestingly, RRM-C 
treatment did not induce significant LDH releases and was non-toxic for all tested cell lines 
(Figure 3.4).  In total, the results indicated that the plasma membrane of the two normal cell lines 
remained intact during incubation with either the bioactive peptide RRM-MV or non-bioactive 
peptide RRM-C.  Yet, RRM-MV treatment significantly induced cytotoxicity in cancer cells. 
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Figure 3.4.  Cytotoxic effects measured by LDH enzymatic activity in human skin cancer and 
normal human skin cells after treatment with RRM-MV or RRM-C.  LDH levels were measured 
following treatment with 400 ng/mL of RRM-MV or RRM-C for 3 h.  RRM-MV produced high 
cellular LDH levels in cancer cells.  Results are average of three independent experiments.  
Cytotoxicity values were analysed using one-way ANOVA and Tukey post hoc test.  They 
showed a significant difference between RRM-MV-treated cells and untreated cells (p < 0.01).  
Significant values are indicated with an * 
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3.4.5 RRM-MV Induces Cell Death in Dose and Time-dependent Manners in Carcinoma 
and Melanoma Cell Lines 
The effects of different doses and incubation periods of RRM-MV or RRM-C on cell death were 
determined in MM96L and COLO-16 cell lines using the MTT cell viability assay.  Cells were 
treated with different concentrations of peptides for 3 h or 18 h.  Cancer cells were treated with 
(100 ng/mL, 200 ng/mL, 400 ng/mL, 600 ng/mL, 800 ng/mL, 1000 ng/mL, 1200 ng/mL, 1400 
ng/mL and 1600 ng/mL) of either RRM-MV or RRM-C for 3 h.  Data analysis of results 
indicated that cell death in MM96L and COLO16 increased noticeably with higher doses of 
RRM-MV compared with RRM-C-treated and untreated cells (p <0.001) in both cell lines.  The 
maximum percentage of cell death was 34.92% and 57.98% at 1600 ng/mL of RRM-MV in 
MM96L and COLO-16 cell lines, respectively (Figure 3.5A and 3.5B).  Additionally, incubation 
of cells with 25 ng/mL, 50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL RRM-MV 
for 18 h caused a statistically significant reduction in cell viability.  At the highest peptide 
concentration (800 ng/mL RRM-MV), the percentage of cell death was 52.9% and 59.95% in 
MM96L and COLO-16 cell lines respectively (p <0.001 in MM96L and COLO16).  Interestingly, 
RRM-C treatment for either 3 h or 18 h in both cell lines had negligible effects on cell viability 
even at the highest concentrations used (1600 ng/mL) (Figure 3.6A and 3.6B).  Cytotoxic 
responses against RRM-MV treatment substantially increased in the cancer cells with increased 
doses.  Hence, RRM-MV treatment decreased cell survival through the induction of cell death in 
dose- and time-dependent manners within 18 h.  However, treatment of cancer cells with RRM-C 
displayed minimal effects on the tested cancer cell lines. 
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3.4.6 The RRM-MV had no Effect on Cell Viability in The Normal Human Skin Cell Line 
(HDF) 
HDF human skin cell line was incubated with RRM-MV or RRM-C 100 ng/mL, 200 ng/mL, 400 
ng/mL, 800 ng/mL and 1600 ng/mL for 3 h, and 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 
ng/mL for 18 h.  Toxic effects of these peptides were evaluated by MTT assay.  There appeared 
to be no significant difference in HDF viability between RRM-MV-treated and untreated cells.  
No significant loss in viability was observed with RRM-C treatment (Figure 3.5C and 3.6C).  
Data analysis of results indicated that even the highest concentration of peptides treatment had 
negligible toxic effects on the tested normal human skin cells. 
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Figure 3.5 (A, B and C). 
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Figure 3.5.  Cellular viability of human skin cancer and normal human skin cell lines treated 
with RRM-designed peptides for 3 h measured by MTT assay.  MM96L cells in (A), COLO-16 
cells in (B), and HDF cells in (C) were incubated with different concentrations of RRM-MV or 
RRM-C for 3 h.  Cells treated with 90% DMSO were used as positive controls.  Results are 
reported as percentage of cell death, where the optical density (OD595nm) value from untreated 
cells was set at 0% of cell death.  The bar graphs show mean ± standard error of three 
independent experiments.  Statistical significance of the differences between RRM-MV-treated 
cells and untreated cells were analysed using one-way ANOVA and Tukey post hoc test.  The 
cellular viability values of RRM-MV-treated melanoma and carcinoma cells were significantly 
different from those of untreated melanoma and carcinoma cells (P<0.001). 
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Figure 3.6 (A, B and C).  
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Figure 3.6.  Cellular viability of human skin cancer and normal human skin cell lines treated 
with RRM-designed peptides for 18 h measured by MTT assay.  MM96L cells in (A), COLO-16 
cells in (B), and HDF cells in (C) were treated with different concentrations of RRM-MV or 
RRM-C for 18 h.  Cells from each cell line were treated with 90% DMSO and used as positive 
controls.  The effect of the peptides on cell viability was determined by MTT assay.  Results are 
reported as percentage of cell death, where the optical density (OD) value from untreated cells 
was set at 0% of cell death.  Bars indicate the mean ± standard error of three independent 
experiments.  Statistical evaluation was performed by using one-way ANOVA and Tukey post 
hoc test.  The RRM-MV-treated cancer cells were significantly different from untreated cells 
(P < 0.001). 
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3.4.7 RRM-MV Induced DNA Degradation in Human Skin Cancer Cell Lines 
DNA fragmentation was analysed by agarose gel electrophoresis to detect apoptosis in human 
skin cancer cells.  MM96L and COLO-16 cell lines were incubated with (200 ng/mL and 400 
ng/mL) of RRM-MV or RRM-C for 18 h.  Agarose gel analysis showed that RRM-MV treatment 
clearly degraded DNA at both peptide concentrations, in contrast with the untreated controls in 
MM96L cell line (Figure 3.7A, lane 4 and 6).  Conversely, DNA degradation could not be 
observed in RRM-MV-treated COLO-16 cell line at similar concentrations within the same 
duration (Figure 3.7B, lane 4 and 6).  The RRM-C treatment caused no changes in DNA patterns 
in MM96L and COLO-16 cell lines.  Taken together, the RRM-MV treatment induced DNA 
degradation in melanoma cells which is the biochemical hallmark of apoptotic cell death, 
however, this degradation could not be observed in carcinoma cells. 
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Figure 3.7.  Effect of RRM-MV treatment on the DNA of cancer cell lines.  MM96L cells in (A) 
and COLO16 cells in (B) were incubated with 200 and 400 ng/mL of RRM-C or RRM-MV for 
18 h.  DNA was extracted and analysed by electrophoresis on 1.5% agarose gel with ethidium 
bromide staining.  DNA samples are labeled as: (M) molecular weight marker, (1) untreated cells, 
(2) cells treated with DMSO as positive controls, (3) cells treated with 200 ng/mL RRM-C, (4) 
cells treated with 200 ng/mL RRM-MV, (5) cells treated with 400 ng/mL RRM-C, and (6) RRM-
MV-treated cells.  In MM96L cells, RRM-MV treatment produced DNA degradation, whereas in 
COLO16 cells, DNA degradation was not detected even with DMSO-treated samples.  Results 
are representative of more than three independent experiments. 
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3.4.8 Effect of RRM-designed Peptides on Human Erythrocytes 
The toxicity of RRM-MV on human erythrocytes was tested using the hemolysis assay to 
evaluate the suitability of RRM-MV as a future therapeutic agent.  Human erythrocytes were 
incubated with various concentrations of RRM-MV (50 ng/mL, 100 ng/mL, 200 ng/mL, 400 
ng/mL, 600 ng/mL, 800 ng/mL, 1000 ng/mL, 1200 ng/mL, 1400 ng/mL and 1600 ng/mL) for 18 
h.  Similar concentrations of RRM-C were also tested on human erythrocytes for comparison.  
Results indicated that treatment of human erythrocytes with RRM-MV or RRM-C did not induce 
erythrocytes lysis at any of the concentrations used when compared with the complete 
erythrocyte lysis positive control (Figure 3.8).  Thus, human erythrocytes appeared to be 
relatively resistant to RRM-MV and RRM-C treatments. 
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Figure 3.8.  The effect of the RRM-designed peptides on human erythrocytes.  Washed human 
erythrocytes in PBS were incubated for 18 h with the following concentrations of RRM-MVor 
RRM-C: 50 ng/mL; 100 ng/mL; 200 ng/mL; 400 ng/mL; 600 ng/mL; 800 ng/mL; 100 ng/mL; 
1200 ng/mL; 1400 ng/mL; and1600 ng/mL.  Human red blood cells were relatively resistant to 
RRM-MV and RRM-C treatment when incubated for up to 18 h, as cytolytic/hemolytic effects 
were not detected after treatment with both peptides.  Data values are the average of three 
independent experiments in triplicates. 
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3.5 DISCUSSION 
Peptide therapy has been applied in developing potential cancer therapeutics.  These therapies 
focus on short peptide with strong tumoricidal activity and low toxicity (Pirogova et al., 2011).  
We recently applied the RRM approach to design a short linear bioactive peptide (RRM-MV), 
mimicking the bioactivity of specific MYXV proteins.  The RRM-MV has selectively potent 
antitumor cytotoxic effects on mouse melanoma in vitro in dose- and time-dependent manners 
(Istivan et al., 2011).  We also used RRM to design the peptide analogue IL-12 to mimic the 
activity of mouse interlukin-12.  This peptide produced cytotoxic effect on the B16F0 mouse 
melanoma cancer cells (B16F0) (Pirogova et al., 2009).   
 
The current study examined and evaluated the suitability of RRM-MV as a candidate for human 
skin cancer therapy.  The toxic effects of RRM-MV on the viability of human skin cancer and 
normal human skin cell lines were investigated.  We found that RRM-MV induced 
apoptotic/necrotic effects in dose- and time-dependent manners in MM96L melanoma and 
COLO-16 carcinoma cell lines.  We used AF488 and PI to detect apoptosis/necrosis in the 
plasma membrane.  Early apoptotic cells were detected after 3 h of incubation with 200 ng/mL 
and 400 ng/mL RRM-MV.  There were also many more apoptotic/necrotic cells to live cells in 
the RRM-MV-treated cancer cell lines when compared with the same ratio in RRM-C-treated and 
untreated cancer cell lines.  When cancer cells were incubated with RRM-MV for a longer period 
(18 h), this bioactive peptide had a significant cytotoxic effect on these cells.  In contrast, normal 
human skin cells were not affected by RRM-MV when incubated with it under similar conditions.  
Our findings suggest that the bioactive peptide RRM-MV can successfully induce apoptosis and 
necrosis in melanoma and carcinoma cells. 
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Moreover, this study showed that the level of LDH released from the RRM-MV-treated cancer 
cells was significantly higher (p < 0.01) than that released from untreated cells.  The raise in 
LDH levels is known to be caused by an increased amount of dead cells or plasma membrane 
damage (Haslam et al., 2000; Wolterbeek & van der Meer, 2005).  Our findings suggest that 
RRM-MV caused plasma membrane damage leading to a greater cytotoxic effect on cancer cells, 
but not on normal cells.   
 
Increased LDH release was also confirmed by examining mitochondrial activity using MTT 
assay.  Our data indicated that RRM-MV displayed significant cytotoxicity (P < 0.001) towards 
human skin cancer cells.  Incubation with higher concentrations (up to 1600 ng/mL) of RRM-MV 
damaged cellular structures and made cells enter the necrotic death pathway, evident by the 
analysis of the cells‘ morphology and increased LDH release with reduction in cell viability.  On 
the other hand, in normal human skin cells neither RRM-MV nor RRM-C increased cell death 
within the investigated concentration range.  This showed that the bioactive peptide has a 
negligible toxic effect on normal human skin cells, but high cytotoxicity towards cancer cells.  In 
addition, the dose- and time-response study revealed that high concentration treatments (above 
400 ng/mL) caused the greatest cytotoxic responses.  This supported our previous findings that 
RRM-MV has cytotoxic effects in a variety of mammalian tumor cell lines (Istivan et al., 2011; 
Pirogova et al., 2010).  Our data also showed that RRM-MV has minimal cytotoxicity on normal 
human skin cells even at high concentrations.   
 
The apoptotic effect of RRM-MV was further confirmed by the DNA fragmentation assay.  
RRM-MV-treatment extensively degraded DNA in melanoma cells, suggesting that cells treated 
with RRM-MV underwent apoptosis.  Normally, DNA degradation is considered a biochemical 
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hallmark of apoptosis that involves cutting the inter-nucleosomal regions into small fragments of 
double-stranded DNA (Hanahan & Weinberg, 2000; Kerr et al., 1994; Wyllie et al., 1980).  Thus, 
changing in the DNA characteristics after RRM-MV treatment confirmed cell death induction in 
melanoma cells.  However, DNA degradation was not noticed in the RRM-MV-treated 
carcinoma cell line, although cellular cytotoxicity was confirmed by CLSM, LDH and MTT 
assays.  This could be explained by the lack of endogenous DNases in this cell line (Kerr et al., 
1994).  Therefore, the potential of cells undergoing early apoptosis can not be eliminated in this 
cell line by the non-appearance of DNA degradation (Bortner et al., 1995; Cohen et al., 1992; 
Elmore, 2007).   
 
Our study also showed that human erythrocytes were relatively resistant to haemolysis when 
treated with RRM-MV even at high concentrations.  This supports the suitability of RRM-MV as 
a potential antitumor therapeutic agent. 
 
3.6 CONCLUSIONS 
We have previously shown that RRM-MV produced toxic effects on the B16F0 mouse melanoma 
cell line.  Here, we found that RRM-MV has a selective pro-apoptotic and cytotoxic activity on 
human melanoma and carcinoma cells without significantly affecting normal cells.  Treatment of 
these cells with RRM-MV caused characteristic cellular morphology changes, apoptosis and/or 
necrosis, reduced cellular viability and induced cell membrane damage, while addition of the 
negative control peptide RRM-C produced no cytotoxic changes in these cells.  Further research 
is currently undertaken to determine the exact mechanism in which cancer cells are affected by 
this bioactive peptide. 
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CHAPTER 4 
Investigation of Cytotoxicity of Negative Control Peptides 
versus Bioactive Peptide on Skin Cancer and Normal Cells: 
A Comparative Study 
 
4.1 ABSTRACT 
 
Background: RRM-MV, a bioactive peptide analogue for myxoma virus MV-T5 protein, was 
computationally designed by the Resonant Recognition Model (RRM).  In this study, the 
anticancer effects of RRM-MV were assessed in vitro against four negative control peptides on 
human skin cancer and normal cells.   
Results/Discussion: The effects of RRM-MV vs negative control peptides on cells were 
evaluated by quantitative and qualitative assays.  The RRM-MV treatment was able to induce cell 
death in cancer cells without triggering similar effects on normal cells.  However, the negative 
control peptides produced no toxic effects on skin cancer and normal cells.  No effects on human 
erythrocytes were detected when treated with all peptides.   
Conclusion: It can be suggested that the RRM can be applied to design therapeutic anticancer 
peptides.   
 
This chapter was published as preliminry communication paper in Future Medicinal Chemistry.  
2012. 4(12):1553-1565. 
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4.2 INTRODUCTION  
Cancer peptide therapy is an emerging field that uses bioactive therapeutic peptides to kill cancer 
cells such as skin cancer and other cancer types while causing minimal undesirable side effects 
on normal cells (Pirogova et al., 2011; Schmidt & Wittrup, 2009).  Anticancer therapeutic 
peptides have many attributes that make them attractive as drugs of choice for cancer therapy 
(Pirogova et al., 2011).  This is mostly due to their ability to easily penetrate cellular membranes 
and to interfere with enzymatic functions or protein-protein interactions within cells.  These 
therapies focus on small molecular weight peptides with strong tumoricidal activity and low 
toxicity (Bidwell & Raucher, 2009; Park et al., 2005; Raucher et al., 2009). 
 
The concept of using viruses to target and destroy cancerous cells as oncolytic virotherapy is not 
new.  (Kirn & Thorne, 2009).  An optimal oncolytic virus candidate is required to possess a 
selective tropism to specifically infect and destroy the cancerous tissue without causing damage 
to normal tissue (Bell et al., 2002; Lin & Nemunaitis, 2004; Mullen & Tanabe, 2002; 
Nemunaitis, 1999; Parato et al., 2005).  A number of oncolytic virus candidates such as poxvirus 
(Guo & Bartlett, 2004) have been reported and have different degrees of oncolytic efficacy in 
various cancer models (Aghi & Martuza, 2005).  More recently, myxoma virus (MYXV) has 
been added to the oncolytic virus candidates list (McFadden, 2005; Sypula et al., 2004).  MYXV 
is a poxvirus of the Leporipoxvirus genus and the Chordopoxvirinae subfamily of Poxviridae 
(Fenner, 2000; Kerr & McFadden, 2002).  It causes a lethal disease known as myxomatosis in the 
European rabbit, Oryctalagus cuniculus (Kerr & McFadden, 2002; Stanford et al., 2007c) but, it 
is non-pathogenic in other vertebrates including humans (Andrewes & Harisijades, 1955; Fenner, 
2000; Jackson et al., 1966; McCabe et al., 2002; McFadden, 2005).  This virus has become of 
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significant attention to researchers due to its oncolytic properties in human cancers (Stanford et 
al., 2007b), which have been reported in several studies both in vitro (Barrett et al., 2007; 
Stanford & McFadden, 2007; Stanford et al., 2008; Sypula et al., 2004; Wang et al., 2006; Woo 
et al., 2008) and in vivo (Lun et al., 2005; Lun et al., 2007; Wu et al., 2008). 
 
Based on the ability of MYXV to proliferate in human tumor cells, the bioactive peptide RRM-
MV has been designed to mimic the bioactivity of the selected MYXV-protein using Resonant 
Recognition Model (RRM) (Istivan et al., 2011).  RRM is a physico-mathematical model that 
incorporates signal processing methods for structure-function analysis of proteins (Cosic, 1995; 
Cosic & Pirogova, 2007).   
 
Recently, our research group used the RRM approach for the design of three short therapeutic 
antitumor peptides and applied it to the structure-function analysis of known antitumor proteins 
including interlukin-12 (IL-12), tumor necrosis factor-α (TNF α), and myxoma virus (MYXV) 
proteins.  Respectively, they are named RRM-IL-12 which is based on the murine IL-12 protein 
(Pirogova et al., 2009; Pirogova et al., 2011), RRM-TNF-2 which based on the murine tumor 
necrosis factor-2 protein (Pirogova et al., 2010) and RRM-MV which based on M-T5 protein 
from myxoma virus (Istivan et al., 2011).  The experimental validation of these three short 
therapeutic anticancer peptides demonstrated that these peptides induced toxic effects on the 
B16F0 mouse melanoma cells in a time- and dose-dependent manner (Istivan et al., 2011; 
Pirogova et al., 2009; Pirogova et al., 2011). 
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In our recent study, we reported that the bioactive peptide RRM-MV displayed a significant 
cytotoxic effect against murine melanoma cells, but had no toxic effect on normal murine cell 
lines (Istivan et al., 2011).  In the current study the negative control peptide RRM-MV-C was 
designed by the RRM lacking the specific bioactive frequencies for the RRM-MV.  In addition, 
three negative control peptides MV-C1; MV-C2; and MV-C3 were designed with a similar RRM-
MV amino acid sequence (MDDRWPLEYTDDTYEIPW) apart from a change in the order of 
one amino acid along that sequence.  The cytotoxic effects of all peptides were tested on both 
cancerous and normal human skin cell lines.  These experiments were performed in order to 
investigate the biological activity of the negative control peptides on human skin cancer cells and 
on human normal skin cells in vitro in comparison with the cytotoxic activity of the RRM-MV.   
 
4.3 METHODS 
4.3.1 Bioactive Peptide Design Procedure 
To test the cytotoxicity of the peptides on n human skin cancer and normal cells in vitro, the 
following peptides were designed as described in section 2.6. 
 
4.3.1.1. The Bioactive Peptide (RRM-MV) 
The characteristic frequencies and corresponding phases for the bioactive peptide are mentioned 
in section in 3.4.1. 
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4.3.1.2 The Non-Bioactive Peptide RRM-MV-C 
RRM-MV-C was designed by the RRM with a frequency other than fMV=0.1152 (fc=0.08, 
φc=0.75).  It was used as a negative control peptide (section 2.6).   
 
4.3.1.3 Negative Control Peptides with a Minor Change in RRM-MV Amino Acid Sequence  
In our attempt to test the activity of scrambled peptides where one amino acid in the bioactive 
peptide sequence has been shifted, the order of one amino acid at different position in the RRM-
MV‘s sequence was changed.  To investigate the effect of this minor change on the peptide‘s 
biological activity, three of the most stable scrambled peptide sequences named MV-C1, MV-C2 
and MV-C3 were tested.   
 
The ExPASy server (Artimo et al., 2012) was used as a tool for the computation of physical and 
chemical parameters for all designed peptide sequences.   
 
4.3.2 Sample Preparation  
Serial dilutions of all peptides 50 ng/mL; 100 ng/mL; 200 ng/mL; 400 ng/mL; 800 ng/mL and 
1600 ng/mL were prepared immediately before in vitro assays carried out as described in section 
3.3.3. 
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4.3.3 Cell Cultures  
The human malignant melanoma cell line (MM96L) and human squamous cell carcinoma cell 
line (COLO-16) were cultured as described in section 2.3.3.1.  Normal human dermal fibroblast 
cell line (HDF) cell line was propagated as described in section 2.3.3.2.  The cell suspensions 
were then grown at a density of 3 × 10
5 
cells/mL in microtiter plates overnight, before treatment 
to allow their adherence.  Cells were assayed by qualitative and quantitative assays as described. 
4.3.4 Apoptosis and Necrosis Assay 
The effects of RRM-MV, RRM-MV-C and the three negative control peptides on cellular 
apoptosis and necrosis were detected using Vybrant Apoptosis Assay kit II (Invitrogen, USA) as 
described in section 3.3.4.  The cells were treated with 400 ng/mL of all peptides and all samples 
were tested at least three times in duplicates.   
 
4.3.5 MTT Cell Viability Assay  
The effects of RRM-MV, RRM-MV-C and three negative control peptides on cell viability in 
human skin cancer cells and normal skin cells were assessed using MTT assay.  The cells were 
treated with 100 ng/mL; 200 ng/mL; 400 ng/mL; 800 ng/mL and 1600 ng/mL of the peptides for 
3 h incubation experiments or with 25 ng/mL; 50 ng/mL; 100 ng/mL; 200 ng/mL; 400 ng/mL and 
800 ng/mL for 18 h.  The cell viability study was carried out as previously described in section 
3.3.6. 
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4.3.6 Lactate Dehydrogenase (LDH) Assay 
The cytotoxic effects of the RRM-MV, RRM-MV-C and three negative control peptides on LDH 
released in human cancer cells and normal skin cells were determined by Lactate dehydrogenase 
(LDH) assay.  The cells were treated in triplicates with 800 ng/mL of all peptides for 3 h.  LDH 
was released from damaged cells measured as directed on the Cytotoxicity Detection Kit (Roche 
Diagnostics, USA) (section 3.3.5). 
 
4.3.7 Hemolysis Assay 
The hemolytic effect of the RRM-MV, RRM-MV-C and three negative control peptides on 
human erythrocytes was examined.  Hemolysis assay was carried out as described in section 
3.3.8.   
4.3.8 Data Analysis 
Statistical analysis was performed using as described in section 3.3.9.   
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4.4 RESULTS & DISCUSSION 
In this study, the biological activity of the non-bioactive control peptide RRM-MV-C and the 
three negative control peptides MV-C1, MV-C2 and MV-C3 was evaluated on human skin 
cancer and normal cells in vitro in comparison with the bioactive peptide RRM-MV.  All 
negative control peptides were specifically designed not to possess the anticancer activity.  
Peptide sequences, formula, number of amino acids, estimated half-life in vitro, instability index, 
predicted theoretical pI MW and experimental MW were analysed by ExPASy as listed in Table 
4.1.  All peptides were classified as stable. 
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Table 4.1.  The characteristics of all peptide used including sequences , formula, number of amino acid, estimated half-life in vitro, the 
instability index, predicted theoretical MW and experimental MW after analysed using ExPASy server.   
 
  
Peptides peptide Sequences Formula 
Amino 
acid (aa) 
Half-life 
Instability 
index (II) 
Theoretical pI 
MW 
Experimental 
MW (kDa) 
RRM-MV MDDRWPLEYTDDTYEIPW C107H145N23O35S1 18 30 h 27.32 3.66 2345.5 
RRM-MV-C DDDCWHVLEKWTDDDRQA C95H135N27O35S1 18 1.1 h 33.92 4.04 2247.3 
MV-C1-end MDDRWPLEYTDDTYEIWP C107H145N23O35S1 18 30 h 30.52 3.66 2345.5 
MV-C2-mid MDDRWPELYTDDTYEIPW C107H145N23O35S1 18 30 h 36.98 3.66 2345.5 
MV-C3-side MDDRWPLEYTDTDYEIPW C107H145N23O35S1 18 30 h 27.32 3.66 2345.5 
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The evaluation of the biological effects of the bioactive peptide RRM-MV, the non-bioactive 
peptide and the three negative control peptides on the human skin cancer cells and normal skin 
cells were performed by qualitative and quantitative assays. 
 
 The effects of peptides on morphological features in human melanoma and carcinoma cells were 
examined by CLSM.  Melanoma and carcinoma cells were treated with 100 ng/mL, 200 ng/mL 
and 400 ng/mL of RRM-MV, RRM-MV-C and three negative control peptides for 3 h.  The 
results revealed that the bioactive peptide (RRM-MV) has a low toxic effect on MM96L 
melanoma cells and COLO-16 carcinoma cells at 100 ng/mL compared to untreated cells (Figure 
4.1A and 4.2A respectively).  Yet, by increasing the dose to 200 ng/mL (Figures 4.1B  and 4.2B) 
and 400 ng/mL of (RRM-MV) (Figure 4.1C and 4.2C), the RRM-MV treatment affected the 
growth of the MM96L and COLO-16 cell lines causing apoptotic and/or necrotic effects and cell 
detachment from the adherent confluent layer.  The necrotic and apoptotic cells which had lost 
their membrane integrity and appeared red or green respectively displayed the changes in 
morphological characteristic of the cells.  It appeared that the RRM-MV treatment led to 
apoptotic and necrotic effects in a dose-dependent manner within 3 h of incubation.  
Interestingly, RRM-MV-C and the other three negative control peptides did not induce apoptotic 
and/or necrotic effects on MM96L melanoma cell line and on COLO-16 carcinoma cell line.  
This finding suggests that the application of the non-bioactive peptide lacking the RRM bioactive 
frequency resulted in the loss of RRM-MV anticancer function.  Similarly, the three negative 
control peptides with changes in the order of one amino acid within the RRM-MV sequence did 
not produce any anticancer effect.    
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                                                              Figure 4.1.A. 
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Figure 4.1.B. 
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Figure 4.1.C. 
 
 
RRM-MV 
  
 
RRM-MV-C 
  
 
MV-C1 
  
 
MV-C2 
  
 
MV-C3 
  
PI Alexa Fluor Combined: Alexa+ PI   
 141  
 
Figure 4.1.  CLSM micrographs of apoptosis and/or necrosis in malignant melanoma cell line 
(MM96L).  Cells were incubated with RRM-MV, RRM-MV-C or three negative control peptides 
(MV-C1, MV-C2 and MV-C3) for 3 h at the following concentrations: 100 ng/mL in (A); 200 
ng/mL in (B); or 400 ng/mL in (C).  After incubation, cells were double stained with Annexin V-
Alexa Fluor 488 (AF488) conjugate and propidium iodide (PI).  These CLSM images show that 
RRM-MV induced cell apoptotic and/or necrotic effects compared with untreated cells.  
However, these effects were not seen in the RRM-MV-C or in any of the three negative control 
peptides.  The panels on the left hand side show the combination of AF488 and PI images. 
AF488 channels show apoptotic cells labeled with green-fluorescent, and PI channels show 
necrotic cells labeled with red-fluorescent (100 x magnification).  CLSM images were taken with 
Nikon Eclipse Ti-E A1 laser-scanning confocal system, and analysed with the NIS-Element 
imaging software.‖  
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Figure 4.2.A. 
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Figure 4.2.B. 
 
  
 
RRM-MV 
  
 
RRM-MV-C 
  
 
MV-C1 
  
 
MV-C2 
  
 
MV-C3  
 
PI Alexa Fluor Combined: Alexa+PI   
 144  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.C. 
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4.2.  CLSM images of apoptosis and/or necrosis in human squamous cell carcinoma (COLO-16) 
cell lines.  Cells were incubated with RRM-MV, RRM-MV-C or three negative control peptides 
for 3 h at the following concentrations: 100 ng/mL in (A); 200 ng/mL in (B); or 400 ng/mL in 
(C).  After incubation, cells were double stained with AF488 and PI.  These CLSM images show 
that RRM-MV caused cell apoptotic/necrotic effects within 3 h of incubation.  AF488 channels 
show apoptotic cells labeled with green-fluorescent, and PI channels show necrotic cells labeled 
with red-fluorescent (100 x magnification). 
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Furthermore, the apoptotic and necrotic effects of peptides on normal human skin cells were also 
examined using CLSM.  HDF cell line was treated with 400 ng/mL and 800 ng/mL of RRM-MV, 
RRM-MV-C and the three negative control peptides for 3 h.  The CLSM micrograph results 
showed no morphological changes and/or observation of apoptosis or necrosis at the 
concentration of 400 ng/mL and 800 ng/mL for all tested peptides incubated for 3 h when 
compared with the untreated cells (Figures 4.3A and 4.3B, respectively).  This suggests that 
RRM-MV, RRM-MV-C and three other negative control peptides did not trigger morphological 
changes and cytotoxic effects in normal human skin cells.  This finding is in agreement with 
research by Istivan et al., (Istivan et al., 2011) showing that RRM-MV has apoptotic and necrotic 
effects on the murine melanoma cell line B16F0 but lacking this effect on normal murine skin 
cells.   
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Figure 4.3.A. 
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Figure 4.3.B. 
  
 
RRM-MV 
  
 
RRM-MV-C 
  
 
MV-C1 
  
 
MV-C2 
 
 
 
 
MV-C3 
  
PI Alexa Fluor Combined: Alexa+PI   
 149  
 
Figure 4.3.  CLSM images of normal human dermal fibroblast (HDF) cell line following 
treatment with RRM-MV, or RRM-MV-C or any of the three negative control peptides for 3 h.  
Cells were incubated with the peptides at the following concentrations: 200 ng/mL in (A); or 400 
ng/mL in (B), then double stained with AF488 and PI.  No apoptotic and/ or necrotic effects were 
detected in human normal skin cell line treated with all peptides (100 x magnifications). 
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The observation of the apoptotic and necrotic assessment was further confirmed by an 
examination of the cell viability by the MTT assay.  Cell viability in the presence of various 
concentrations of the RRM-MV, RRM-MV-C and three control peptides was determined to 
assess the effect of peptides on human skin cancer cell viability using cell viability MTT assay.  
MM96L and COLO-16 cell lines were incubated with 100 ng/mL, 200 ng/mL, 400 ng/mL, 800 
ng/mL and 1600 ng/mL of all peptides for 3 h.  Data analysis of results demonstrate that cell 
survival in MM96L and COLO-16 cell lines reduced clearly with increasing doses of RRM-MV 
as compared to untreated cells after 3 h incubation time in both cell lines (p < 0.001).  Incubation 
of skin cancer cells for 3 h at the highest concentration (1600 ng/mL) indicated that RRM-MV 
significantly reduced cell survival in both MM96L and COLO-16 cell lines.  The percentage of 
cell viability was 65.07% in MM96L cell line and 44.10% in COLO-16 cell line.  On the other 
hand, RRM-MV-C and the three control peptides did not show any effect on cell survival at all 
concentration used during the 3 h incubation time (Figure 4.4A for MM96L and 4.4B for COLO-
16).   
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                                                   Figure 4.4 (A, B and C). 
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Figure 4.4.  Cellular viability of human skin cancer and normal skin cell lines incubated with 
RRM-MV, or RRM-MV-C or any of the three negative control peptides for 3 h.  MM96L cell 
line in (A), COLO-16 cell line in (B) and HDF cell line in (C) were incubated with 100 ng/mL, 
200 ng/mL, 400 ng/mL, 800 ng/mL and 1600 ng/mL of peptides for 3 h.  Cells treated with 90% 
DMSO were used as positive controls.  The effect on cell viability was measured by MTT assay 
and the optical density (OD) was measured at 595 nm.  Results were reported as percentage of 
cell viability, where the OD value from untreated cells was set at 100% of cell viability.  The bars 
in the graph show mean ± standard error of three independent experiments in triplicate.  
Statistical significance of the differences between RRM-MV-treated cells and untreated cells 
were analysed using one-way ANOVA and Tukey post hoc test.  RRM-MV treatment caused 
reduction in cell viability in melanoma and carcinoma cells.  The cellular viability values of 
RRM-MV treated cells were significantly different from those of untreated melanoma and 
carcinoma cells (P<0.001). 
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Interestingly, longer incubation time of MM96L and COLO-16 cell lines with all peptides up to 
18 h with 25 ng/mL, 50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL, showed that 
even lower concentration of 25 ng/mL of RRM-MV triggered a statistically significant 
diminution in cell survival comparing with untreated cells (p < 0.001 in MM96L and COLO-16).  
The percentage of cell viability was 73.03% and 71.38% in MM96L and COLO-16 cell lines 
respectively (Figures 4.5A and 4.5B).  However, RRM-MV-C and the three control peptides did 
not show cell survival reduction in any of the concentration used during the 18 h incubation 
period.  This observation clearly indicates that the toxic responses in human skin cancer cells 
substantially increased with the increasing doses of RRM-MV treatment and time incubation; 
thus, the RRM-MV treatment decreases cell survival in dose- and time-dependent manners within 
18 h.  Nevertheless, RRM-MV-C and the three negative control peptides did not display any toxic 
effect on the tested cancer cells. 
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                                                       Figure 4.5 (A, B and C).  
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Figure 4.5.  Cellular viability assessment for dose and time responses to RRM-MV, RRM-MV-C 
or the three negative control peptides treatment in human skin cancer and normal cell lines.  
MM96L cell line in (A), COLO-16 cell line in (B) and HDF cell line in (C) were incubated  with 
25 ng/mL, 50 ng/mL,100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL of all peptides for 18 h.  
Cells from each cell line were treated with 90% DMSO and used as positive controls.  The effect 
of the peptides on cell viability was assessed using MTT assay.  Results were reported as 
percentage of cell viability, where the OD value from untreated cells was set at 100% of cell 
viability.  Bars indicate the mean ± standard error of three independent experiments in triplicate.  
Statistical evaluation was performed by using one-way ANOVA and Tukey post hoc test.  The 
RRM-MV-treated cells were significantly different from untreated cells in cancer cells (P < 
0.001). 
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Furthermore, the effects of the RRM- MV, RRM-MV-C and the three control peptides on the 
viability of normal human skin cells were evaluated using the cell viability MTT assay.  The cells 
were incubated with 100 ng/mL, 200 ng/mL, 400 ng/mL, 800 ng/mL and 1600 ng/mL of all 
peptides for 3 h or for 18 h.  Data analysis of results revealed that the RRM-MV treatment had no 
effect on HDF cell survival within the investigated concentration range and incubation period as 
compared to untreated cells.  Moreover, no significant loss in cell survival was observed with the 
non-bioactive peptide and the three control peptides even at the highest concentration of 1600 
ng/mL on the HDF cell line for 3 h or for 18 h (Figures 4.4C and 4.5C, respectively).  This 
clearly indicates that none of the peptide has a toxic effect on normal human skin cells or 
reduction in cell viability, indicating that RRM-MV was selective for the cancer cells only.  
Moreover, RRM-MV-C and the three control peptides showed non-specific apoptotic induction 
and non cytotoxic action in both cancer cells and normal cells.  This is supported by previous 
studies showing that the high concentrations of the bioactive peptide resulted in the significant 
toxic effect on a variety of mammalian tumor cell lines but not in mouse normal cells and this 
toxic effect was in a dose and time dependent manner (Istivan et al., 2011; Pirogova et al., 2010; 
Pirogova et al., 2011). 
 
 The assessment of cellular viability was further documented by an evaluation of the LDH release 
by Lactate dehydrogenase (LDH) assay.  LDH release was measured to determine the membrane 
integrity after peptide treatment in skin cancer cells (MM96L and COLO-16 cell lines) and 
normal skin cells (HDF cell line).  The cells were treated with 800 ng/ml of RRM-MV, RRM-
MV-C, and three negative control peptides for 3 h.  Data analysis of results indicated that the 
release of LDH from cells into the culture medium had a statistically significant increase in 
MM96L and COLO-16 cell lines after the RRM-MV treatment as compared to the untreated 
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cells.  The percentage of cytotoxicity was 26.47% in MM96L cell line and 59.53% in COLO-16 
cell line, whereas, it was below 4% in both cancer cells after treatment with RRM-MV-C and the 
three negative control peptides.  Yet, RRM-MV did not significantly induced LDH release in 
HDF normal cells as the cytotoxicity remained at the rate of 0.52%.   In addition, there was no 
significant difference in LDH release post treatment between the non-bioactive peptides sample 
and the three negative control peptides (Figure 4.6).  This finding suggests that the RRM-MV 
treatment caused plasma membrane rupture and cellular damage leading to a greater cytotoxic 
effect in melanoma cells and carcinoma cells with the investigated concentration range.  It is 
known that an increase in the amount of dead cells or plasma membrane rupture resulted in rise in 
LDH release from damaged cells and it is a signal of high membrane permeability, usually linked 
to membrane rupture (Haslam et al., 2000).  On the other hand, the plasma membrane remains 
intact during treatment with the bioactive peptide, the non-bioactive peptide or the three negative 
control peptides in all normal cells.   
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Figure 4.6.  The toxic effects measured by LDH release from human skin cancer and normal skin 
cells following peptide treatment.  LDH levels in the cells were measured after incubation with 
with 800 ng/mL of the tested peptide for 3 h.  RRM-MV produced high cellular LDH levels in 
cancer cells.  Cytotoxicity values were analysed using one-way ANOVA and Tukey post hoc test.  
They showed a significant difference between RRM-MV-treated cells and untreated cells (p < 
0.01).  Results are the average of three independent experiments in triplicates. 
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The observations from the apoptotic and necrotic assay by CLSM, the cell viability MTT assay 
and the cytotoxicity LDH assay indicated that the cancer cells are permeable and endured major 
cell membrane perturbations.  In most cases, this is related to cell death; hence our data 
confirmed the toxicity of the bioactive peptide in cancer cells, also the lack of toxic activity of the 
non-bioactive peptide and the three negative control peptides.   
 
Furthermore, in this study, the effect of peptides on human erythrocytes was assessed after 
peptide treatment using hemolysis assay.  The human erythrocytes were incubated with RRM-
MV, RRM-MV-C or the three negative control peptides at the following concentrations: 50 
ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL, 600 ng/mL, 800 ng/mL, 1000 ng/mL, 1200 
ng/mL, 1400 ng/mL and 1600 ng/mL for 18 h.   The results showed that none of the peptides had 
a hemolytic effect on human erythrocytes at all the concentrations used as compared to the 
positive control of complete lysis (Figure 4.7).  Hence, human erythrocytes appear to be 
relatively resistant to the treatment with all above mentioned peptides.    
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Figure 4.7.  The hemolytic effect of RRM-MV, RRM-MV-C, and the three negative control 
peptides on human erythrocytes.  Washed erythrocytes in PBS were incubated for 18 h with the 
following concentrations of the peptides: 50 ng/mL; 100 ng/mL; 200 ng/mL; 400 ng/mL; 600 
ng/mL; 800 ng/mL; 100 ng/mL; 1200 ng/mL; 1400 ng/mL; and 1600 ng/mL Erythrocytes 
without peptide treatment were used as a no hemolysis control.  Erythrocytes in distilled water 
were used as a total hemolysis control.   Human erythrocytes were relatively resistant to all 
peptides treatment when incubated for up to 18 h, as hemolytic effects were not detected after 
treatment with all peptides.  Data values are the average of three independent experiments in 
triplicates. 
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4.5 CONCLUSION 
Peptides have enormous potential as therapeutic agents due to their ease of rational design and 
target specificity, moreover, the peptide properties have high biological activity, high specificity 
to cancer cells and low toxicity to normal cells that give them a larger application in cancer 
therapy (Zompra et al., 2009).  In our previous study, we demonstrated that the bioactive peptide 
(RRM-MV) designed with special frequencies and phases to mimic the bioactivity of the 
myxoma virus protein M-T5 has cytotoxic effects on murine skin cancer cells when compared 
with the negative control peptide RRM-C in a dose and time-dependent manner (Istivan et al., 
2011). 
 
In the current study and as a continuation of the results obtained in the previous work (Istivan et 
al., 2011), we proved that this bioactive peptide also has a dose and time-dependent anticancer 
activity on human skin cancer cells.  Here we demonstrated that the designed non-bioactive 
peptide did not produce the same toxic effect of the bioactive peptide.  The non-bioactive peptide 
possesses non-active frequencies and phases and does not express M-T5 protein activity.  
Moreover, we postulated that changing the order of one amino acid within the sequence of the 
bioactive peptide would lead to loss of its anticancer activity; thus, the three negative control 
peptides were designed.  We have examined the toxic efficacy of all peptides mentioned earlier 
on human skin cancer cells and normal cells in vitro by quantitative and qualitative cytotoxicity 
assays and compared the cytotoxic activity of the bioactive peptide with all negative control 
peptides.  These have been evaluated by measuring characteristic morphological changes 
(apoptotic and necrotic effect), cell survival and by hemolytic effects on human erythrocytes.   
 162  
 
 
Based on quantitative and qualitative cytotoxicity assays, the bioactive peptide (RRM-MV) 
induced significant cellular apoptotic and /or necrotic effects in human skin cancer cells while the 
non-bioactive peptide (RRM-MV-C) and the three negative control peptides did not show the 
same effect on these cells.  Cell viability results showed the reduction in cell survival in a dose 
and time dependent manner and also induced plasma membrane damage by an increase of LDH 
release in human skin cancer cell lines.  This evidences that the cells enter a cell death pathway 
(Elmore, 2007; Halliwell, 2000), but, these events did not occur in normal human skin cell lines 
when treated with the bioactive peptide.  On the other hand, the findings revealed that the effects 
of the non-bioactive peptide and the three negative control peptides were negligible on cancerous 
and normal cells.  The cytotoxicity data of the bioactive peptide substantiates the observations 
seen in the CLSM micrographs where an increase of LDH release from cancer cells and a 
reduction of cancer cell viability corresponded to the intensity of cellular apoptosis and necrosis 
detected by CLSM.  Overall, the experimental results clearly indicate that the bioactive peptide 
has a significant cytotoxic effects directed against cancer cells, yet it has negligible effects on 
normal cells.  No cytotoxic effects were detected with the non-bioactive peptide or the three 
negative control peptides.  The experimental data also indicates that the bioactive peptide could 
be a promising candidate for use as an anticancer therapy. 
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4.6 FUTURE PERSPECTIVE 
Cancer is one of the leading causes of death worldwide including in the developed countries, and 
its occurrence is increasing (Xue & Stauss, 2007).  Anticancer peptides are treatments with high 
therapeutic action on cancer cells and minimum undesirable side effect on normal cells (Park et 
al., 2005; Zompra et al., 2009). 
The biological effects of RRM-MV on human skin cancer cells are interesting and require further 
investigation.  Recently, we demonstrated that RRM-MV was able to induce cell death in cancer 
cells; however, it had negligible toxic effect on normal skin cells.  These features are making it an 
attractive candidate as a therapeutic agent.  Studies on the anticancer effects of this bioactive 
peptide can be extended to include cancer types such as breast cancer will help to proof their 
apoptotic effect.    
 
 It is believed that the regulation of Akt activation is impaired in cancer cells (Wang et al., 2006).  
It was previously shown that viral M-T5 binds with phospho-Akt to regulate Akt signalling in 
some human cancer cells (Werden et al., 2007; Werden & McFadden, 2008).  Thus, the effect of 
the bioactive peptide on Akt activation in skin cancer cell lines will be studied to detect the 
possible cellular pathway that is affected by the bioactive peptide.   
 
Likewise, the cytotoxicity of the bioactive peptide needs to be further investigated in vivo in 
animal models (mice with induced tumors) to assess its suitability as a future cancer therapeutic.   
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4.7 EXECUTIVE SUMMARY  
 RRM-MV is a bioactive peptide designed using RRM with special frequencies and phases that 
mimic the bioactivity of the specific myxoma virus protein such as M-T5. 
 RRM-MV-C is a non-bioactive peptide designed by RRM as a negative control peptide which 
possesses non-active frequencies and phases. 
 MV-C1, MV-C2 and MV-3 are three negative control peptides which are designed by altering the 
order of one amino acid within the sequence of the bioactive peptide. 
 RRM-MV targets and lethally harms cancer cells and leaves normal cells unharmed, thus, it has 
selective biological effects on cancer cells and with little or no potential side effects on normal 
cells. 
 RRM-MV enhanced toxicity effects on the cancer cells and their anticancer activity is dose and 
time dependent. 
 RRM-MV-C is found to have no toxicity effects on human skin cancer and normal human skin 
cell lines.   
 The three negative control peptides for RRM-MV did not induce any cytotoxic activity on human 
skin cancer and normal human skin cell lines.    
 The outcome of this study awards important information for the development of potential 
anticancer agents.   
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CHAPTER 5 
Molecular Evaluation of a Bioactive de novo Designed 
Peptide on Apoptosis Signalling Pathways in Human Skin 
Cancer in vitro 
 
 
5.1 ABSTRACT 
Background: The development of innovative therapies with improved efficacy is critical to 
treatment of cancer.  Peptide therapy is one of novel approaches in developing cancer 
therapeutics.  It focuses on small peptides with maximum antitumor activity to cancer cells and 
minimum toxicity to normal cells.  It was reported that M-T5, the ankyrin-repeat protein, is 
critical for virus replication in the majority of human tumor cells.  RRM-MV is a bioactive 
peptide analogue for myxoma virus protein (M-T5) designed by the Resonant Recognition Model 
(RRM) to mimic the activity of M-T5.  The objective of this study/chapter was to evaluate the 
biological effects of RRM-MV treatment on survival of human skin cancer cells and normal cells 
in vitro. A second objective was to investigate the possible cell death pathways in skin cancer 
cells that are affected by the RRM-MV treatment. 
Methodology/Principal Findings: The toxic effects of the bioactive peptide treatment were 
determined on cell viability of melanoma, carcinoma and normal cells at different doses and 
different incubation times using Prestoblue cell viability assay.  The levels of apoptosis-related 
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proteins before and after treatment with RRM-MV in melanoma and carcinoma cells were 
detected using Human Apoptosis Protein Array Kit.  The results indicated that RRM-MV 
produced time and dose dependent cytotoxic effects on cancer cells, while it has negligible 
effects on normal cells.  The treated cells recovered after 16 h of the treatments.  We also found 
that the levels of pro-apoptotic proteins were increased, while the levels of anti-apoptotic proteins 
were decreased after RRM-MV treatment in in melanoma and carcinoma cells.  Because p53 and 
cleaved casapase-3 proteins play a significant role in cell death and are the potential targets for 
RRM-MV treatment, the cellular expression of p53 and cleaved casapase-3 proteins in melanoma 
and carcinoma cells were assessed by immunoblotting at different incubation times.  We found 
that the levels of these proteins increased after RRM-MV treatment.   
Conclusions/Significance: The findings of this study/chapter indicate that the RRM-MV induced 
cell death via increase of pro-apoptotic proteins expression and reduction of anti-apoptotic 
proteins expression in the studied melanoma and carcinoma cells.  
 
This chapter has been prepared as a full paper manuscript accepted in PLoS ONE journal. 
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5.2 INTRODUCTION 
Oncolytic virotherapy is the use of viruses to target and destroy cancer cells, as a novel form of 
cancer treatment where virus infections tend to have a positive effect on tumor regression (Dock, 
1904).  The ideal oncolytic virus candidate is required to possess a selective tropism for a tumor 
tissue by exploiting the same cellular defects that promote tumor‘s growth, and little or no ability 
to cause significant effect on normal tissues (Bell et al., 2002; Mullen & Tanabe, 2002; Pedrero 
et al., 2005).  More recently, myxoma virus (MYXV) has been added to an expanding list of 
oncolytic virus candidates (Sypula et al., 2004).  MYXV is a poxvirus of the Leporipoxvirus 
genus and the Chordopoxvirinae subfamily of Poxviridae (Fenner, 2000).  This virus displayed 
oncolytic properties in human cancers in vitro (Barrett et al., 2007; Stanford & McFadden, 2007; 
Sypula et al., 2004; Wang et al., 2006; Woo et al., 2008) and in vivo studies (Lun et al., 2005; 
Lun et al., 2007; Wu et al., 2008).  New ideas and approaches are needed because most cancers 
are resistant to the conventional therapies.  Therefore, an increasing number of small molecules 
and therapeutic peptides have been developed in recent years (Eberle et al., 2008).  Peptides may 
be the key to cancer therapeutics development, and have shown to be promising agents for skin 
cancer therapy and other types of cancer.  They have been classified as a novel class of drugs 
(Bidwell & Raucher, 2009; Raucher et al., 2009).  Therapeutic peptides have many attributes that 
make them attractive as drugs for cancer therapy (Pirogova et al., 2011).  Moreover, these 
bioactive therapeutic peptides have the ability to easily penetrate cellular membranes and to 
interfere with enzymatic functions or protein-protein interactions within cells (Park et al., 2005). 
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In our previous studies, the Resonant Recognition Model (RRM) was applied for structure-
function analysis of known antitumor proteins that include tumor necrosis factor TNF-2 
(Pirogova et al., 2010) interlukin-12 (Pirogova et al., 2011) and myxoma virus (Istivan et al., 
2011).  The RRM is an attempt to identify the selectivity of protein interactions within an amino 
acid sequence (Cosic, 1994b; Cosic, 1995).  It is a physico-mathematical approach to the analysis 
of protein-protein and protein-DNA interactions.  The RRM interprets a protein sequence‘s linear 
information using digital signal analysis (Cosic et al., 1991; Cosic, 1994b; Cosic, 1995; Cosic, 
1997). 
 
RRM-MV is a novel bioactive peptide analogue for MYXV protein (M-T5) designed using the 
RRM (Cosic, 1994b; Cosic, 1997).  It is a synthetic short peptide that was computationally 
designed to mimic the activity of the M-T5 protein (AAC55050, 483 amino acids in length) 
(Istivan et al., 2011).  Non-bioactive peptide RRM-C was also designed using the RRM and was 
used as a negative control peptide (Pirogova et al., 2010).  In addition, our previous research 
showed that the RRM-MV has anti-cancer effect on the B16F0 mouse melanoma cells and lacks 
or produces ineligible cytotoxic effects on normal cells in vitro (Almansour et al., 2012a; 
Almansour et al., 2012b; Istivan et al., 2011)   
 
An external stress such as radiation (UV light) or hypoxia leads to cell death through either 
apoptosis or necrosis.  Apoptosis or programmed cell death occurs in various physiological and 
pathological situations (Hengartner, 2000).  It is characterized by distinctive morphological and 
biochemical hallmarks including membrane blebbing, nuclear pyknosis, DNA fragmentation, and 
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cell shrinkage (Elmore, 2007; Hengartner, 2000).  The two pathways are associated with 
apoptosis called the intrinsic (mitochondrial) and extrinsic (receptor death) pathways.  The first 
type is initiated from cell stress signals and involves activation of pro-apoptosis proteins, for 
instance, Bax and Bak (members of BcL-2 family).  Activation of these proteins leads to release 
of cytochrome c as a result of permeability of mitochondria and also to activation of initiator 
caspases through apoptosome assembly such as initiated caspase-2, 8, 9 and 10.  Hence, 
activation of initiator caspases induce an expanding cascade to activation that eventually leads to 
stimulation of effectors caspase-3, 6 and 7 (Kurokawa & Kornbluth, 2009).  Overall, activation of 
initiator and effector caspases leads to cleavage of specific cellular substrate and hence, 
apoptosis.  In addition, the extrinsic pathway of apoptosis is caused after binding of a pro-
apoptotic ligand to death receptors, which induces receptor clustering and adapter proteins 
recruitment.  This event directly activates initiator caspases, thus converging to the intrinsic 
pathway (Kurokawa & Kornbluth, 2009). 
 
In the current study, cell survival following RRM-MV treatment in human skin cancer and 
normal human skin cells was determined by the cell viability assay.  In addition, to explain the 
mechanism of RRM-MV, as anti-cancer therapy, in human skin cancer cells in vitro, we 
investigated the molecular pathways induced by the RRM-MV to promote apoptosis in cancer 
cells. 
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5.3 METHODS 
5.3.1 Peptides Design  
In the present study, the bioactive peptide (RRM-MV) and the non-bioactive peptide (RRM-C) 
were designed using the RRM approach as described in section 3.6. 
 
5.3.2 Peptides Preparation 
RRM-MV and RRM-C at different concentrations were prepared as described in section 3.3.3. 
 
5.3.3 Cell Culture  
The human malignant melanoma (MM96L) and human squamous cell carcinoma cell lines 
(COLO-16) were cultured as described in section 2.3.3.1.  Normal human dermal fibroblast 
(HDF) cell line was propagated as described in section 2.3.3.2.   
 
5.3.4 Cell Survival Assay 
To determine the effect of the bioactive and non-bioactive peptides on cell viability of skin 
cancer and normal skin cells, the number of viable cells was measured by Prestoblue
TM
 Cell 
Viability assay which was conducted according to the manufacturer‘s protocol.  Briefly, cells 
were cultured in 96 well plates at a density 2 × 10
5
 cells/mL and incubated overnight.  Skin 
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cancer cells were then treated with 50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL 
of RRM-MV or RRM-C for 4 h, 8 h, 16 h, 24 h, 48 h and 72 h.  Normal skin cells were treated 
with 50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL of RRM-MV or 800ng/mL 
RRM-C for 4 h, 24 h, 48 h and 72 h.  Following incubation, 10 µL of Prestoblue
TM
 Cell Viability 
reagent (Invitrogen, USA) were added and incubated under standard conditions of 5% CO2 and 
37ºC for 30 min.  OD values were measured using POLARstar Omega Microplate Reader (BMG 
LABTECH, Australia) at 570nm.  The absorbance of the background (medium) was subtracted 
from each well of untreated and treated cells.  The OD at 570nm measured from untreated cells 
was considered to be 100% of cell viability.  The percentage of cell viability was calculated as 
follows: 
100 × [(OD 570nm of treated cells) / (OD 570nm of untreated cells)].  The experiments were 
performed at least three times independently in triplicates. 
 
5.3.5 Cell Recovery Assay 
To determine whether the bioactive and the non-bioactive peptides effects on viability were 
reversible and to assess the degree of cell recovery, the Prestoblue cell viability assay was 
performed according to the manufacturer‘s protocol.  Skin cancer cells were seeded in 96 well 
plates at a density of 2 × 10
5
 cells/mL and incubated overnight.  Cells were treated with 50 
ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL of RRM-MV or 800 ng/mL of RRM-
C for 16 h.  After the 16 h treatment, a second dose of RRM-MV or RRM-C, at each of the 
concentrations mentioned above, was added and cells were further incubated for another 4 h, 8 h, 
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24 h and 48 h.  Cell viability was evaluated as indicated in cell viability assay.  The experiments 
were performed at least three times independently in triplicates. 
 
5.3.6 Human Apoptosis Related Proteins Array 
To assess the levels of apoptosis related proteins before and after the bioactive peptide treatment 
in human skin cancer cells, a human apoptosis protein array (R&D Systems, Minneapolis, MN, 
USA) was performed as directed by the manufacturer‘s protocol.  Briefly, cells plated on 75 cm2 
culture flasks were grown to about 90% confluence.  The MM96L cell line was then treated with 
400 ng/mL of RRM-MV for 4 h and the COLO-16 cell line treated with 200 ng/mL for 1 h.  
Proteins were extracted and quantified by Bradford method (Bradford, 1976) as described in 
section 2.4.2.1.1.  Cell lysates (500 µg) were incubated onto an array membrane at 4 ºC overnight 
and the membrane were washed three times for 10 min.  The array membranes were then 
incubated with the reconstituted detection antibody cocktail for 1 h and washed three times for 10 
min.  After incubating with horseradish peroxidase (HRP)-linked secondary antibody at a dilution 
of 1:2000, the signals were visualized by Chemiluminescent HRP reagent (Millipore, Australia).  
Densitometry of protein spot signals were detected and quantified with the Quantity One 
Analysis 4.3.0 software (Bio-Rad Laboratories).  The average density of duplicate spots 
representing each apoptosis-related protein was calculated.   
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5.3.7 Protein Extraction 
Cancer cells were seeded in a six-well tissue culture plate overnight with a density of 7 × 10
 5 
cells/mL and cells were then treated with 200ng/mL of RRM-MV for 15 min, 30 min and 60 min.  
Cells were washed twice with cold PBS.  After treatment, PhosphoSafe™ Extraction reagent 
(Novagen, USA) mixed with Protease Inhibitor Cocktails (Sigma-Aldrich, USA) was added and 
the plate was incubated for 10 min at room temperature.  Cells were scraped and centrifuged at 
16,000 xg for 5 min at 4 °C.  The supernatants were collected and the protein concentration was 
quantified by the Bradford method as described in section 2.4.2.1.1  . 
 
5.3.8 Immunoblot Analysis 
Protein samples (30 µg) were mixed 1:5 with 5x sample buffer and heated to 95
o
 C for 5 min.  
Proteins were separated on 12.5% SDS polyacrylamide gel and then transferred onto a 
nitrocellulose membrane by iBlot Dry Blotting System (Invitrogen, USA).  The primary 
antibodies, anti-phospho-p53 (S46) (dilution, 1:1000) and cleaved casapaes-3 (dilution, 1:2000), 
were purchased from R&D Systems (Minneapolis, MN, USA).  The β-Actin (dilution, 1:3000) 
was purchased from Cell Signaling Technology (Beverly, MA).  Membranes were blocked, 
washed and incubated with the primary antibodies according to the manufacturer's protocol.  The 
membranes were incubated with peroxidase-conjugated anti-rabbit secondary antibody diluted 
1:3000 at room temperature for 1 h and then washed.  Specific bands were detected 
colorimetrically with BCIP/NBT substrate (Amresco, USA) mixed with the detection buffer (v/v) 
and quantified using the Quantity One Analysis 4.3.0 software (Bio-Rad Laboratories).   
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5.3.9 Statistical Analysis 
Statistical analysis of cell viability and recovery assays was performed as described in section 
3.3.9.  Significant changes of protein expression in the human apoptosis protein array, before and 
after the RRM-MV treatment, were determined by two-way ANOVA followed by a Tukey post 
hoc test. 
 
5.4 RESULTS 
5.4.1 Evaluation of Cell Viability in RRM-MV Treated Cancer Cell Lines 
The toxic effects of the bioactive peptide RRM-MV and the negative control peptide RRM-C on 
cell viability were examined with different dose and incubation periods in human skin cancer 
cells using Prestoblue cell viability assay.  Skin cancer cells were treated with 50 ng/mL, 100 
ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL of RRM-MV or RRM-C for 4 h, 8 h, 16 h, 24 h, 
48 h and 72 h.  The results showed that a significant reduction in cell viability was noticed for the 
MM96L cell line at 4 h of treatment with the RRM-MV concentrations‘ range of 50 ng/mL to 
800 ng/mL as compared to untreated cells.  The cells then started to recover slowly after 16 h up 
to 72 h.  The highest concentration (800 ng/mL) of RRM-MV produced a maximum cytotoxic 
effect in the MM96L cell line during the incubation times (Figure 5.1A).  On the other hand, the 
cellular viability of the COLO-16 cell line was decreased at 8 h of incubation with the highest 
concentrations of RRM-MV (200 ng/mL, 400 ng/mL and 800 ng/mL) as compared to untreated 
cells.  However, after 16 h of the treatment, cell viability was gradually increased and cell grew 
faster than average after 42 h of the treatment with the higher concentrations of RRM-MV 
(Figure 5.2A).  Apparently, melanoma cells were more sensitive to the RRM-MV treatment than 
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carcinoma cells and the treatment had a limited time effect on these cell lines; hence, the cells 
required to be treated with a second dose of the treatment.  Interestingly, RRM-C treatment 
showed no significant differences in cellular viability of the MM96L and COLO-16 cell lines at 
all doses and incubation times compared to untreated cells (Figures 5.1B and 5.2B, respectively).  
In summary, the melanoma and carcinoma cells responded differently to the RRM-MV treatment, 
with melanoma cells tend to be more sensitive to the treatment than the carcinoma cells.  
Moreover, the bioactive peptide induced toxic effects on both cell types in dose- and time-
dependent manner.  However, the non-bioactive peptide did not produce a significant cytotoxic 
effect toward tested cell lines even at the longest treatment period.   
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Figure 5.1.  Cell viability of melanoma cells incubated with the bioactive and non-bioactive peptides 
at different concentrations up to 72 h.  The MM96L cell line treated with RRM-MV is presented in 
(A) or RRM-C in (B).  Cells were seeded at a density 2 × 10
5 
cells/mL overnight and incubated for 4 
h, 8 h, 16 h, 24 h, 48 h and 72 h with 50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL 
of RRM-MV or with RRM-C.  Cell viability was determined using Prestoblue
TM
 reagent.  The optical 
density (OD) was measured at 570 nm and set at 100% of cell viability.  Each bar represents the 
mean± standard error of three independent experiments in triplicates.  Statistical evaluation was 
carried out using one-way ANOVA followed by Tukey post hoc test.  The RRM-MV treated cells 
were significantly different to untreated cells in melanoma cells (P<0.05).  
(A) 
(B) 
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Figure 5.2.  Cell viability of carcinoma cells incubated with the bioactive and non-bioactive peptides at 
different concentrations up to 72 h.  The COLO-16 cell line treated with RRM-MV is presented in (A) or 
treated RRM-C in (B).  Cells were plated at a density 2 × 10
5 
cells/mL
 
overnight and treated with 50 
ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL of RRM-MV or with RRM-C for 4 h, 8 h, 16 
h, 24 h, 48 h and 72 h.  Cell viability was determined using Prestoblue
TM
 reagent.  The optical density 
(OD) was measured at 570 nm and set at 100% of cell viability.  Each bar represents the mean± standard 
error of three independent experiments in triplicates.  Statistical analysis was performed using one-way 
ANOVA and Tukey post hoc test.  The RRM-MV treated cells were significantly different to untreated 
cells in carcinoma cells (P<0.05).  
(B) 
(A) 
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5.4.2 Evaluation of Cell Viability in RRM-MV Treated Normal Skin Cell Line 
The toxic effects of the bioactive peptide and the control peptide on cell viability were assessed 
in normal human skin cell lines at different doses and incubation periods using Prestoblue cell 
viability assay.  Cells were treated with 50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 
ng/mL of RRM-MV or 800 ng/mL RRM-C for 4 h, 24 h and 72 h.  Data analysis of results 
revealed that treatment of HDF cell line with RRM-MV did not trigger toxic effects on cell 
viability at concentrations up to 72 h of incubation period (Figure 5.3) and cells continued to 
grow normally.  In addition, RRM-C treatment did not produce a significant reduction in cell 
viability at 800ng/mL during incubation periods.  Taken together, normal human skin cell 
viability was not affected by different incubation times and doses of RRM-MV treatment.   
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Figure 5.3.  Cell viability of normal human skin cells incubated with the bioactive and non-bioactive 
peptides at different concentrations up to 72 h.  The HDF cell line (3 × 10
5
 cells/mL)
 
was treated with (50 
ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL) of RRM-MV or with 800 ng/mL of RRM-C 
for 4 h, 24 h and 72 h.  Cell viability was determined using Prestoblue
TM
 reagent.  The optical density 
(OD) was measured at 570 nm and set at 100% of cell viability.  Each bar represents the mean± standard 
error of three independent experiments in triplicates.  Statistical evaluation was conducted using one-way 
ANOVA and Tukey post hoc test.  The RRM-MV treated cells were significantly different to untreated 
cells in normal human skin cells (P<0.05). 
 180  
 
5.4.3 Evaluation of Repeated Dose of RRM-MV on Melanoma and Carcinoma Cell 
Viability over Time  
The degree of cell recovery after treatment with different concentrations of RRM-MV was 
determined using PrestoBlue
 
cell viability assay.  The MM96L and COLO-16 cell lines were 
treated with a second dose after 16 h of treatment with the first dose of peptides at similar 
concentrations of RRM-MV (50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL) or 
with 800 ng/mL of RRM-C.  The cell lines were then incubated for further 4 h, 8 h, 24 h and 48 
h.  Data analysis indicated that the second dose affected the viability of MM96L cell line, and the 
highest concentration of RRM-MV (800 ng/mL) reduced cell viability at 4 h of incubation.  
Moreover, all concentrations used produced a significant reduction in cell viability at 8 h as 
compared to untreated cells.  Of note, MM96L cell line started to recover slowly after 24 h, and 
the cells treated with 800 ng/mL of RRM-MV recovered slower than those treated with lower 
concentrations (50 ng/mL, 100 ng/mL, 200 ng/mL and 400 ng/mL) through the incubation times 
(Figure 5.4A).  In the COLO-16 cell line, the second dose of RRM-MV, at 200 ng/mL, 400 
ng/mL and 800 ng/mL, induced significant reductions in cell viability at 4 h of incubation time.  
However, cells slowly reversed to an increase in the percentage of viable cells at all 
concentrations after 24 h as compared to untreated cells (Figure 5.4B).  Interestingly, treatment of 
MM96L and COLO-16 with a second dose of RRM-C (800 ng/mL) did not impact on cell 
viability at any point time during these experiments.  In total, it can be concluded that the second 
dose of RRM-MV at 16 h significantly reduced cell viability and enhanced its cytotoxic effect on 
the melanoma and carcinoma cells.   
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Figure 5.4.  Cell recovery assessment for the second dose of the bioactive and non-bioactive 
peptides after treatment with a first dose at 16 h in melanoma and carcinoma cells.  The MM96L 
cell line in (A) and the COLO-16 cell line in (B) were treated with the first dose of 50 ng/mL, 100 ng/mL, 
200 ng/mL, 400 ng/mL or 800 ng/mL of RRM-MV or with 800 ng/mL of RRM-C for 16 h.  A second 
dose of RRM-MV with the concentrations mentioned above was added after the initial 16 h treatment.  
The cell line was then incubated further for 4 h, 8 h, 24 h and 48 h.  The toxic effect of the peptides on cell 
recovery was determined using Prestoblue
TM
 Cell Viability assay.  Results are reported as percentage of 
cell viability, where the optical density (OD) value from untreated cells was set at 100% of cell viability.  
Bars show the mean± standard error of three independent experiments in triplicates.  Statistical evaluation 
was conducted using one-way ANOVA and Tukey post hoc test.  The RRM-MV treated cells were 
significantly different to untreated cells in melanoma and carcinoma cells (P<0.05).  
(A) 
(B) 
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5.4.4 Assessment of Apoptosis-related Proteins after RRM-MV Treatment in Melanoma 
Cell Line 
To characterize molecular events leading to apoptosis, after being treated with RRM-MV, the 
levels of apoptosis-related proteins in MM96L cell line were detected before and after treatment 
with 400 ng/mL of RRM-MV for 4 h using the apoptosis-related protein antibody array analysis.  
The data analysis revealed that apoptosis related proteins, either pro-apoptotic or anti-apoptotic 
proteins, were significantly affected.  All pro-apoptotic proteins in MM96L treated cells 
increased significantly with 400 ng/mL of RRM-MV after 4 h compared to the levels of pro-
apoptotic protein in MM96L untreated cells.  Among proteins known to mediate apoptosis, the 
levels of pro-apoptotic proteins in RRM-MV treated cells were increased, including Bad, Bax, 
pro-caspase-3, cleaved caspase-3, cytochrome c, TRAIL R1/DR4, TRAIL R2/DR5, FADD, 
Fas/TNFRSF6, HIF-1, HTRA2/Omi, p53 (S15), p53 (S46), p53 (S392), Rad17 (S635) 
SMAC/Diablo and TNF RI/TNFRSF1A proteins (Figure 5.5A).  Conversely, the levels of some 
anti-apoptotic proteins targets within the MM96L treated cells were declined, including Bcl-2, 
Bcl-x, p21/CIP1/CDNK1A, p27/Kip1, cIAP-1, members of the inhibitor apoptosis family (IAPs) 
such as XIAP, survivin and livin, members of the heat shock proteins (HSPs) such as HSP60 and 
Hsp70, detoxifying enzymes such as catalase, HO-1/HMOX1/HSP32, HO-2/HMOX2 as well as 
paraoxonase-2 (PON2).  Noticeably, some of the anti-apoptotic proteins, namely cIAP-2, claspin, 
clusterin and HSP27 were increased after the treatment. In spite of this, there was no influence on 
apoptosis process due to most of anti-apoptotic proteins decreasing after the RRM-MV treatment 
(Figure 5.5B).  Hence, RRM-MV treatment induced mitochondrial transmembrane receptors and 
caused apoptosis via an effect on pro-apoptotic and anti-apoptotic proteins leading to cell death in 
melanoma cells.   
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Figure 5.5.A. 
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Figure 5.5.  The human apoptosis array detection of multiple apoptosis-related proteins from 
MM96L untreated and RRM-MV treated cell lysates.  Pro-apoptotic portions are presented in 
(A) and anti-apoptotic proteins in (B).  The MM96L cell line was were either untreated or 
treated with 400 ng/mL of RRM-MV for 4 h.  The array membranes were incubated with 500 
μg of each cell lysate then array images were collected from 1 min exposures to X-ray film.  
Densitometry of protein spot signals was detected, visualized and quantified with the 
Quantity One Analysis software (Bio-Rad Laboratories).  Image analysis shows that the 
levels of pro-apoptotic proteins increased but levels of anti-apoptotic proteins decreased after 
RRM-MV treatment as an apoptosis response.  Statistical significance of differences in 
RRM-MV treated cells and untreated cells was observed during incubation times and was 
calculated using two-way ANOVA and indicated where significant (p < 0.05).   
(B) 
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5.4.5 Assessment of Aapoptosis-related Proteins after RRM-MV Treatment in Carcinoma 
Cell Line 
To better characterize molecular events leading to apoptosis in COLO-16 cell line after RRM-
MV treatment, apoptosis-related protein array analysis was performed.  Cells were either 
untreated or treated with 200 ng/mL of RRM-MV for 1 h.  The data analysis indicated that 
apoptosis proteins, either pro-apoptotic or anti-apoptotic, were significantly affected.  Among 
proteins known to mediate apoptosis, levels of pro-apoptotic proteins in RRM-MV treated cells 
were increased compared to untreated cells.  The pro-apoptotic proteins, included Bad, Bax, pro-
caspase-3, cleaved Caspase-3, cytochrome c, TRAILR1/DR4, TRAILR2/DR5, FADD, 
Fas/TNFRSF6, HIF-1, HTRA2/Omi, p53 (S15), (S46), and (S392); Rad17 (S635), 
SMAC/Diablo and TNF RI/TNFRSF1A proteins (Figure 5.6A).  On the other hand, members of 
the IAPs family such as cIAP-1, cIAP-2, XIAP, survivin and livin were reduced anti-apoptotic 
proteins were also repressed by RRM-MV treatment such as members of HSPs such as Hsp60 
Hsp27 and Hsp70, as well as detoxifying enzymes such as catalase, hemeoxygenase catalase, 
HO-1/HMOX1/HSP32, HO-2/HMOX2 and PON2; Bcl-2, Bcl-x, p21/CIP1/CDNK1A, p27/Kip1, 
claspin, clusterin (Figure 5.6B).  These findings suggest that RRM-MV treatment affected 
apoptosis-related proteins levels and induced mitochondrial transmembrane receptors which led 
to cell death in carcinoma cells. 
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Figure 5.6.A. 
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Figure 5.6.  The human apoptosis array detection of multiple apoptosis-related proteins from 
COLO16 untreated and RRM-MV treated cell lysates.  Pro-apoptotic portions are presented in 
(A) and anti-apoptotic proteins in (B).  The COLO-16 cell line was either untreated or treated 
with 200 ng/mL of RRM-MV for 1 h.  The array membranes were incubated with 500 μg of each 
cell lysate then array images were collected from 1 min exposures to X-ray film.  Densitometry 
of protein spot signals was detected, visualized and quantified with the Quantity One Analysis 
software (Bio-Rad Laboratories).  Image analysis shows the levels of pro-apoptotic proteins 
induced but levels of anti-apoptotic proteins inhibited after RRM-MV treatment as an apoptosis 
response.  Statistical significance of differences in RRM-MV treated cells and untreated cells was 
observed during incubation time and was calculated using two-way ANOVA (p < 0.05).  
(B) 
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5.4.6 The Effect of RRM-MV Treatment on p53 Activity in Melanoma and Carcinoma Cells  
The effects of the RRM-MV treatment in tumor-suppressor protein p53 activity in MM96L and 
COLO-16 cell lines were assessed by immunoblotting.  Cell lines were incubated with RRM-MV 
for 15 min, 30 min and 60 min at a concentration of 200 ng/mL.  Immunoblot results indicated 
that the level of p53 protein in MM96L treated cells was unchanged at 15 min but increased after 
30 min, and an increase was noticed in the level of p53 at 60 min compared to untreated cells 
(Figures 5.7A and 5.7B).  The same case was observed in COLO-16 cell line when treated with 
RRM-MV (Figures 5.7C and 5.7D).  Hence, these findings show that the RRM-MV treatment 
induced p53 levels within 60 min of treatment in both melanoma cells and carcinoma cells. 
 
6.4.7 The Effect of RRM-MV Treatment on Caspase Activity in Melanoma and Carcinoma 
Cells  
To determine if caspases-3 is involved in inducing apoptosis in MM96L and COLO-16 cell lines 
after RRM-MV treatment, the expression level of cleaved caspases-3 was examined by 
immunoblotting.  The cell lines were incubated with 200 ng/mL of RRM-MV peptide for 15 min, 
30 min and 60 min.  Immunoblot analysis showed that the expression of cleaved caspase-3 in 
MM96L treated cells was unchanged at 15 min but started to increase slightly within 30 min and 
further increased at 60 min as compared to untreated cells (Figures 5.7A and 5.7B).  This 
observation was also noticed in the COLO-16 cell line treated with RRM-MV (Figures 5.7C and 
5.7D).  It appears that the bioactive peptide treatment has affected expression of caspase-3 in 
melanoma cells and carcinoma cells; hence, RRM-MV treatment induced apoptosis via the 
activated caspase-dependent pathways. 
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Figure 5.7.  The effect of the bioactive peptide on the expression of p53 and cleaved caspase-3 in 
melanoma and carcinoma cells.  Immunoblot and analysis for the MM96L cell line are presented 
in (A and B) and the COLO-16 cell line in (C and D).  Cell lysates were prepared and immune-
blotted using p53 antibody and cleaved caspase-3 antibodies.  The β-Actin antibody was also 
used as an internal control.  The figures indicate that RRM-MV treatment affected the expression 
of p53 and cleaved caspase-3 proteins in the MM96L and COLO-16 cell lines at different 
incubation times.  Densitometry of protein spot signals were detected and quantified with the 
Quantity One Analysis 4.3.0 software.  The figure is representative of three independent 
immunoblot experiments.  
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5.5 DISCUSSION 
Peptides present themselves as promising candidates in applications for skin cancer therapy and 
other types of cancer.  They are classified as novel potential therapeutics in cancer treatment 
according to the latest research findings (Pirogova et al., 2011).  These therapies focus on small 
molecular weight peptides with strong tumoricidal activity and low toxicity on normal cells (Park 
et al., 2005).  In recent application of the RRM approach, a short linear bioactive peptide (RRM-
MV) mimicking the activity of the specific MYXV protein (M-T5) was computationally designed 
and then commercially synthesised.  RRM-MV was specifically designed to target and kill cancer 
cells while leaving normal cells unscathed (Istivan et al., 2011; Pirogova et al., 2009; Pirogova et 
al., 2010; Pirogova et al., 2011).  Our research group has been evaluating the activity/toxicity of 
RRM-MV on cancer cells and normal cell in vitro to assess its efficacy in eliminating cancer cells 
and study its toxicity on normal cells.  It has been found that RRM-MV peptide has a toxic effect 
on mouse melanoma cells (Almansour et al., 2012b; Istivan et al., 2011; Pirogova et al., 
2010))(Pirogova et al., 2010).   
 
The current study has evaluated the dose- and time- dependent cytotoxic effects of RRM-MV 
treatment on the cell viability of human skin cancer cells and normal human skin cells at different 
concentrations, ranging from 50 ng/mL to 800 ng/mL, at incubation time periods ranging from 8 
h to 72 h.  Data analysis indicated that although the maximum cytotoxic effect of RRM-MV was 
reached at 4 h and 8 h for melanoma and carcinoma cells, respectively, the cytotoxic effect of 
RRM-MV reduced steadily after 16 h in both treated cells.  A reduction in RRM-MV toxicity was 
observed because the RRM-MV‘s half-life in mammalian reticulocytes in vitro has been 
estimated at 30 h (Artimo et al., 2012).  Therefore, melanoma and carcinoma cells were 
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recovered after 24 h of RRM-MV treatment, indicating the need for a second dose.  However, the 
RRM-MV treatment did not have a significant effect on normal skin cell lines within the 
investigated concentrations ranges for all incubation times.  This result reveals that the bioactive 
peptide targeted and affected cancer cells and left normal skin cells unscathed.  Furthermore, the 
non-bioactive peptide, RRM-C, did not show cytotoxic effects on either human skin cancer or 
normal cells at all concentrations even at the longest treatment periods.   
 
This study also investigated the degree of cancer cell recovery after treatment with a second dose 
of RRM-MV and RRM-C following 16 h of treatment with the first dose of peptides at similar 
concentrations.  The data indicated that a second dose of the RRM-MV treatment significantly 
enhanced the cytotoxic effect on melanoma and carcinoma cells over 72 h, indicating that the cell 
viability was affected by RRM-MV treatment leading to enhancement of cell toxicity with a 
second dose of the bioactive peptide.  On the other hand, RRM-C treatment did not induce the 
cytotoxic effect on both melanoma and carcinoma cells even at the longest treatment period.   
 
Cytotoxic effects of anticancer drugs have been shown to induce apoptosis in target cells 
(Debatin, 1999; Debatin et al., 2002; Herr & Debatin, 2001; Kaufmann & Gores, 2000; Lowe & 
Lin, 2000).  Proteolytic enzymes such as caspases play a critical role as effector molecules in 
apoptosis including cytotoxic therapy-induced cell death (Degen et al., 2000; Earnshaw et al., 
1999; Slee et al., 1999; Thornberry & Lazebnik, 1998; Utz & Anderson, 2000) because the 
activation of caspases leads to induction of apoptosis via disturbance of pro-apoptotic and anti-
apoptotic protein mediators (Reed, 1999).  Therefore, the present study investigated the apoptosis 
signalling pathways in melanoma and carcinoma cells that are targeted by the RRM-MV 
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treatment.  The data obtained from the human apoptosis-related proteins analysis showed that 
pro-apoptotic proteins expressions were enhanced in the RRM-MV treated cells in both tested 
cell lines.  It has been established that anti-cancer drugs can cause activation of most apoptosis 
signalling pathways that eventually leads to activation of caspases, a family of cysteine proteases, 
that perform as common death effector molecules, in several forms of cell death (Earnshaw et al., 
1999; Slee et al., 1999; Thornberry & Lazebnik, 1998; Utz & Anderson, 2000).  We found that 
the RRM-MV treatment induced apoptosis in melanoma and carcinoma cells via the 
mitochondrial pathway such as cytochrome c, apoptosis-inducing factor (AIF), Smac/Diablo, 
Omi/HtrA2, endonuclease G, caspase-2, or caspase-9 (Costantini et al., 2000; Kroemer & Reed, 
2000; Martinou & Green, 2001; Suzuki et al., 2001; van Loo et al., 2002a).  This RRM-MV 
treatment probably also released cytochrome c into the cytosol and triggered caspase-3 activation 
through formation of the cytochrome c/Apaf-1/caspase-9-complex, whereas, Smac/Diablo and 
Omi/HtrA2 promoted caspase activation through neutralizing the inhibitory effects of IAPs.  
These observations support the emerging evidence which suggest that the cytotoxic drugs can 
initiate cell death by triggering the cytochrome c/Apaf-1/caspase-9-dependent pathway through 
the mitochondria (Debatin et al., 2002; Herr & Debatin, 2001). 
 
The current study also showed that the RRM-MV treatment initiated apoptosis through 
transmembrane receptor-mediated interactions in melanoma and carcinoma cells, these death 
receptors are considered as members of the tumor necrosis factor (TNF) receptor (Locksley et al., 
2001).  The treatment also affected other death receptors that include FasL/FasR, TNF-α/TNFR1, 
Apo3L/DR3, Apo2L/DR4 and Apo2L/DR5.  This finding is in agreement with previous studies 
of several groups (Ashkenazi & Dixit, 1998; Chicheportiche et al., 1997; Peter & Krammer, 
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1998; Rubio-Moscardo et al., 2005; Suliman et al., 2001) that showed the death receptors have a 
direct link to cell death processes, and treatment with cytotoxic drugs targeted the death receptors 
leading to apoptosis in cancer cells.  On the other hand, this study found that the protein levels of 
Fas, TRAIL R2 and FADD decreased after 4 h of the RRM-MV treatment in melanoma cells.   
 
The analysis of human apoptosis-related proteins also showed that, after RRM-MV treatment, the 
anti-apoptotic protein expressions were decreased in carcinoma cells including the family of 
caspase inhibitors and IAPs such as XIAP, cIAP1, cIAP2, survivin, and livin.  The induction of 
pro-apoptotic proteins and inhibition of anti-apoptotic proteins, as a response to cytotoxic 
therapy, has been demonstrated by several studies (Adida et al., 1998a; Adida et al., 2000; Li et 
al., 2001a; Salvesen & Duckett, 2002; Tamm et al., 2000).  Our findings obtained for carcinoma 
cells treated with RRM-MV are in agreement with previous studies.   
 
Although most of the anti-apoptotic protein levels were decreased in melanoma cells after RRM-
MV treatment, some of them were increased, including cIAP-2, claspin, clusterin and HSP27.  
This result is in agreement with a previous study that found that the high level of some anti-
apoptotic proteins expression such as survivin in cancer cells make them an attractive target for 
anticancer drug discovery (Zaffaroni et al., 2005).  Moreover, a number of previous studies 
showed that cIAP2 was expressed at high levels in many tumor cells, for example, leukemia, 
neuroblastoma, and several carcinomas (Adida et al., 2000b; Salvesen & Duckett, 2002; Tamm et 
al., 2000).  The induction of some anti-apoptotic protein levels in melanoma cells after RRM-MV 
treatment was not influenced on apoptosis due to most of them decreasing.   
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Due to the p53 and cleaved casapase-3 proteins playing a significant role in cell death and being 
potential targets for RRM-MV treatment, the cellular expression of p53 and cleaved casapase-3 
proteins were further assessed by immunoblotting in melanoma and carcinoma cells at variable 
incubation times.  The immunoblot analysis of p53 protein expression showed that the levels of 
p53 protein increased in RRM-MV treated cells compared with untreated cells at different 
incubation times.  The immunoblot results support our previous studies reporting that RRM-MV-
treatment caused DNA degradion in melanoma cells (Almansour et al., 2012a) which can be 
linked to the increase of p53 expression in these treated cells.   
 
Furthermore, the immunoblot analysis of cleaved caspase-3 protein expression in melanoma and 
carcinoma cells displayed that RRM-MV treatment enhanced the expression of cleaved caspase-3 
during incubation times.  An increased activity of caspase 3 can be linked to the reduction of 
cellular IAP levels (mainly XIAP and livin) which are potent inhibitors of caspases, and their 
repression might change the balance towards apoptosis. 
 
In conclusion, this study demonstrates that RRM-MV can significantly affect cancer progression 
in melanoma and carcinoma cells but leaving normal cells unscathed.  The non-bioactive peptide, 
RRM-C, did not induce cytotoxic effects in these cell lines.  This study also provides clear 
evidence that RRM-MV stimulated apoptosis in melanoma and carcinoma cells, which is 
mediated by the induction of pro-apoptotic proteins and the reduction of anti-apoptotic proteins.  
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The activity of the RRM-MV with maximum toxic effect on cancer cells and minimal toxic effect 
on normal cells needs to be further investigated using an animal model in vivo. 
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CHAPTER 6  
Investigating Akt Phosphorylation in Cancer Cell Lines 
Treated with a Novel Computationally  
Designed Peptide 
 
6.1 ABSTRACT 
The resonant recognition model (RRM) is a physico-mathematical approach to the analysis of 
protein-protein and protein-DNA interactions.  The RRM interprets a protein sequence‘s linear 
information using digital signal analysis.  This study presents a novel synthetic peptide (RRM-
MV) that was computationally designed using RRM and scrutinizes the Akt pathway as one of 
the major pathways activated in human cancers.  Akt expression levels in human skin cancer cells 
treated with RRM-MV, in the presence or absence of a PI3 kinase inhibitor, were detected by 
immunoblotting.  The results indicate that different levels of p-Akt were observed in the skin 
cancer cells but not in normal cells following treatment.  The bioactive peptide RRM-MV 
appears to be targeting the Akt pathway in cancer cells, hence, it can be suggested that the RRM 
is a valid tool to design bioactive peptides with targeted therapeutic functions.   
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6.2 INTRODUCTION 
Malignant melanomas can be resistant to conventional therapies such as chemotherapy, 
immunotherapy, radiation therapy and/or surgery.  The patient's chances of survival often depend 
on melanoma‘s early diagnosis and treatment, hence new effective therapeutic agents are required 
(Douek & Taylor, 2003).  Oncolytic virotherapy is a novel therapy that can be applied solely or in 
conjunction with the conventional therapies.  In particular, some viruses have the ability to target 
and destroy malignant cancerous cells without harming the normal cells (Bell et al., 2002; Mullen 
& Tanabe, 2002; Parato et al., 2005; Yu et al., 2002).  Myxoma virus (MYXV) is a new poxvirus 
oncolytic candidate that has been added to the list of oncolytic viruses used in virotherapy.  
MYXV is a member of Poxviridae family and the Chordopoxvirinae subfamily (Fenner, 2000; 
Kerr & McFadden, 2002; Liu et al., 2012).  It is a rabbit-specific pathogen that causes 
myxomatosis in European rabbits (Oryctolagus cuniculus), which is considered as a fatal disease 
(Stanford et al., 2007a).  However, MYXV is non-pathogenic in humans and all other vertebrate 
species (Andrewes & Harisijades, 1955; Fenner, 2000; Jackson et al., 1966; McCabe et al., 2002; 
McFadden, 2005).   
 
Recently, MYXV was shown to be able to selectively kill human cancer cells (Correa et al., 
2012; Lun et al., 2005; Stanford et al., 2008; Wennier et al., 2012).  Intense in vitro 
investigations have indicated that replication of MYXV in human cancer cells is associated with 
the hyperactivation of the serine/threonine kinase Akt in cancer cells (Hyun et al., 2000; Kim et 
al., 2005; Kim et al., 2010; Li et al., 2005b; Nicholson & Anderson, 2002; Pedrero et al., 2005; 
Shi et al., 2002; Staal et al., 2002; Testa & Bellacosa, 2001; Wang et al., 2006; Wennier et al., 
2012).  In addition, human cancer cells have been grouped into three types depending on the 
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ability of being productively infected with MYXV, and the capability of MYXV to activate Akt 
through the action of a M-T5 viral protein (Sypula et al., 2004; Wang et al., 2006).  M-T5 is an 
ankyrin-repeat host range protein that is shown to be required for virus replication in rabbit 
lymphocytes, and is critical for virus replication in the majority of human tumor cells (Mossman 
et al., 1996).  M-T5 interacts with two human cellular proteins.  The first cellular protein is 
Cullin-1, an E3 ubiquitin ligase that is involved in the progression through the cell cycle 
(Johnston et al., 2005b).  The interaction of M-T5 with Cullin-1 inhibits MYXV-infected cells 
from cell cycle arrest and stress-induced cell death (Johnston et al., 2005b).  The second cellular 
protein is Akt-1/protein kinase B (PKB) that directly interacts with M-T5 (Wang et al., 2004b; 
Wang et al., 2006).  Akt is a serine/threonine kinase that essential for normal cell processes such 
as programmed cell death, proliferation, cell cycle progression, angiogenesis and metabolism 
(Nicholson & Anderson, 2002).  It is activated via the phosphorylation of its central component at 
ser-473/474 and thr-308/309 (Harlan et al., 1995).  Akt dysregulation is commonly detected in an 
extensive spectrum of human cancers (Aghi & Martuza, 2005; Amornphimoltham et al., 2004; 
Chen et al., 2005; Chow & Baker, 2006; Dahia et al., 1999; Haas-Kogan et al., 1998; Hafner et 
al., 2012; Pedrero et al., 2005).  It was found that many human cancer cells exhibit a high 
endogenous activation of Akt in vitro (Dahia et al., 1999; Haas-Kogan et al., 1998; Hyun et al., 
2000; Stiles et al., 2002).  Akt is a central regulator of cellular signalling; hence, it is not 
surprising that many viruses have developed new strategies to control the activation of Akt 
(Lawlor & Alessi, 2001). 
 
The Resonant Recognition Model (RRM) (Cosic, 1997) was applied to design the bioactive 
peptide RRM-MV and the non-bioactive control peptide RRM-C.  The RRM-MV is a short linear 
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peptide analogue for myxoma virus M-T5 protein which was specifically designed to exhibit anti-
cancer activity (Almansour et al., 2012b; Istivan et al., 2011).  The RRM-C is a short linear 
peptide lacking the bioactive frequencies for RRM-MV, and was used as a negative control 
peptide (Pirogova et al., 2010; Pirogova et al., 2011).  In a more recent study, we have examined 
the biological activity of RRM-MV on mammalian skin cancer cells and normal skin cells in 
vitro and we found that the RRM-MV treatment induced toxic effects in mammalian cancer cell 
lines but had a negligible toxic effect on mammalian normal cell lines (Almansour et al., 2012a; 
Almansour et al., 2012b; Pirogova et al., 2009; Pirogova et al., 2010).  It has been shown that 
viral M-T5 binds with phospho-Akt to regulate Akt signalling in some human cancer cell lines 
(Stanford et al., 2008; Werden & McFadden, 2008).  Therefore, in the current study, we 
investigated the influence of RRM-MV treatment on Akt activation in mammalian skin cancer 
and normal cell lines.  This study provides important information for the development of anti-
cancer agents.   
 
6.3 METHODS 
6.3.1 Bioactive Peptide Design Procedure 
In this study, the bioactive peptide (RRM-MV) and the negative control peptide (RRM-C) were 
designed using RRM as described in section 2.6.   
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6.3.2 Peptides Preparation 
The bioactive peptide RRM-MV and the non-bioactive RRM-C were prepared as described in 
section 3.3.3. 
 
6.3.2 Cell Cultures 
The human malignant melanoma cell line (MM96L), human squamous cell carcinoma cell line 
(COLO-16) and mouse melanoma (B16F0) were cultured as described in section 2.3.3.1.  Normal 
human dermal fibroblast cell line (HDF) cell line was propagated as described in section 2.3.3.2. 
 
6.3.3 Treatment of Cell Lines with Peptides 
The peptide treatment of cells was performed as described previously (Wang et al., 2006) with 
some modifications.  All cell lines were treated at different conditions before protein isolating as 
describe bellow: 
 
6.3.3.1 Treatment with Peptides 
The influence of the RRM-MV treatment on Akt activity was investigated.  The MM96L, COLO-
16 and HDF cell lines were incubated with 400 ng/mL RRM-M or RRM-C for 3 h either in 
complete growth medium with 10% FBS or in serum starvation.  The B16F0 cell line was 
incubated with 800 ng/mL RRM-MV or RRM-C for 3 h in serum starvation condition.  The HDF 
cell line was incubated with 400 ng/mL RRM-MV or RRM-C for 3 h.   
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6.3.3.2 Treatment with Peptide Akt Different Incubation Period 
The influence of different incubation periods on Akt activity after RRM-MV treatment was 
evaluated.  The MM96L and COLO-16 cell lines, at the concentrations of 400 ng/mL, were 
incubated in serum starvation for 15 min, 30 min and 60 min.   
 
6.3.3.3 Treatment with PI3 Kinase Inhibitor  
To confirm that PI3 Kinase inhibitor (LY294002) can block the Akt pathway, MM96L and 
COLO-16 cell lines were treated with 100 µM of LY294002 for 1 h, while the B16F0 cell line 
was treated with 50 µM of LY294002 for 1 h.  The HDF cell line was also treated with either 50 
µM of LY294002 for 1 h or with 100 µM of LY294002 for 2 h.  Cells were incubated either in 
complete growth medium with 10% FBS or in serum starvation conditions. 
 
6.3.3.4 Treatment with PI3 Kinase Inhibitor and Peptides 
The influence of the RRM-MV treatment on Akt activity, after blocking the Akt pathway, was 
assessed.  The MM96L and COLO-16 cell lines were incubated with 100 µM of LY294002 for 1 
h, while the B16F0 cell line was incubated with 50 µM of LY294002 for 1 h.  The HDF cell line 
was also incubated with 100 µM of LY294002 for 2 h.  Following the incubation, The MM96L, 
COLO-16 and HDF cell lines were retreated with 400 ng/mL of peptides and further incubated 
for 3 h under complete growth medium with 10% FBS or serum deprivation conditions.  Peptides 
(800 ng/mL) were added to the B16F0 cell line and further incubated for 3 h. 
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6.3.4 Protein Isolation 
Protein was isolated as described in section 5.3.7.  Protein concentration of each sample was 
determined as described in section 2.4.2.1. 
 
6.3.5 Western Blot Analysis 
Western blotting was carried out as described in section 5.3.8. 
 
6.4 RESULTS 
5.4.1 The Influence of RRM-MV Treatment on Akt Activity 
To determine whether RRM-MV or RRM-C treatment modulates Akt activity in skin cancer cells 
and normal skin cells, the total Akt protein levels and the endogenous phosphorylated Akt levels 
at Thr-308 and Ser-473 were assessed using Western blots as mentioned below:  
 
6.4.1.1 In Skin Cancer Cells 
The levels of p-Akt and total Akt protein were detected after RRM-MV or RRM-C treatment of 
MM96L, COLO-16 and B16F0 cell lines in 10% FBS or in serum starvation in comparison with 
the untreated cell lines.  The results indicated that low levels of p-Akt at Thr-308 and Ser-473 
were detected in MM96L and COLO-16 cell lines; however, high levels of total Akt were 
observed in these cells in general.  In contrast, high levels of p-Akt and total Akt were detected in 
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B16F0 cell line.  In MM96L cell line, the bands‘ intensity of p-Akt (60 kDa) at Ser-473 was 
slightly increased but no changes were observed at Thr-308 (Figure 6.1A, lane 3) under growth 
conditions with serum.  Similar p-Akt band intensities were observed in COLO-16 cell line under 
similar conditions (Figure 6.2A, lane 2).  Incubation in serum starvation showed that the bands‘ 
intensity slightly increased at Ser-473 but no changes at Thr-308 in MM96L cell line were 
detected (Figure 6.1B, lane 3).  However, the bands‘ intensity was slightly increased in COLO-16 
cell line at both Ser-473 and Thr-308 (Figure 6.2B, lane 2).  These results suggest that when 
treated with the RRM-MV, carcinoma and melanoma cells did not depend on serum-derived 
growth factors for either Ser-473 or Thr-308 phosphorylation.  Moreover, Western blot results of 
B16F0 treated with 800 ng/mL of RRM-MV showed similar intensity of p-Akt bands (at Thr-308 
and Ser-473) (Figure 6.3, lane 2).  Interestingly, with the RRM-C treatment, p-Akt and total Akt 
protein levels remained unchanged in the MM96L cell line (Figures 6.1A and B, lane 2), COLO-
16 cell line (Figures 6.2A and 6.2B, lane 3), and B16F0 cell line (Figures 6.3, lane 3), thus 
indicating that the RRM-C treatment has no effect on the Akt expression in all tested cell lines.  
Of note, the levels of p-Akt and total Akt were unaffected after RRM-MV treatment in either 
serum starved or complete growth medium. 
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Figure 6.1.A. 
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Figure 6.1.B. 
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Figure 6.1.  The effects of the bioactive and non-bioactive peptides on cellular expression of Akt 
in melanoma cells.  The MM96L cell line was plated at 5 × 10
7
 cells/mL
 
and was treated in 
presence (A) or in absence (B) of serum.  Cell lysates (20µg) were prepared and immunoblotted 
using p-Akt (Ser-473 and Thr-308) and total Akt antibodies.  β-actin was used as a loading 
control.  The Western blots results show that treatment with RRM-MV, but not RRM-C, slightly 
induces the levels of p-Akt in both conditions.  Inhibition of Akt activity and then treatment with 
RRM-MV also affected the expression of p-Akt protein in tested cells.  These figures are 
representative of three separate Western blot experiments.   
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Figure 6.2.A. 
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Figure 6.2.B. 
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Figure 6.2.  Cellular expression of p-Akt and total Akt in carcinoma cells after treatment with the 
bioactive and non-bioactive peptides.  The COLO-16 cell line was plated at 5 × 10
7
 cells/mL and 
was treated in growth medium with serum (A) or in serum starvation conditions (B).  Western 
blot analysis was used to assess the expression of Akt in treated cells using p-Akt (Ser-473 and 
Thr-308) and total Akt antibodies.  β-actin was used as a loading control.  The Western blot 
results show that the expressions of p-Akt in carcinoma cells slightly increased after RRM-MV 
treatment.  Inhibition of Akt activity and then treatment with RRM-MV also affected the 
expression of p-Akt protein in tested cells.  The experiments were repeated at least three times.   
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Figure 6.3.  Cellular expression of p-Akt and of total Akt was assessed in mouse skin melanoma 
cells after the treatment with the bioactive and non-bioactive peptides.  The B16F0 cell line was 
treated with 800 ng/mL RRM-MV or RRM-C in the presence or absence of 50 µM LY294002 or 
was treated with 50 µM LY294002 alone for 1 h.  The levels of p-Akt expression in the cells 
were detected by immunoblotting using p-Akt (Ser-473 and Thr-308) and total Akt antibodies.  
β-actin was used as a loading control.  The results of Western blots show that the levels of p-Akt 
and total Akt in mouse skin cells were not affected by RRM-MV treatment.  Inhibition of Akt 
activity and then treatment with RRM-MV also did not affect expression of p-Akt protein in 
tested cells.  The experiments were performed at least three times.   
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6.4.1.2 In Normal Skin Cells 
The levels of total Akt protein and p-Akt were detected after treatment of HDF cell line with 
RRM-MV or RRM-C at concentration of 400 ng/mL.  The Western blot results revealed that low 
levels of p-Akt at Ser-473 were detected and the band‘s intensity was unchanged in the RRM-
MV treated cells compared to RRM-C treated cells and untreated cells (Figure 6.4, lane 2 and 3, 
respectively).  Moreover, high levels of total Akt protein were noticed and the band‘s intensity 
was similar in all samples.  This result suggests that RRM-MV treatment in normal human skin 
cells did not affect the expression of total Akt protein and p-Akt. 
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Figure 6.4.  Cellular expression of p-Akt and total Akt in normal human dermal fibroblast cell 
line treated with RRM-MV or RRM-C.  The HDF cell line was treated with 400 ng/mL RRM-
MV or RRM-C in the presence or absence of 100 µM LY294002, or treated with 100 µM 
LY294002 alone for 2 h.  Cell lysates were prepared and immunoblotted using p-Akt (Ser-473) 
and total Akt antibodies.  β-actin was used as a loading control.  The figure shows RRM-MV 
treatment did not affect the expression of p-Akt or total Akt in normal human skin cells.  
Inhibition of Akt activity and then treatment with RRM-MV also had no effect on the expression 
of p-Akt protein in tested cells.  The blots are derived from multiple immunoblotting 
experiments.   
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6.4.2 The Influence of Different Incubation Times on Akt Expression in Skin Cancer Cells 
after RRR-MV Treatment  
To further evaluate the effect of different incubation times on Akt expression after RRM-MV 
treatment in MM96L and COLO-16 cell lines, cells were incubated with 200 ng/mL of RRM-MV 
for 15 min, 30 min and 60 min under conditions of serum starvation.  Western blots results 
showed that in MM96L cell line, the p-Akt band‘s intensity was unchanged after 15 min of 
treatment (Figure 6.5A, lane 2), but p-Akt at S-473 was slightly enhanced with the same dose at 
30 min and 60 min (Figure 6.5A, lane 4 and 6, respectively).  The bands‘ intensity of total Akt 
protein was unchanged during all different incubation times (Figure 6.5A).  Furthermore, 
treatment of COLO-16 cell line with RRM-MV did not induce an increase in p-Akt protein levels 
(Thr-308 and Ser-473) after 15 min (Figure 6.5B, lane 2); however, phosphorylated Akt was 
increased noticeably at both Thr-308 and Ser-473 after 30 min and 60 min (Figure 6.5B, lane 4 
and 6, respectively).  The intensity of total Akt band was unaffected during times course (Figure 
6.5B).  These findings indicate that RRM-MV treatment enhanced Akt phosphorylation in a time-
dependent manner in melanoma and carcinoma cells.   
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Figure 6.5.A. 
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Figure 6.5.B. 
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Figure 6.5.  The effect of different incubation times on Akt expression after the bioactive peptide 
treatment in melanoma and carcinoma cells.  MM96L in (A) and COLO-16 in (B) cell lines were 
treated with 400 ng/mL with RRM-MV for 15 min, 30 min and 60 min.  Whole cells extracts 
were prepared and immunoblotted using p-Akt (Ser-473 and Thr-308) and total Akt antibodies.  
β-actin was used as a loading control.  Western blots show that treatment with RRM-MV induced 
the levels of p-Akt in a time dependent manner in melanoma and carcinoma cells.  The 
experiments were repeated at least three times.   
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6.4.3 The Influence of PI3K Akt Inhibitors on Akt Activity 
To test whether PI3K/Akt inhibitor (LY294002) could block Akt phosphorylation, the skin 
cancer and normal human skin cells were treated with LY294002 under conditions of complete 
growth medium or serum starvation.  The results showed that incubation of MM96L cell line 
with 100 µM LY294002 for 1 h blocked Akt phosphorylation either under conditions of complete 
growth medium or serum starvation compared to untreated cells (Figures 6.1A and 6.1B, lane 8).  
Similar results were noticed in B16F0 cell line after treatment with 50 µM of LY294002 for 1 h 
(Figure 6.3, lane 8).  Nevertheless, the blocking was incomplete at Ser-473 and Thr-308 in 
COLO-16 cell line in growth medium with serum (Figure 6.2A, lane 8), yet a complete blocking 
in phosphorylation of Akt was observed with serum starvation (Figure 6.2B, lane 8), suggesting 
that blocking of Akt activation in carcinoma cells was affected by serum conditions.  Western 
blots results for normal skin showed that 50 µM of LY294002 did not block the phosphorylation 
of Akt after incubation for 1 h; however, incubation with 100 µM of LY294002 for 2 h blocked 
the Akt phosphorylation, suggesting that inhibition of Akt activation in normal cells was time-
and dose-dependent.  On the other hand, LY294002 treatment did not appear to significantly 
block the total Akt protein levels in all tested cell lines.   
 
6.4.4 The Influence of RRM-MV Treatment after Inhibition of Akt Activity 
To determine whether PI3K Akt inhibitor would suppress Akt activity in the presence of RRM-
MV under complete growth medium or serum starvation conditions, cells were treated with 
LY294002.  The cells were then further incubated with RRM-MV and whole cell lysates were 
immunoblotted with the specific antibodies as indicated below:  
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6.4.4.1 In Skin Cancer Cells 
The MM96L and COLO-16 cell lines were incubated with 100 µM LY294002 for 1 h and then 
further incubated with 400 ng/mL RRM-MV for 3 h.  The Western blot results showed Akt 
becomes activated at Ser-473 after RRM-MV treatment in MM96L cells but no p-Akt band was 
detected at Thr-308 under complete growth medium conditions (Figure 6.1A, lane 5).  Moreover, 
similar results were found with cells that were incubated under serum starvation conditions 
(Figure 6.1B, lane 5).  When Akt activation was blocked in the COLO-16 cell line and then 
treated with RRM-MV, p-Akt activation was restored at both Ser-473 and Thr-308 under 
complete growth medium (Figure 6.2A, lane 5) or serum starvation conditions (Figure 6.2B, lane 
5).  Similar results were obtained with B16F0 cell line treated with 50 µM LY294002 for 1 h and 
then further incubated with 800 ng/mL RRM-MV for 3 h (Figure 6.3, lane 5).  As expected, 
inhibition of Akt phosphorylation followed by treatment with RRM-MV did not have an effect on 
the expression of total Akt protein in the MM96L, COLO-16 and B16F0 cell lines.  The findings 
of this experiment suggest that treatment with LY294002 was not able to block Akt activity after 
treatment with RRM-MV in all tested cancer cell lines; thus, confirming RRM-MV treatment 
interferes with inhibition of Akt signalling pathway.   
 
6.4.4.2 In Normal Skin Cells 
The HDF cell line was incubated with 100 µM of LY294002 for 2 h and then further incubated 
with 400 ng/mL RRM-MV for 3 h.  The Western blot results showed that RRM-MV treatment 
did not restore p-Akt activation after inhibition with LY294002 compared to untreated cells.  
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These data demonstrate that RRM-MV treatment did not reestablish p-Akt activity after 
inhibition with LY294002.   
 
6.5  DISCUSSION 
Therapeutic peptides have been emerging as a novel class of drugs for cancer therapy and are 
being intensively studied for their role in developing of novel cancer therapeutics (Pirogova et 
al., 2009; Pirogova et al., 2011).  This is due to the fact that peptides have a high potential to 
penetrate cellular membranes, interfere with enzymatic functions and protein-protein interactions 
within cells (Bidwell & Raucher, 2009; Park et al., 2005; Raucher et al., 2009).  Many proteins 
play a crucial role in the regulation of multiple cellular processes such as Akt, also known as 
protein kinase B (PKB).  It is believed that the regulation of Akt activation is impaired in cancer 
cells (Wang et al., 2006).  It was previously shown that viral M-T5 binds with p-Akt to regulate 
Akt signalling in some human cancer cells (Wang et al., 2006; Werden & McFadden, 2008).  In 
the current study, we investigated the influence of the RRM-MV, a linear short peptide analogue 
of the MYXV protein, M-T5, on Akt activation in skin cancer cells to detect a possible cell death 
pathway.  It was previously found that RRM-MV is able to induce apoptotic/ necrotic effects in 
the mouse melanoma cell lines but produced no cytotoxic effects on normal cell lines (Istivan et 
al., 2011). 
 
The present study showed that the levels of total Akt in all cells tested were not affected by the 
RRM-MV treatment.  A high level of p-Akt was detected in the B16F0 cell line at both Ser-473 
and Thr-308; however, MM96L and COLO-16 cell lines expressed lower levels of p-Akt at Ser-
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473 and Thr-308.  This result corroborates with previous studies (Shi et al., 2002; Staal et al., 
2002) indicating that infected MYXV cancer cells expressed measurable phosphorylated Akt 
levels either high, low or very low levels but some cancer cells did not express any levels of p-
Akt.  As an example, melanoma (SK-MEL5) cell line expressed total Akt protein but did not 
express p-Akt (both Ser-473 and Thr-308) (Wang et al., 2006).  Another example of high levels 
of Akt is in B16F10 cell line, which correlates with permissiveness to MV (Stanford & 
McFadden, 2007).   
 
The Western blot results showed that p-Akt expression was slightly increased at Ser-473 after 
RRM-MV treatment under 10% FBS and serum deprivation conditions, suggesting that RRM-
MV interacts with the Ser-473 component of the Akt (Brunet et al., 1999; Datta et al., 1997; 
Downward, 1998; Dudek et al., 1997).  Conversely, the RRM-MV treatment did not produce an 
effect on Akt activation in the B16F0 cell line.  This finding is consistent with the results of a 
previous study (Jetzt et al.  2003). 
 
This study also showed that different incubation times affected Akt expression in melanoma and 
carcinoma cells after the RRM-MV treatment.  The band‘s intensity of p-Akt was unchanged at 
15 min of incubation time with RRM-MV while it started to increase after 30 min and 60 min.  
However, there was no change in the intensity of total Akt band detected during the course of 
treatment, indicating that Akt phosphorylation was induced by RRM-MV treatment in a time-
dependent manner in both melanoma and carcinoma cells.  It has been demonstrated that 
exposure of cells to various chemotherapies and cytotoxic agents leads to changes in the p-Akt 
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expression (Jetzt et al., 2003; Tang et al., 2001; Winograd-Katz & Levitzki, 2006) and this could 
be the case in RRM-MV treatment.  Furthermore, Wang et al  (Wang et al., 2006) found that the 
Akt phosphorylation can be activated in the presence of M-T5 myxoma virus protein by forming 
a complex between M-T5 and Akt in permissive human cancer cells. 
 
The inhibition of Akt by LY294002, which is a potent and specific inhibitor of PI3K that can 
blocks downstream pathways of PI3K including Akt activation (King et al., 1997; Wennström & 
Downward, 1999; Werden & McFadden, 2010), blocked PI3K or downstream activation of Akt 
in melanoma and carcinoma cells.  Moreover, this inhibition of Akt activation was observed to be 
a time-and dose-dependent in normal human skin cells.  In contrast, LY294002 was unable to 
block the total Akt protein levels in all tested cell lines. 
 
This study also examined the influence of RRM-MV after inhibition of the Akt activity by 
LY294002 in cancer and normal cells.  We found that LY294002 did not suppress Akt activity in 
the presence of RRM-MV in melanoma and carcinoma cells.  This result suggests that PI3K 
kinase inhibitor is unable to block Akt activation following RRM-MV treatment; thus, it is 
suggested that the RRM-MV has a unique capacity to modulate Akt activation directly at the Akt 
level itself (Soares et al., 2009).  This finding is in agreement with studies by Dhawan et al 
(Dhawan et al., 2002) and Wang et al (Wang et al., 2006) that reported the MYXV infection 
leads to increased Akt activation in the presence of LY294002.  Therefore, specific Akt inhibitors 
are unable to significantly block Akt activation after treatment with RRM-MV and acts 
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downstream of these inhibitors, indicating that RRM-MV is able to specifically interact with Akt 
and this RRM-MV-Akt interaction is required for enhancement of the Akt activation.   
6.6 CONCLUSION 
It can be concluded that RRM-MV treatment could activate Akt measured by the phosphorylation 
of the Ser-473 site.  Further work will focus on binding of RRM-MV with tumor specific 
biomarkers to achieve targeted delivery.  The molecular mechanism of the RRM-MV cytotoxicity 
will be investigated in an animal model.   
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CHAPTER 7  
Final Discussion 
 
 
Human malignant melanoma is one of the deadliest forms of skin cancer, and its occurrence rate, 
compared with other common types of cancer, has been increasing for decades (Li & Herlyn, 
2000; Ries et al., 2000; Xue & Stauss, 2007).  The current therapy approach for most solid 
tumors is limited by the tolerance of normal tissue resulting in a narrow therapeutic index 
(Massodi et al., 2009).  Therefore, it is necessary to search for a more efficient therapy, such as 
using bioactive peptides.  Therapeutic peptides can be developed to inhibit or reactivate diverse 
pivotal signalling molecules.  These peptides can be specific to their target proteins and, in some 
cases, to cancer cell types (Pirogova et al., 2011; Zompra et al., 2009).  Peptides can penetrate 
cellular membranes and interfere with enzymatic functions and protein-protein interactions 
within cells (Park et al., 2005), giving them a wider application in cancer therapy (Zompra et al., 
2009).  Existing peptide therapies focus on short peptides with strong tumoricidal activity and 
minimal side effects on normal cells (Cosic & Pirogova, 2007; Pirogova et al., 2010; Pirogova et 
al., 2011).   
 
The RRM approach was applied to design de novo peptides with anticancer activity such as 
RRM-IL12 and RRM-TNF (Istivan et al., 2011; Pirogova et al., 2009; Pirogova et al., 2010; 
Pirogova et al., 2011).  RRM is a physical-mathematical model that incorporates a signal 
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processing methodology for structure-function analysis of proteins.  Once the RRM characteristic 
frequency is identified, it is possible to design peptides having the same frequency and thus the 
desired function (Cosic et al., 1991; Cosic, 1994b; Cosic, 1997).  Therefore, in this study, RRM 
approach was utilised for structure function analysis of myxoma virus (MYXV) proteins (M-T5) 
and to design a short therapeutic peptide with MYXV-like antitumor activity.  RRM-C is a non-
bioactive peptide that lacks the bioactive frequencies of RRM-MV.  It was also designed by 
RRM and was used as a negative control. 
 
A major objective of the present study was to evaluate the toxicity of the bioactive peptide RRM-
MV against skin cancer cells and normal cells in vitro and to assess their efficacy in eliminating 
cancer cells.  The toxicity of the bioactive peptide was also compared with the toxicity of a 
number of peptides which were designed as negative control peptides.  Moreover, the cell death 
signalling pathways were investigated to detect the apoptosis pathway that could possibly be 
affected by the bioactive peptide treatment.   
 
Qualitative and quantitative assays were performed to evaluate the toxicity of RRM-MV to 
cancer cells and to compare its toxicity with that of RRM-C.  Although results showed that the 
bioactive peptide treatment caused apoptosis and/or necrosis and changes in the morphological 
characteristics of the melanoma and carcinoma cells, normal human skin cells were not affected 
by the treatment.  These effects occurred in a dose-dependent manner within 3 h of incubation of 
melanoma and carcinoma cells with RRM-MV treatment.  A longer incubation (up to 18 h) 
showed a more significant apoptosis/necrosis effect, revealing that these cancer cells are 
undergoing apoptosis or necrosis.  This observation is consistent with previous studies conducted 
by our research group (Pirogova et al., 2010; Pirogova et al., 2011), in which RRM-designed 
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peptides (e.g., RRM-IL and RRM-TNF) produced apoptosis and necrosis on a mouse skin cell 
line in a dose-dependent manner.  other studies have also shown that different injurious stimuli, 
such as cytotoxic anticancer drugs can induce apoptosis only at low doses and necrosis at high 
doses (Denecker et al., 2001; Leist et al., 1997). 
 
The assessment of the apoptosis and necrosis assay was documented by an examination of the 
lactate dehydrogenase (LDH) release using LDH assay.  The results of the LDH assay showed 
that both melanoma and carcinoma cells released a significant level of LDH after the RRM-MV 
treatment compared to the untreated cells and the RRM-C treatment.  Plasma membrane damage 
or an increase in the number of dead cells resulted in an increase in LDH release from damaged 
cells (Haslam et al., 2000; Wolterbeek & van der Meer, 2005).  This finding indicates that 
bioactive peptides trigger plasma membrane damage and cellular structures damages, leading to 
significant cytotoxicity towards melanoma and carcinoma cells.  However , this was not the case, 
, for normal cells.   
 
The result of the LDH assessment was further confirmed by an evaluation of cell viability using 
MTT and PrestoBlue cell viability assays.  The data obtained from the MTT assay indicated that 
RRM-MV showed a significant induction of cell death and damaged cellular structures in 
melanoma and carcinoma cells at all tested concentrations used (up to 1600 ng/mL) in the RRM-
MV treatment after 3 h.  This was evident thruogh the analysis of the cells‘ morphology and 
increased LDH release from treated cells with induced death.  Similarly, over time, the incubation 
of melanoma and carcinoma cells with RRM-MV for up to 18 h clearly resulted in substantially 
increased toxic responses in these cells with increasing treatment doses (above 400 ng/mL).  
Hence, the anticancer activity of the bioactive peptide was dose- and time-dependent, triggering 
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cell death within 18 h.  On the other hand, no increase in cell death ratios were detected in normal 
human skin cells when RRM-MV or RRM-C treatments were incubated with the cell line within 
the investigated time and concentration ranges.  This finding confirms apoptosis and necrosis 
data.   
 
Furthermore, the treatment of melanoma and carcinoma cells with different concentrations of 
bioactive peptides (ranging from 50 to 800 ng/mL) and for incubation time periods of 8–72 h 
using the PrestoBlue cell viability assay revealed that in longer incubation periods over 24 h, the 
melanoma and carcinoma cells restored viability and grew more aggressively.  This could be 
explained by calculated half-life of the RRM-MV in vitro, which is at 30 h (Artimo et al., 2012).  
The redaction of RRM-MV activity over longer incubation led cancer cells to recover from its 
toxic effect.  Therefore, a second dose of same concentrations of RRM-MV was added after 16 h 
of the first dose.  This has actually enhanced the cytotoxic effect of RRM-MV and led to the 
death of the cancer cells with the second dose.  On the other hand, the results obtained from 
normal skin cell lines indicated that the bioactive peptide treatment did not have a significant 
effect on cell viability.  The data also showed that the non-bioactive peptide treatment did not 
affect the cell viability of both human skin cancer cells and normal skin cells and cells did not 
respond to the second dose of treatment at all concentrations at the longest treatment period. 
 
For further confirmation of the RRM efficacy, we designed a non-bioactive peptide RRM-MV-C 
using the RRM.  It was postulated that this non-bioactive peptide does not express MYXV 
protein (MT-5) activity.  We also designed three negative control peptides (MV-C1, MV-C2, and 
MV-C3) by changing the order of one amino acid within the sequence of the bioactive peptide.  
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We assumed that these three negative control peptides will not possess of the anticancer activity 
of the bioactive peptide according to the RRM theory. 
 
The toxic efficacy of all negative control peptides mentioned earlier on melanoma, carcinoma, 
and normal human skin cells in vitro was evaluated by measuring characteristic morphological 
changes (apoptotic and necrotic effects), quantitating the LDH activity released from damaged 
cells and the cell viability.  Then, the toxic efficacy of all negative control peptides was compared 
with that of the bioactive control peptide.  
 
According to the apoptosis and necrosis assessment, the non-bioactive peptide RRM-MV-C and 
the three negative control peptides did not affect the morphological features of melanoma and 
carcinoma cells compared to the bioactive peptide.  In addition, there were no morphological 
changes or detection of apoptosis and/or necrosis for all tested peptides in normal human skin 
cells within 3 h of incubation when compared with the untreated cells.  This finding reveals that 
all tested negative control peptides did not trigger morphological changes and cytotoxic effects in 
both human skin cancer and normal cells.   
 
The evaluation of the LDH release after treatment with all negative control peptides indicates that 
the level of LDH released from damaged cancer cells into the culture medium did not increase in 
melanoma and carcinoma cells after the non-bioactive peptide (RRM-MV-C) and the three 
negative control treatments.  However, the bioactive peptide increased the LDH level in the same 
tested cells.  In normal human skin cells, LDH release was not induced after treatment with either 
the bioactive peptide, the non-bioactive peptide, or the three negative control peptides.  These 
results suggest that the plasma membrane remains intact in human skin cancer and normal cells 
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during treatment with all tested negative control peptides.  Furthermore, the results from the MTT 
cell viability measurement assay showed that the non-bioactive peptide and the three control 
peptides did not show cell viability reduction in any of the concentrations used (ranging from 100 
to 1600 ng/mL) during either the 3 or 18 h incubation time compared to the bioactive peptide.  
Moreover, none of the tested peptides displayed toxic effects or reduction in cell viability in 
normal human skin cells within the investigated concentration range and incubation period 
compared to the untreated cells.   
 
The evaluation of the safety of the bioactive peptide as a therapeutic candidate was performed by 
hemolysis assay.  Vlieghe et al has reported that peptides generally have to be injected and they 
cannot be taken orally (Vlieghe et al., 2010).  Thus, in this study, the hemolytic effect of the 
bioactive peptide and all negative control peptides, on human erythrocytes was investigated at 
different concentrations, ranging from 50 ng/mL to 1600 ng/mL.  The data showed that none of 
the tested peptides induced hemolytic effect on human erythrocytes at all the concentrations used 
as compared to the positive control of complete lysis.  This result indicates that human 
erythrocytes appear to be relatively resistant to all peptide treatments.    
 
Taken together, the findings from the apoptosis and necrosis assay, the LDH activity assay, the 
MTT cell viability assay, and the PrestoBlue assay confirmed that the incubation of skin cancer 
cells with the bioactive peptide caused cell membrane perturbations, reduction in cell visibility, 
and LDH release within the cells, leading to cell death.  In addition, the application of the non-
bioactive peptide to treated skin cancer cells and normal cells resulted in the loss of RRM-MV 
anticancer function.  Similarly, the three negative control peptides, with the placement of the 
order of one amino acid within the RRM-MV sequence, did not show anticancer activity and 
 230  
 
resulted in a marked diminution in the cytotoxicity of these three negative control peptides to 
cancer cells.  Therefore, these findings confirmed the toxicity of the bioactive peptide to cancer 
cells and the lack of toxicity of the non-bioactive peptide and the three negative control peptides, 
indicating that the RRM can be applied successfully to design anticancer therapy.   
 
Anticancer drugs are known to induce apoptosis in targeted cells and are considered as cytotoxic 
agents (Lowe and Lin 2000).  Thus, this study further examined the molecular pathways that 
were induced by RRM-MV to promote apoptosis in melanoma and carcinoma cells.  This was 
examined by the human apoptosis array analysis. 
 
The data analysis of results suggested that although the majority of anti-apoptotic protein levels 
were repressed after RRM-MV treatment in melanoma cells, a few of them were induced, 
including cIAP-2, Claspin, Clusterin and HSP27.  This induction was not influenced on apoptosis 
due to most of anti-apoptotic proteins decreasing after RRM-MV treatment.  Indeed, the 
induction of apoptosis was associated with a disturbance of pro-apoptotic and anti-apoptotic 
proteins mediators and led to cell death (Fulda & Debatin, 2004). 
 
The data obtained from this study also indicated that the levels of all pro-apoptotic proteins were 
induced; however, the levels of all anti-apoptotic protein were inhibited in carcinoma cells after 
RRM-MV treatment.  This is agreement with several studies that  reported  the induction of pro-
apoptotic proteins and inhibition of anti-apoptotic proteins as a response to cytotoxic therapy 
(Adida et al., 1998a; Adida et al., 2000; Li et al., 2001a; Salvesen & Duckett, 2002; Tamm et al., 
2000).  As human apoptosis related proteins array analysis demonstrated that p53 and cleaved 
caspase-3 proteins were affected by RRM-MV treatment in melanoma and carcinoma cells, 
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further examination of these proteins levels were performed.  The immunoblot analysis showed 
that RRM-MV treatment enhanced the expression of p53 and cleaved caspase-3 at variable 
incubation times.   
 
The RRM-MV toxic activity was further confirmed by DNA degradation assessment.  The gel 
electrophoresis results showed that the RRM-MV-treatment caused DNA degradation in 
melanoma cells, this event is considered a biochemical hallmark of apoptosis; thus, changes in 
the DNA characteristics confirmed cell death induction in this cell line.  This degradation of 
DNA can be linked to the increase in p53 activity in the tested cells (Zapata et al., 1998).  It has 
been reported that p53 accumulates in response to DNA damage, which induces the transcription 
of the p53 gene and results in an increase in the p53 protein level, thereby enhancing apoptosis in 
cancer cells.  On the other hand, DNA degradation was not observed in the RRM-MV-treated 
carcinoma cells although the cytotoxicity of RRM-MV was confirmed by CLSM, LDH activity, 
MTT and PrestoBlue cell viability assays, and human apoptosis array analysis.  This could be 
explained by lack of endogenous DNases in this cell line (Kerr et al., 1994).  Hence, the DNA 
degradation depends on cell type, repair of the damage, and sensitivity to destructive agents 
(Sancar et al., 2004).   
 
Akt, or protein kinase B (PKB), is a serine-threonine kinase that plays an essential role in the 
regulation of several cellular processes including cell growth, apoptosis and metabolism (Brazil 
et al., 2004).  This pathway is one of the most often activated proliferation and survival pathways 
in cancer (Hennessy et al., 2005).  Recent studies indicated that the regulation of Akt activation is 
impaired in cancer cells (Wang et al., 2006) and the viral protein (M-T5) binds with p-Akt to 
regulate Akt signalling in some human cancer cells (Wang et al., 2006; Werden & McFadden, 
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2008), suggesting this pathway could be influenced by RRM-MV treatment.  Therefore, in the 
current study, the PI3K/Akt signalling pathway in RRM-MV treated skin cancer cells was 
investigated using Western blot analysis  
 
Although phosphorylated Akt expression was slightly increased in the melanoma and carcinoma 
cells after 3 h of the RRM-MV treatment, it did not affect in the B16F0 cell and the human 
normal skin cells.  Previous studies have demonstrated that exposure of cells to various 
chemotherapies and cytotoxic agents leading to changes in the expression levels of p-Akt (Tang 
et al., 2001; Winograd-Katz & Levitzki, 2006) and this may be including RRM-MV treatment.  
Noticeably, the levels of total Akt in both types of cells did not show any changes after the 
treatment.  Moreover, the influence of RRM-MV after inhibition of the Akt activity in cancer and 
normal cells was investigated.  The results indicated that after blocking the Akt with LY294002 
and adding RRM-MV to the melanoma, carcinoma and mouse skin melanoma cells resulted in 
restoring Akt activation.  This observation is in agreement with the results published by (Dhawan 
et al., 2002; Wang et al., 2006) showing that infection with MYXV enhanced Akt activation in 
the presence of LY294002.  The data therefore suggested that specific Akt inhibitors are unable 
to significantly block Akt activation after treatment with RRM-MV and it is likely that RRM-MV 
acts downstream of these inhibitors similar to M-T5.   
 
All the data taken together reveal that the bioactive peptide RRM-MV, at all different 
concentrations used, resulted in skin cancer cell death, but the normal skin cells remained 
relatively unaffected.  The evaluation of experimental data has proved the successful application 
of the RRM concept to the design of the bioactive peptide  RRM-MV.  The findings showed that 
RRM-MV is suitable to be developed as a potential cancer therapeutic product.   
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CHAPTER 8 
 
Conclusion and Future Perspectives 
 
 
8.1 CONCLUSION  
This thesis addressed the aims of this study and investigated the use of de novo designed peptides 
as anti-cancer therapeutics using RRM-MV, which is computationally designed as an analogue 
for MV protein (M-T5) using the RRM approach.  Experimental evaluation of the designed 
peptide‘s efficacy for treatment has been undertaken on cancer cells (malignant melanoma 
(MM96L) and human squamous carcinoma (COLO-16) cell lines); and on normal cells (normal 
human epidermal melanocytes (HEM) and normal human dermal fibroblast (HDF) cell line).   
The data accumulated in this study demonstrates that the bioactive peptide RRM-MV has a 
selective cytotoxic activity towards melanoma and carcinoma cells with no significant effect on 
normal cells.  The biological effects were found to include characteristic cellular morphology 
changes, apoptosis and/or necrosis, reduced cell viability, and induced plasma membrane damage 
shown by an increase of LDH release, in a dose- and time-dependent manner.  All of which are 
evidences that the cells entered the cell death pathway.  However, these events did not occur 
when the non-bioactive peptides RRM-C and the RRM-MV-C were added to these tested cell 
lines.  Similar observations were noted for the addition of MV-C1, MV-C2, and MV-C3 to skin 
cancer cells and normal cells.  Therefore, the non-bioactive peptide, that possesses non-active 
frequencies and phases, did not express M-T5 activity.  Hence, a change in the order of one 
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amino acid within the sequence of the bioactive peptide led to loss of its anti-cancer activity.  The 
RRM-MV and all negative-control peptides (RRM-C, RRM-MV-C, MV-C1, MV-C2 and MV-
C3) did not induce hemolytic effects in human erythrocytes even at high concentrations.  This 
study also highlights the molecular mechanism of RRM-MV treatment that can be affected by 
this treatment.  The study showed that RRM-MV treatment can activate Akt as measured by 
serine-308 and threonine-473 phosphorylation in melanoma and carcinoma cells, but not in 
normal cells.  Moreover, RRM-MV treatment stimulated apoptosis in melanoma and carcinoma 
cells by mediating the induction of pro-apoptosis proteins and the reduction of anti-apoptosis 
proteins.   
 
The outcomes of this experimental validation indicate the suitability of the RRM approach to the 
design of bioactive peptides with desired biological functions.  Rational design approaches and 
de novo designed peptides would have a significant impact on biotechnology and pharmacology 
industries.  The RRM presents a valuable bioinformatics tool for designing short peptides.  
Therefore, a successful development of computationally designed peptides for myxoma virus 
protein delivery could lead to a novel and safe therapy, particularly presenting a promising class 
of anticancer drugs. 
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8.2 FUTURE PERSPECTIVES  
The anti-cancer therapeutic action of the bioactive peptide RRM-MV on cancer cells and its 
minimal undesirable side effects on normal cells are interesting and should be further 
investigated.  Its biological features make it an attractive candidate as a therapeutic agent. 
 
Although this thesis has added new knowledge by employing RRM to design of a bioactive 
therapeutic peptide with the selected biological functions to treat skin cancer cell line, further 
studies are required to clarify the anti-cancer effects of the bioactive peptide on a broad spectrum 
screening of cancer cell types such as breast cancer and prostate cancer.  Moreover, the activity 
of this bioactive peptide should be further examined in patient tumor samples or in animal models 
to test the inhibitory effects.  This will be helpful for proving its apoptotic effect and to assess its 
suitability as a future cancer therapeutic. 
 
An effort to understand the mechanism of bioactive peptide toxicity by studying the effect of 
RRM-MV on mitochondria metabolism and on cell cycle should be established.   
 
In addition, DNA double-strand breaks in individual cells caused by exposure to toxic agents are 
considered a biochemical hallmark of apoptosis.  Therefore, evaluations of the genotoxicity and 
chromosomal aberrations induced by RRM-MV in cancer cells should be further examined at the 
molecular level by quantifying immunostaining.  The evaluation of gene expression levels also 
should be quantified in order to validate cell death induction in cancer cells after bioactive 
peptide treatment. 
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